Patent Publication Number: US-2023145575-A1

Title: Methods for spatial analysis using targeted rna depletion

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a continuation of U.S. patent application Ser. No. 17/546,625, filed on Dec. 9, 2021, which is a continuation of International Application PCT/US2021/028397, with an international filing date of Apr. 21, 2021, which claims priority to U.S. Provisional Patent Application No. 63/014,054, filed Apr. 22, 2020, which is incorporated herein by reference in its entirety. 
    
    
     SEQUENCE LISTING 
     This application contains a Sequence Listing that has been submitted electronically as an XML file named 47706-0200002_SL_ST26.xml. The XML file, created on Dec. 21, 2022, is 178,862 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety. 
     BACKGROUND 
     Cells within a tissue of a subject have differences in cell morphology and/or function due to varied analyte levels (e.g., gene and/or protein expression) within the different cells. The specific position of a cell within a tissue (e.g., the cell&#39;s position relative to neighboring cells or the cell&#39;s position relative to the tissue microenvironment) can affect, e.g., the cell&#39;s morphology, differentiation, fate, viability, proliferation, behavior, and signaling and cross-talk with other cells in the tissue. 
     Spatial heterogeneity has been previously studied using techniques that only provide data for a small handful of analytes in the context of an intact tissue or a portion of a tissue, or provide a lot of analyte data for single cells, but fail to provide information regarding the position of the single cell in a parent biological sample (e.g., tissue sample). 
     Undesirable RNA (e.g, ribosomal RNA) constitutes a considerable proportion of the total nucleic acid pool from the biological sample, which can compete with hybridization of target analytes of interest. In certain settings, undesireable RNA is capable of hybridizing to randomers, poly-adenylated sequences, and even gene specific capture sequences, thus creating increased background signal that interferes with target analyte binding. 
     One option for decreasing background signal of undesireable RNA molecules is to add depletion probes during the reverse transcription step of the spatial array gene expression protocol. Depletion probes can be designed to tile various types of undesireable RNA molecules (e.g., both nuclear and mitochondrial RNA molecules). In this setting, by tiling rRNA molecules, the molecules are largely inhibited from interacting with the spatial capture array. However, one drawback could be that it is possible that a considerable fraction of rRNA are already interacting with the array when the depletion probes are added, thereby limited their utility. Thus, there is a need to remove such undesirable RNA. 
     RNA-templated ligation (RTL) is the process by which multiple oligonucleotides hybridize to an analyte at nearby or adjacent sequences followed by ligation of the oligonucleotides to create a ligation product. After hybridization and ligation, a DNA-RNA hybrid complex that includes the analyte of interest (e.g., RNA) and the ligated probe (made of DNA or DNA/RNA combination) is created. RTL utilizes a ribonuclease (e.g., RNAse H) to digest the DNA-RNA hybrid complex, freeing the ligated probe for downstream applications such as spatial array probe hybridization and sequencing. Here, Applicants have identified that undesireable RNA probes can also be added and hybridized to undesireable RNAs. Further, because the undesireable RNA probes/undesireable RNA complex creates a DNA-RNA hybrid complex, the same endonuclease step can digest the analyte also digests the undesirable RNA. Because there remains a need to remove such undesirable RNA, this approach simplifies the necessity for multiple enzymatic steps that could affect nucleic acid integrity and function. 
     SUMMARY 
     The present invention relates to methods of depleting undesirable RNA from nucleic acid samples. The invention is useful for preparing cDNA from the RNA-depleted nucleic acid samples, for example, from fixed paraffin embedded (FFPE) tissue samples. 
     In one aspect, provided herein is a method for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting a biological sample with a first probe oligonucleotide, a second probe oligonucleotide, and a plurality of undesirable RNA depletion probes, wherein the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of the analyte, wherein the second probe oligonucleotide comprises a capture probe binding domain that is capable of binding to a capture domain of a capture probe, and wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; (b) hybridizing the first probe oligonucleotide and the second probe oligonucleotide to the analyte; (c) hybridizing the undesirable RNA depletion probe to the undesirable RNA molecule; (d) ligating the first probe oligonucleotide and the second probe oligonucleotide, thereby creating a ligated probe that is substantially complementary to the analyte; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes and releasing the ligated probe from the analyte; (f) hybridizing the capture probe binding domain of the ligated probe to a capture domain of a capture probe that is affixed to the substrate; and (g) determining (i) all or a part of the sequence of the ligated probe specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof, and using the determined sequence of (i) and (ii) to identify the location of the analyte in the biological sample. 
     In some embodiments, the first probe oligonucleotide comprises at least two ribonucleic acid bases at the 3′ end. 
     In some embodiments, the first probe oligonucleotide further comprises a functional sequence. In some embodiments, the functional sequence is a primer sequence. 
     In some embodiments, the second probe oligonucleotide comprises a phosphorylated nucleotide at the 5′ end. 
     In some embodiments, the method further comprises providing a capture probe binding domain blocking moiety that interacts with the capture probe binding domain. 
     In some embodiments, the method further comprises releasing the capture probe binding domain blocking moiety from the capture probe binding domain prior to step (f). 
     In some embodiments, the capture probe binding domain comprises a poly-adenylated (poly(A)) sequence or a complement thereof. 
     In some embodiments, the capture probe binding domain blocking moiety comprises a poly-uridine sequence, a poly-thymidine sequence, or both. 
     In some embodiments, releasing the poly-uridine sequence from the poly(A) sequence comprises denaturing the ligated probe or contacting the ligated probe with an endonuclease or exonuclease. 
     In some embodiments, the capture probe binding domain comprises a sequence that is complementary to all or a portion of the capture domain of the capture probe. In some embodiments, the capture probe binding domain comprises a degenerate sequence. 
     In some embodiments, the ligation step comprises ligating the first and second probe oligonucleotides using enzymatic ligation or chemical ligation. In some embodiments, the enzymatic ligation utilizes a ligase. 
     In some embodiments, the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase. In some embodiments, the ligase is a T4 RNA ligase 2 (Rnl2) ligase. 
     In some embodiments, the first probe oligonucleotide and the second probe oligonucleotide are DNA probes. In some embodiments, the undesirable RNA depletion probe is a DNA probe. 
     In some embodiments, the steps (b) and (c) each creates a RNA: DNA hybrid. 
     In some embodiments, step (e) comprises contacting the undesirable RNA depletion probe with a ribonuclease. 
     In some embodiments, the ribonuclease is RNase H. In some embodiments, the RNase H is RNase H1. In some embodiments, the RNase H is RNase H2. In some embodiments, the RNase H is a thermostable RNase. 
     In some embodiments, the method further comprises amplifying the ligated probe prior to step (f). In some embodiments, steps (b) and (c) are performed at substantially the same time. 
     In one aspect, provided herein is a method for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting the biological sample with a substrate comprising a plurality of attached capture probes, wherein a capture probe of the plurality comprises (i) the spatial barcode and (ii) a capture domain that binds specifically to a sequence present in the analyte; and a plurality of undesirable RNA depletion probes, wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; (b) hybridizing the undesirable RNA depletion probe to the undesirable RNA; (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; (d) hybridizing the analyte to a capture domain of a capture probe that is affixed to the substrate; (e) extending a 3′ end of the capture probe using the analyte that is specifically bound to the capture domain as a template to generate an extended capture probe; and (f) amplifying the extended capture probe to produce a nucleic acid. 
     In some embodiments, provided herein is the method for identifying a location of an analyte in a biological sample, further comprising determining (i) all or a part of the sequence of the spatial barcode or the complement thereof, and (ii) all or a portion of the sequence of the analyte from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample. 
     In one aspect, provided herein is a method for identifying a location of an analyte in a biological sample, the method comprising: (a) contacting the biological sample with a plurality of undesirable RNA depletion probes, wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; (b) hybridizing the undesirable RNA depletion probe to the undesirable RNA; (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; (d) contacting a plurality of nucleic acids with a plurality of target oligonucleotide probes, wherein a nucleic acid of the plurality of nucleic acids comprises (i) a spatial barcode or a complement thereof, and (ii) a portion of a sequence of an analyte from a biological sample, or a complement thereof; and a target oligonucleotide probe of the plurality of target oligonucleotide probes comprises: a domain that binds specifically to (i) all or a portion of the spatial barcode or a complement thereof, and/or (ii) all or a portion of the sequence of the analyte from the biological sample, or a complement thereof, and a molecular tag; (e) enriching a complex of the target oligonucleotide probe specifically bound to the nucleic acid using a substrate comprising an agent that binds specifically to the molecular tag; and (f) determining (i) all or a portion of the sequence of the spatial barcode or the complement thereof, and (ii) all or a portion of the sequence of the analyte from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample. 
     In some embodiments, the method further comprises generating the plurality of nucleic acids comprises: (a) contacting the biological sample with a substrate comprising a plurality of attached capture probes, wherein a capture probe of the plurality comprises (i) the spatial barcode and (ii) a capture domain that binds specifically to a sequence present in the analyte; (b) extending a 3′ end of the capture probe using the analyte that is specifically bound to the capture domain as a template to generate an extended capture probe; and (c) amplifying the extended capture probe to produce the nucleic acid. 
     In some embodiments, the domain of the target oligonucleotide probe comprises a total of about 40 nucleotides to about 160 nucleotides. 
     In some embodiments, the molecular tag comprises a moiety. In some embodiments, the moiety is streptavidin, avidin, biotin, or a fluorophore. 
     In some embodiments, the molecular tag comprises a small molecule, a nucleic acid, or a carbohydrate. 
     In some embodiments, the molecular tag is positioned 5′ or 3′ to the domain in the target oligonucleotide probe. 
     In some embodiments, the agent that binds specifically to the molecular tag comprises a protein. In some embodiments, the protein is an antibody. 
     In some embodiments, the agent that binds specifically to the molecular tag comprises a nucleic acid. In some embodiments, the nucleic acid is DNA. 
     In some embodiments, the agent that binds specifically to the molecular tag comprises a small molecule. 
     In some embodiments, the analyte from the biological sample is associated with a disease or condition. In some embodiments, the analyte from the biological sample comprises a mutation. In some embodiments, the analyte from the biological sample comprises a single nucleotide polymorphism (SNP). In some embodiments, the analyte from the biological sample comprises a trinucleotide repeat. 
     In some embodiments, the biological sample is a tissue sample. 
     In some embodiments, the tissue sample is a formalin-fixed, paraffin-embedded (FFPE) tissue sample, a fresh or a frozen tissue sample. In some embodiments, the tissue sample is the FFPE tissue sample, and the tissue sample is decrosslinked. 
     In some embodiments, the biological sample was previously stained. In some embodiments, the biological sample was previously stained using hematoxylin and eosin (H&amp;E). In some embodiments, the biological sample was previously stained using immunofluorescence or immunohistochemistry. 
     In some embodiments, the method further comprises contacting the biological sample with a permeabilization agent. 
     In some embodiments, the biological sample is a permeabilized biological sample that has been permeabilized with a permeabilization agent. 
     In some embodiments, the permeabilization agent is selected from an organic solvent, a detergent, and an enzyme, or a combination thereof. In some embodiments, the permeabilization agent is an endopeptidase or protease. In some embodiments, the endopeptidase is pepsin or proteinase K. 
     In some embodiments, the determining step comprises amplifying all or part of the ligated probe specifically bound to the capture domain. 
     In some embodiments, the amplifying is isothermal. In some embodiments, the amplifying is not isothermal. 
     In some embodiments, an amplifying product comprises (i) all or part of sequence of the ligated probe specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof. 
     In some embodiments, the determining step comprises sequencing. 
     In some embodiments, the analyte is RNA. In some embodiments, the RNA is an mRNA. 
     In one aspect, provided herein is a method for enriching a target nucleic acid in a spatial array comprising (a) adding a plurality of undesirable RNA depletion probes to the spatial array, wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the spatial array; (b) hybridizing an undesirable RNA depletion probe to the undesirable RNA; (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; and (d) amplying remaining nucleic acids to enrich the target nuclei acid. 
     In one aspect, provided herein is a method for depleting undesirable RNA molecules in a spatial array, comprising (a) adding a plurality of undesirable RNA depletion probes to the spatial array, wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the spatial array; (b) hybridizing an undesirable RNA depletion probe to the undesirable RNA; and (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes to deplete the undesirable RNA molecules. 
     In some embodiments, the undesirable RNA depletion probe is a DNA probe. 
     In some embodiments, the hybridizing step comprises hybridizing the DNA probe with the undesirable RNA molecule that creates a RNA: DNA hybrid. 
     In some embodiments, the removing step comprises contacting the undesirable RNA depletion probe with a ribonuclease. 
     In some embodiments, the ribonuclease is RNase H. In some embodiments, the RNase H is RNase H1. In some embodiments, the RNase H is RNase H2. In some embodiments, the RNase H is a thermostable RNase. 
     In some embodiments, the undesirable RNA depletion probe is substantially complementary to all or a portion of the sequence of the undesirable RNA molecule in the biological sample. 
     In some embodiments, at least one undesirable RNA depletion probe specifically hybridizes to substantially one or more portions of the sequence of the undesirable RNA molecule. 
     In some embodiments, at least one undesirable RNA depletion probe specifically hybridizes to substantially the entire full length sequence of the undesirable RNA molecule. 
     In some embodiments, the undesirable RNA molecule is a transfer RNA (tRNA), a ribosomal RNA (rRNA), a messenger RNA (mRNA), or any combinations thereof. 
     In some embodiments, the undesirable RNA molecule is a mitochondrial RNA, nuclear RNA, or cytoplasmic RNA. 
     In some embodiments, the undesirable RNA depletion probe further comprises a capture moiety. In some embodiments, the removing step comprises using a capture moiety-binding agent that binds specifically to the capture moiety. 
     In some embodiments, the capture moiety is streptavidin, avidin, biotin, or a fluorophore. In some embodiments, the capture moiety is a biotin. 
     In some embodiments, the capture moiety comprises a small molecule, a nucleic acid, or a carbohydrate. 
     In some embodiments, the capture moiety is positioned 5′ or 3′ to the domain in the undesirable RNA depletion probe. 
     In some embodiments, a capture moiety-binding agent that binds specifically to the capture moiety comprises a protein. 
     In some embodiments, the protein is an antibody. In some embodiments, the protein is streptavidin. 
     In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety comprises a nucleic acid. In some embodiments, the nucleic acid is DNA. 
     In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety comprises a small molecule. 
     In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety is attached to a substrate. 
     In some embodiments, the substrate is a bead. In some embodiments, the bead is a magnetic bead. In some embodiments, the capture moiety is a biotin and the capture moiety-binding agent is streptavidin. In some embodiments, the streptavidin is attached to a magnetic bead that allows the undesirable RNA depletion probe-undesirable RNA complexes to be removed magnetically from the biological sample. 
     In some embodiments, the capture probes are capable of hybridizing to the ligated probe as described herein. 
     In some embodiments, the capture probes further comprises a functional sequence. In some embodiments, the functional sequence is primer sequence or a complement thereof. In some embodiments, the capture probe further comprises a unique molecular sequence or a complement thereof. In some embodiments, the capture probe further comprises an additional primer binding sequence or a complement thereof. 
     In one aspect, provided herein is a kit comprising (a) an array comprising a plurality of capture probes; (b) a plurality of probe oligonucleotides comprising a first probe oligonucleotide and a second oligonucleotide, wherein the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of an analyte, wherein the second probe oligonucleotide comprises a capture probe binding domain that is capable of binding to a capture domain of the capture probe; (c) a plurality of enzymes comprising a ribonuclease and a ligase; and (d) an instruction for using the kit. 
     In some embodiments, the ribonuclease is RNase H. 
     In some embodiments, the ligase is one or more of a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase. In some embodiments, the ligase is a T4 RNA ligase 2 (Rnl2) ligase. 
     All publications, patents, patent applications, and information available on the internet and mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, patent application, or item of information was specifically and individually indicated to be incorporated by reference. To the extent publications, patents, patent applications, and items of information incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material. 
     Where values are described in terms of ranges, it should be understood that the description includes the disclosure of all possible sub-ranges within such ranges, as well as specific numerical values that fall within such ranges irrespective of whether a specific numerical value or specific sub-range is expressly stated. 
     The term “each,” when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise. 
     Various embodiments of the features of this disclosure are described herein. However, it should be understood that such embodiments are provided merely by way of example, and numerous variations, changes, and substitutions can occur to those skilled in the art without departing from the scope of this disclosure. It should also be understood that various alternatives to the specific embodiments described herein are also within the scope of this disclosure. 
    
    
     
       DESCRIPTION OF DRAWINGS 
       The following drawings illustrate certain embodiments of the features and advantages of this disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner. Like reference symbols in the drawings indicate like elements. 
         FIG.  1    is a schematic diagram showing an example of a barcoded capture probe, as described herein. 
         FIG.  2    is a schematic illustrating a cleavable capture probe, wherein the cleaved capture probe can enter into a non-permeabilized cell and bind to target analytes within the sample. 
         FIG.  3    is a schematic diagram of an exemplary multiplexed spatially-barcoded feature. 
         FIG.  4    is a schematic diagram of an exemplary analyte capture agent. 
         FIG.  5    is a schematic diagram depicting an exemplary interaction between a feature-immobilized capture probe  524  and an analyte capture agent  526 . 
         FIGS.  6 A,  6 B, and  6 C  are schematics illustrating how streptavidin cell tags can be utilized in an array-based system to produce spatially-barcoded cells or cellular contents. 
         FIG.  7    shows a schematic workflow illustrating exemplary, non-limiting, non-exhaustive steps for in situ ribosomal RNA depletion. 
         FIG.  8 A  shows a schematic illustrating an exemplary workflow for ribosomal depletion (RD). 
         FIG.  8 B  shows an H&amp;E staining image and an 18S rRNA staining image. No ribosomal depletion was performed. 
         FIG.  8 C  shows an H&amp;E staining image and an 18S rRNA staining image. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  8 D  shows an H&amp;E staining image and an mRNA staining image using polyA probes. No ribosomal depletion was performed. 
         FIG.  8 E  shows an H&amp;E staining image and an mRNA staining image using polyA probes. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  9 A  shows the gene-gene scatter plot between normal and ribosomal depleted mouse olfactory bulb (MOB) tissues. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  9 B  shows the gene-gene scatter plot between normal and ribosomal depleted childhood brain cancer (PNET) tissues. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  9 C  shows the gene-gene scatter plot between normal and ribosomal depleted adipose (fat) tissues. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  10    shows tissue plots illustrating the gene expression level of MT-RNR1 or MT-RNR2 of normal or ribosomal depleted tissues. Ribosomal depletion was performed using RD probes designed to block both the cytoplasmic RNA (18S, 28S, 5S and 5.8S) and mitochondrial RNA (16S and 12S). 
         FIG.  11    shows the UMIs per gene in normal or ribosomal depleted tissues. The tissues include adipose (fat), mouse olfactory bulb (MOB), MOB-181218, and childhood brain cancer (PNET) tissues. 
         FIG.  12    shows the detection rate comparison between normal and ribosomal depleted tissues. The tissues include adipose (fat), mouse olfactory bulb (MOB), MOB-181218, and childhood brain cancer (PNET) tissues. 
         FIG.  13 A  shows tissue plots by Seurat clustering for 7 clusters from a normal tissue. 
         FIG.  13 B  shows tissue plots by Seurat clustering for 7 clusters from a ribosomal depleted tissue. 
         FIG.  14 A  shows a tSNE plot of Seurat clustering corresponding to the tissue plots in  FIG.  13 A . 
         FIG.  14 B  shows a tSNE plot of Seurat clustering corresponding to the tissue plots in  FIG.  13 B . 
         FIG.  15    shows tissue plots of 7 clusters from a normal tissue (same clusters from  FIG.  14 A ). 
         FIG.  16    shows tissue plots of 7 clusters from a ribosomal depleted tissue (same clusters from  FIG.  14 B ). 
         FIG.  17 A  shows tissue plots of 8 clusters from a normal tissue corresponding to the Seurat clusters in the tSNE plot in  FIG.  17 B . The two arrows indicate clusters 1 and 5 (also indicated by numerals). 
         FIG.  17 B  shows a tSNE plot of Seurat clustering corresponding to the indicated tissue plots in  FIG.  17 A . The two arrows indicate clusters 1 and 5 (also indicated by numerals). 
         FIG.  18 A  shows tissue plots of 8 clusters from a ribosomal depleted tissue corresponding to the Seurat clusters in the tSNE plot in  FIG.  18 B . The two arrows indicate clusters 3 and 4, (also indicated by numerals). 
         FIG.  18 B  shows a tSNE plot of Seurat clustering corresponding to the indicated tissue plots in  FIG.  18 A . The two arrows indicate clusters 3 and 4 (also indicated by numerals). 
         FIGS.  19 A- 19 D  show H&amp;E staining images and gene expression heat maps for control samples (samples 1 and 2) and ribosomal depletion samples (samples 3 and 4).  FIGS.  19 B- 19 D  show gene expression heat maps for samples 1˜4 for Penk, Doc2g, and Kctd12, respectively. 
         FIGS.  20 A- 20 D  show gene expression heat maps for control samples (sample 1 and 2) and ribosomal depletion samples (samples 3 and 4).  FIGS.  20 A and  20 B  show gene expression heat maps for house keeping genes: Actb and Gapdh, respectively.  FIGS.  20 C and  20 D  show gene expression heat maps for two targets of the ribosomal depletion probes: mt-Rnr1 and mt-Rnr2, respectively. 
     
    
    
     DETAILED DESCRIPTION 
     I. Introduction 
     Disclosed herein are methods and compositions predicated on using targeted RNA depletion to remove one or more species of undesirable RNA molecules (e.g., ribosomal RNA and/or mitochondrial RNA) to reduce the pool and concentration of undesirable RNA molecules in a sample which could interfere with desired target detection (e.g., detection of mRNA). To achieve depletion, one or more probes are designed that hybridize to one or more undesirable RNA molecules. For example, in one embodiment, probes can be administered to a biological sample that selectively hybridize to ribosomal RNA (rRNA), thereby reducing the pool and concentration of rRNA in the sample. Here, this type of RNA depletion is combined with spatial analysis techniques in order to determine abundance and/or location of one or more analytes in a biological sample. The ability to reduce interference with detection of desired targets by removing undesirable RNA increases efficiency and sensitivity 
     +y of the spatial analysis techniques. For example, subsequent or concurrent application of capture probes to the sample can result in improved capture of other types of RNA (e.g., mRNA or products of RNA-templated ligation) due to a reduction in undesirable RNA (e.g., down-selected RNA) present in the sample. 
     Spatial analysis methodologies and compositions described herein can provide a vast amount of analyte and/or expression data for a variety of analytes within a biological sample at high spatial resolution, while retaining native spatial context. Spatial analysis methods and compositions can include, e.g., the use of a capture probe including a spatial barcode (e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample (e.g., mammalian cell or a mammalian tissue sample) and a capture domain that is capable of binding to an analyte (e.g., a protein and/or a nucleic acid) produced by and/or present in a cell. Spatial analysis methods and compositions can also include the use of a capture probe having a capture domain that captures an intermediate agent for indirect detection of an analyte. For example, the intermediate agent can include a nucleic acid sequence (e.g., a barcode) associated with the intermediate agent. Detection of the intermediate agent is therefore indicative of the analyte in the cell or tissue sample. 
     Non-limiting aspects of spatial analysis methodologies and compositions are described in U.S. Pat. Nos. 10,774,374, 10,724,078, 10,480,022, 10,059,990, 10,041,949, 10,002,316, 9,879,313, 9,783,841, 9,727,810, 9,593,365, 8,951,726, 8,604,182, 7,709,198, U.S. Patent Application Publication Nos. 2020/239946, 2020/080136, 2020/0277663, 2020/024641, 2019/330617, 2019/264268, 2020/256867, 2020/224244, 2019/194709, 2019/161796, 2019/085383, 2019/055594, 2018/216161, 2018/051322, 2018/0245142, 2017/241911, 2017/089811, 2017/067096, 2017/029875, 2017/0016053, 2016/108458, 2015/000854, 2013/171621, WO 2018/091676, WO 2020/176788, Rodrigues et al., Science 363(6434):1463-1467, 2019; Lee et al., Nat. Protoc. 10(3):442-458, 2015; Trejo et al., PLoS ONE 14(2):e0212031, 2019; Chen et al., Science 348(6233):aaa6090, 2015; Gao et al., BMC Biol. 15:50, 2017; and Gupta et al., Nature Biotechnol. 36:1197-1202, 2018; the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020), both of which are available at the 10× Genomics Support Documentation website, and can be used herein in any combination. Further non-limiting aspects of spatial analysis methodologies and compositions are described herein. 
     Some general terminology that may be used in this disclosure can be found in Section (I)(b) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Typically, a “barcode” is a label, or identifier, that conveys or is capable of conveying information (e.g., information about an analyte in a sample, a bead, and/or a capture probe). A barcode can be part of an analyte, or independent of an analyte. A barcode can be attached to an analyte. A particular barcode can be unique relative to other barcodes. For the purpose of this disclosure, an “analyte” can include any biological substance, structure, moiety, or component to be analyzed. The term “target” can similarly refer to an analyte of interest. 
     Analytes can be broadly classified into one of two groups: nucleic acid analytes, and non-nucleic acid analytes. Examples of non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins, phosphoproteins, specific phosphorylated or acetylated variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitylation variants of proteins, sulfation variants of proteins, viral proteins (e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.), extracellular and intracellular proteins, antibodies, and antigen binding fragments. In some embodiments, the analyte(s) can be localized to subcellular location(s), including, for example, organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc. In some embodiments, analyte(s) can be peptides or proteins, including without limitation antibodies and enzymes. Additional examples of analytes can be found in Section (I)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. In some embodiments, an analyte can be detected indirectly, such as through detection of an intermediate agent, for example, a connected probe (e.g., a ligation product) or an analyte capture agent (e.g., an oligonucleotide-conjugated antibody), such as those described herein. 
     A “biological sample” is typically obtained from the subject for analysis using any of a variety of techniques including, but not limited to, biopsy, surgery, and laser capture microscopy (LCM), and generally includes cells and/or other biological material from the subject. In some embodiments, a biological sample can be a tissue section. In some embodiments, a biological sample can be a fixed and/or stained biological sample (e.g., a fixed and/or stained tissue section). Non-limiting examples of stains include histological stains (e.g., hematoxylin and/or eosin) and immunological stains (e.g., fluorescent stains). In some embodiments, a biological sample (e.g., a fixed and/or stained biological sample) can be imaged. Biological samples are also described in Section (I)(d) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     In some embodiments, a biological sample is permeabilized with one or more permeabilization reagents. For example, permeabilization of a biological sample can facilitate analyte capture. Exemplary permeabilization agents and conditions are described in Section (I)(d)(ii)(13) or the Exemplary Embodiments Section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     Array-based spatial analysis methods involve the transfer of one or more analytes from a biological sample to an array of features on a substrate, where each feature is associated with a unique spatial location on the array. Subsequent analysis of the transferred analytes includes determining the identity of the analytes and the spatial location of the analytes within the biological sample. The spatial location of an analyte within the biological sample is determined based on the feature to which the analyte is bound (e.g., directly or indirectly) on the array, and the feature&#39;s relative spatial location within the array. 
     A “capture probe” refers to any molecule capable of capturing (directly or indirectly) and/or labelling an analyte (e.g., an analyte of interest) in a biological sample. In some embodiments, the capture probe is a nucleic acid or a polypeptide. In some embodiments, the capture probe includes a barcode (e.g., a spatial barcode and/or a unique molecular identifier (UMI)) and a capture domain). In some embodiments, a capture probe can include a cleavage domain and/or a functional domain (e.g., a primer-binding site, such as for next-generation sequencing (NGS)). 
       FIG.  1    is a schematic diagram showing an exemplary capture probe, as described herein. As shown, the capture probe  102  is optionally coupled to a feature  101  by a cleavage domain  103 , such as a disulfide linker. The capture probe can include a functional sequence  104  that is useful for subsequent processing. The functional sequence  104  can include all or a part of sequencer specific flow cell attachment sequence (e.g., a P5 or P7 sequence), all or a part of a sequencing primer sequence, (e.g., a R1 primer binding site, a R2 primer binding site), or combinations thereof. The capture probe can also include a spatial barcode  105 . The capture probe can also include a unique molecular identifier (UMI) sequence  106 . While  FIG.  1    shows the spatial barcode  105  as being located upstream (5′) of UMI sequence  106 , it is to be understood that capture probes wherein UMI sequence  106  is located upstream (5′) of the spatial barcode  105  is also suitable for use in any of the methods described herein. The capture probe can also include a capture domain  107  to facilitate capture of a target analyte. The capture domain can have a sequence complementary to a sequence of a nucleic acid analyte. The capture domain can have a sequence complementary to a connected probe described herein. The capture domain can have a sequence complementary to a capture handle sequence present in an analyte capture agent. The capture domain can have a sequence complementary to a splint oligonucleotide. Such splint oligonucleotide, in addition to having a sequence complementary to a capture domain of a capture probe, can have a sequence of a nucleic acid analyte, a sequence complementary to a portion of a connected probe described herein, and/or a capture handle sequence described herein. 
     The functional sequences can generally be selected for compatibility with any of a variety of different sequencing systems, e.g., Ion Torrent Proton or PGM, Illumina sequencing instruments, PacBio, Oxford Nanopore, etc., and the requirements thereof. In some embodiments, functional sequences can be selected for compatibility with non-commercialized sequencing systems. Examples of such sequencing systems and techniques, for which suitable functional sequences can be used, include (but are not limited to) Ion Torrent Proton or PGM sequencing, Illumina sequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing. Further, in some embodiments, functional sequences can be selected for compatibility with other sequencing systems, including non-commercialized sequencing systems. 
     In some embodiments, the spatial barcode  105  and functional sequences  104  are common to all of the probes attached to a given feature. In some embodiments, the UMI sequence  106  of a capture probe attached to a given feature is different from the UMI sequence of a different capture probe attached to the given feature. 
       FIG.  2    is a schematic illustrating a cleavable capture probe, wherein the cleaved capture probe can enter into a non-permeabilized cell and bind to analytes within the sample. The capture probe  201  contains a cleavage domain  202 , a cell penetrating peptide  203 , a reporter molecule  204 , and a disulfide bond (—S—S—).  205  represents all other parts of a capture probe, for example a spatial barcode and a capture domain. 
       FIG.  3    is a schematic diagram of an exemplary multiplexed spatially-barcoded feature. In  FIG.  3   , the feature  301  can be coupled to spatially-barcoded capture probes, wherein the spatially-barcoded probes of a particular feature can possess the same spatial barcode, but have different capture domains designed to associate the spatial barcode of the feature with more than one target analyte. For example, a feature may be coupled to four different types of spatially-barcoded capture probes, each type of spatially-barcoded capture probe possessing the spatial barcode  302 . One type of capture probe associated with the feature includes the spatial barcode  302  in combination with a poly(T) capture domain  303 , designed to capture mRNA target analytes. A second type of capture probe associated with the feature includes the spatial barcode  302  in combination with a random N-mer capture domain  304  for gDNA analysis. A third type of capture probe associated with the feature includes the spatial barcode  302  in combination with a capture domain complementary to a capture handle sequence of an analyte capture agent of interest  305 . A fourth type of capture probe associated with the feature includes the spatial barcode  302  in combination with a capture domain that can specifically bind a nucleic acid molecule  306  that can function in a CRISPR assay (e.g., CRISPR/Cas9). While only four different capture probe-barcoded constructs are shown in  FIG.  3   , capture-probe barcoded constructs can be tailored for analyses of any given analyte associated with a nucleic acid and capable of binding with such a construct. For example, the schemes shown in  FIG.  3    can also be used for concurrent analysis of other analytes disclosed herein, including, but not limited to: (a) mRNA, a lineage tracing construct, cell surface or intracellular proteins and metabolites, and gDNA; (b) mRNA, accessible chromatin (e.g., ATAC-seq, DNase-seq, and/or MNase-seq) cell surface or intracellular proteins and metabolites, and a perturbation agent (e.g., a CRISPR crRNA/sgRNA, TALEN, zinc finger nuclease, and/or antisense oligonucleotide as described herein); (c) mRNA, cell surface or intracellular proteins and/or metabolites, a barcoded labelling agent (e.g., the MHC multimers described herein), and a V(D)J sequence of an immune cell receptor (e.g., T-cell receptor). In some embodiments, a perturbation agent can be a small molecule, an antibody, a drug, an aptamer, a miRNA, a physical environmental (e.g., temperature change), or any other known perturbation agents. See, e.g., Section (II)(b) (e.g., subsections (i)-(vi)) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Generation of capture probes can be achieved by any appropriate method, including those described in Section (II)(d)(ii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     In some embodiments, more than one analyte type (e.g., nucleic acids and proteins) from a biological sample can be detected (e.g., simultaneously or sequentially) using any appropriate multiplexing technique, such as those described in Section (IV) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     In some embodiments, detection of one or more analytes (e.g., protein analytes) can be performed using one or more analyte capture agents. As used herein, an “analyte capture agent” refers to an agent that interacts with an analyte (e.g., an analyte in a biological sample) and with a capture probe (e.g., a capture probe attached to a substrate or a feature) to identify the analyte. In some embodiments, the analyte capture agent includes: (i) an analyte binding moiety (e.g., that binds to an analyte), for example, an antibody or antigen-binding fragment thereof; (ii) analyte binding moiety barcode; and (iii) a capture handle sequence. As used herein, the term “analyte binding moiety barcode” refers to a barcode that is associated with or otherwise identifies the analyte binding moiety. As used herein, the term “analyte capture sequence” or “capture handle sequence” refers to a region or moiety configured to hybridize to, bind to, couple to, or otherwise interact with a capture domain of a capture probe. In some embodiments, a capture handle sequence is complementary to a capture domain of a capture probe. In some cases, an analyte binding moiety barcode (or portion thereof) may be able to be removed (e.g., cleaved) from the analyte capture agent. 
       FIG.  4    is a schematic diagram of an exemplary analyte capture agent  402  comprised of an analyte-binding moiety  404  and an analyte-binding moiety barcode domain  408 . The exemplary analyte-binding moiety  404  is a molecule capable of binding to an analyte  406  and the analyte capture agent is capable of interacting with a spatially-barcoded capture probe. The analyte-binding moiety can bind to the analyte  406  with high affinity and/or with high specificity. The analyte capture agent can include an analyte-binding moiety barcode domain  408 , a nucleotide sequence (e.g., an oligonucleotide), which can hybridize to at least a portion or an entirety of a capture domain of a capture probe. The analyte-binding moiety barcode domain  408  can comprise an analyte binding moiety barcode and a capture handle sequence described herein. The analyte-binding moiety  404  can include a polypeptide and/or an aptamer. The analyte-binding moiety  404  can include an antibody or antibody fragment (e.g., an antigen-binding fragment). 
       FIG.  5    is a schematic diagram depicting an exemplary interaction between a feature-immobilized capture probe  524  and an analyte capture agent  526 . The feature-immobilized capture probe  524  can include a spatial barcode  508  as well as functional sequences  506  and UMI  510 , as described elsewhere herein. The capture probe can also include a capture domain  512  that is capable of binding to an analyte capture agent  526 . The analyte capture agent  526  can include a functional sequence  518 , analyte binding moiety barcode  516 , and a capture handle sequence  514  that is capable of binding to the capture domain  512  of the capture probe  524 . The analyte capture agent can also include a linker  520  that allows the capture agent barcode domain  516  to couple to the analyte binding moiety  522 . 
       FIGS.  6 A,  6 B, and  6 C  are schematics illustrating how streptavidin cell tags can be utilized in an array-based system to produce a spatially-barcoded cell or cellular contents. For example, as shown in  FIG.  6 A , peptide-bound major histocompatibility complex (MHC) can be individually associated with biotin (β2m) and bound to a streptavidin moiety such that the streptavidin moiety comprises multiple pMHC moieties. Each of these moieties can bind to a TCR such that the streptavidin binds to a target T-cell via multiple MHC/TCR binding interactions. Multiple interactions synergize and can substantially improve binding affinity. Such improved affinity can improve labelling of T-cells and also reduce the likelihood that labels will dissociate from T-cell surfaces. As shown in  FIG.  6 B , a capture agent barcode domain  601  can be modified with streptavidin  602  and contacted with multiple molecules of biotinylated MHC  603  such that the biotinylated MHC  603  molecules are coupled with the streptavidin conjugated capture agent barcode domain  601 . The result is a barcoded MHC multimer complex  605 . As shown in  FIG.  6 B , the capture agent barcode domain sequence  601  can identify the MHC as its associated label and also includes optional functional sequences such as sequences for hybridization with other oligonucleotides. As shown in  FIG.  6 C , one example oligonucleotide is capture probe  606  that comprises a complementary sequence (e.g., rGrGrG corresponding to C C C), a barcode sequence and other functional sequences, such as, for example, a UMI, an adapter sequence (e.g., comprising a sequencing primer sequence (e.g., R1 or a partial R1 (“pR1”), R2), a flow cell attachment sequence (e.g., P5 or P7 or partial sequences thereof)), etc. In some cases, capture probe  606  may at first be associated with a feature (e.g., a gel bead) and released from the feature. In other embodiments, capture probe  606  can hybridize with a capture agent barcode domain  601  of the MHC-oligonucleotide complex  605 . The hybridized oligonucleotides (Spacer C C C and Spacer rGrGrG) can then be extended in primer extension reactions such that constructs comprising sequences that correspond to each of the two spatial barcode sequences (the spatial barcode associated with the capture probe, and the barcode associated with the MHC-oligonucleotide complex) are generated. In some cases, one or both of the corresponding sequences may be a complement of the original sequence in capture probe  606  or capture agent barcode domain  601 . In other embodiments, the capture probe and the capture agent barcode domain are ligated together. The resulting constructs can be optionally further processed (e.g., to add any additional sequences and/or for clean-up) and subjected to sequencing. As described elsewhere herein, a sequence derived from the capture probe  606  spatial barcode sequence may be used to identify a feature and the sequence derived from spatial barcode sequence on the capture agent barcode domain  601  may be used to identify the particular peptide MHC complex  604  bound on the surface of the cell (e.g., when using MHC-peptide libraries for screening immune cells or immune cell populations). 
     Additional description of analyte capture agents can be found in Section (II)(b)(ix) of WO 2020/176788 and/or Section (II)(b)(viii) U.S. Patent Application Publication No. 2020/0277663. 
     There are at least two methods to associate a spatial barcode with one or more neighboring cells, such that the spatial barcode identifies the one or more cells, and/or contents of the one or more cells, as associated with a particular spatial location. One method is to promote analytes or analyte proxies (e.g., intermediate agents) out of a cell and towards a spatially-barcoded array (e.g., including spatially-barcoded capture probes). Another method is to cleave spatially-barcoded capture probes from an array and promote the spatially-barcoded capture probes towards and/or into or onto the biological sample. 
     In some cases, capture probes may be configured to prime, replicate, and consequently yield optionally barcoded extension products from a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a connected probe (e.g., a ligation product) or an analyte capture agent), or a portion thereof), or derivatives thereof (see, e.g., Section (II)(b)(vii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663 regarding extended capture probes). In some cases, capture probes may be configured to form a connected probe (e.g., a ligation product) with a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof), thereby creating ligations products that serve as proxies for a template. 
     As used herein, an “extended capture probe” refers to a capture probe having additional nucleotides added to the terminus (e.g., 3′ or 5′ end) of the capture probe thereby extending the overall length of the capture probe. For example, an “extended 3′ end” indicates additional nucleotides were added to the most 3′ nucleotide of the capture probe to extend the length of the capture probe, for example, by polymerization reactions used to extend nucleic acid molecules including templated polymerization catalyzed by a polymerase (e.g., a DNA polymerase or a reverse transcriptase). In some embodiments, extending the capture probe includes adding to a 3′ end of a capture probe a nucleic acid sequence that is complementary to a nucleic acid sequence of an analyte or intermediate agent specifically bound to the capture domain of the capture probe. In some embodiments, the capture probe is extended using reverse transcription. In some embodiments, the capture probe is extended using one or more DNA polymerases. The extended capture probes include the sequence of the capture probe and the sequence of the spatial barcode of the capture probe. 
     In some embodiments, extended capture probes are amplified (e.g., in bulk solution or on the array) to yield quantities that are sufficient for downstream analysis, e.g., via DNA sequencing. In some embodiments, extended capture probes (e.g., DNA molecules) act as templates for an amplification reaction (e.g., a polymerase chain reaction). 
     Additional variants of spatial analysis methods, including in some embodiments, an imaging step, are described in Section (II)(a) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Analysis of captured analytes (and/or intermediate agents or portions thereof), for example, including sample removal, extension of capture probes, sequencing (e.g., of a cleaved extended capture probe and/or a cDNA molecule complementary to an extended capture probe), sequencing on the array (e.g., using, for example, in situ hybridization or in situ ligation approaches), temporal analysis, and/or proximity capture, is described in Section (II)(g) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Some quality control measures are described in Section (II)(h) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     Spatial information can provide information of biological and/or medical importance. For example, the methods and compositions described herein can allow for: identification of one or more biomarkers (e.g., diagnostic, prognostic, and/or for determination of efficacy of a treatment) of a disease or disorder; identification of a candidate drug target for treatment of a disease or disorder; identification (e.g., diagnosis) of a subject as having a disease or disorder; identification of stage and/or prognosis of a disease or disorder in a subject; identification of a subject as having an increased likelihood of developing a disease or disorder; monitoring of progression of a disease or disorder in a subject; determination of efficacy of a treatment of a disease or disorder in a subject; identification of a patient subpopulation for which a treatment is effective for a disease or disorder; modification of a treatment of a subject with a disease or disorder; selection of a subject for participation in a clinical trial; and/or selection of a treatment for a subject with a disease or disorder. 
     Spatial information can provide information of biological importance. For example, the methods and compositions described herein can allow for: identification of transcriptome and/or proteome expression profiles (e.g., in healthy and/or diseased tissue); identification of multiple analyte types in close proximity (e.g., nearest neighbor analysis); determination of up- and/or down-regulated genes and/or proteins in diseased tissue; characterization of tumor microenvironments; characterization of tumor immune responses; characterization of cells types and their co-localization in tissue; and identification of genetic variants within tissues (e.g., based on gene and/or protein expression profiles associated with specific disease or disorder biomarkers). 
     Typically, for spatial array-based methods, a substrate functions as a support for direct or indirect attachment of capture probes to features of the array. A “feature” is an entity that acts as a support or repository for various molecular entities used in spatial analysis. In some embodiments, some or all of the features in an array are functionalized for analyte capture. Exemplary substrates are described in Section (II)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. Exemplary features and geometric attributes of an array can be found in Sections (II)(d)(i), (II)(d)(iii), and (II)(d)(iv) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     Generally, analytes and/or intermediate agents (or portions thereof) can be captured when contacting a biological sample with a substrate including capture probes (e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells) comprising capture probes). As used herein, “contact,” “contacted,” and/or “contacting,” a biological sample with a substrate refers to any contact (e.g., direct or indirect) such that capture probes can interact (e.g., bind covalently or non-covalently (e.g., hybridize)) with analytes from the biological sample. Capture can be achieved actively (e.g., using electrophoresis) or passively (e.g., using diffusion). Analyte capture is further described in Section (II)(e) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     In some cases, spatial analysis can be performed by attaching and/or introducing a molecule (e.g., a peptide, a lipid, or a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., to a cell in a biological sample). In some embodiments, a plurality of molecules (e.g., a plurality of nucleic acid molecules) having a plurality of barcodes (e.g., a plurality of spatial barcodes) are introduced to a biological sample (e.g., to a plurality of cells in a biological sample) for use in spatial analysis. In some embodiments, after attaching and/or introducing a molecule having a barcode to a biological sample, the biological sample can be physically separated (e.g., dissociated) into single cells or cell groups for analysis. Some such methods of spatial analysis are described in Section (III) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. 
     In some cases, spatial analysis can be performed by detecting multiple oligonucleotides that hybridize to an analyte. In some instances, for example, spatial analysis can be performed using RNA-templated ligation (RTL). Methods of RTL have been described previously. See, e.g., Credle et al., Nucleic Acids Res. 2017 Aug. 21; 45(14):e128. Typically, RTL includes hybridization of two oligonucleotides to adjacent sequences on an analyte (e.g., an RNA molecule, such as an mRNA molecule). In some instances, the oligonucleotides are DNA molecules. In some instances, one of the oligonucleotides includes at least two ribonucleic acid bases at the 3′ end and/or the other oligonucleotide includes a phosphorylated nucleotide at the 5′ end. In some instances, one of the two oligonucleotides includes a capture domain (e.g., a poly(A) sequence, a non-homopolymeric sequence). After hybridization to the analyte, a ligase (e.g., SplintR ligase) ligates the two oligonucleotides together, creating a connected probe (e.g., a ligation product). In some instances, the two oligonucleotides hybridize to sequences that are not adjacent to one another. For example, hybridization of the two oligonucleotides creates a gap between the hybridized oligonucleotides. In some instances, a polymerase (e.g., a DNA polymerase) can extend one of the oligonucleotides prior to ligation. After ligation, the connected probe (e.g., a ligation product) is released from the analyte. In some instances, the connected probe (e.g., a ligation product) is released using an endonuclease (e.g., RNAse H). The released connected probe (e.g., a ligation product) can then be captured by capture probes (e.g., instead of direct capture of an analyte) on an array, optionally amplified, and sequenced, thus determining the location and optionally the abundance of the analyte in the biological sample. 
     During analysis of spatial information, sequence information for a spatial barcode associated with an analyte is obtained, and the sequence information can be used to provide information about the spatial distribution of the analyte in the biological sample. Various methods can be used to obtain the spatial information. In some embodiments, specific capture probes and the analytes they capture are associated with specific locations in an array of features on a substrate. For example, specific spatial barcodes can be associated with specific array locations prior to array fabrication, and the sequences of the spatial barcodes can be stored (e.g., in a database) along with specific array location information, so that each spatial barcode uniquely maps to a particular array location. 
     Alternatively, specific spatial barcodes can be deposited at predetermined locations in an array of features during fabrication such that at each location, only one type of spatial barcode is present so that spatial barcodes are uniquely associated with a single feature of the array. Where necessary, the arrays can be decoded using any of the methods described herein so that spatial barcodes are uniquely associated with array feature locations, and this mapping can be stored as described above. 
     When sequence information is obtained for capture probes and/or analytes during analysis of spatial information, the locations of the capture probes and/or analytes can be determined by referring to the stored information that uniquely associates each spatial barcode with an array feature location. In this manner, specific capture probes and captured analytes are associated with specific locations in the array of features. Each array feature location represents a position relative to a coordinate reference point (e.g., an array location, a fiducial marker) for the array. Accordingly, each feature location has an “address” or location in the coordinate space of the array. 
     Some exemplary spatial analysis workflows are described in the Exemplary Embodiments section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See, for example, the Exemplary embodiment starting with “In some non-limiting examples of the workflows described herein, the sample can be immersed . . . ” of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See also, e.g., the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020). 
     In some embodiments, spatial analysis can be performed using dedicated hardware and/or software, such as any of the systems described in Sections (II)(e)(ii) and/or (V) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, or any of one or more of the devices or methods described in Sections Control Slide for Imaging, Methods of Using Control Slides and Substrates for, Systems of Using Control Slides and Substrates for Imaging, and/or Sample and Array Alignment Devices and Methods, Informational labels of WO 2020/123320. 
     Suitable systems for performing spatial analysis can include components such as a chamber (e.g., a flow cell or sealable, fluid-tight chamber) for containing a biological sample. The biological sample can be mounted for example, in a biological sample holder. One or more fluid chambers can be connected to the chamber and/or the sample holder via fluid conduits, and fluids can be delivered into the chamber and/or sample holder via fluidic pumps, vacuum sources, or other devices coupled to the fluid conduits that create a pressure gradient to drive fluid flow. One or more valves can also be connected to fluid conduits to regulate the flow of reagents from reservoirs to the chamber and/or sample holder. 
     The systems can optionally include a control unit that includes one or more electronic processors, an input interface, an output interface (such as a display), and a storage unit (e.g., a solid state storage medium such as, but not limited to, a magnetic, optical, or other solid state, persistent, writeable and/or re-writeable storage medium). The control unit can optionally be connected to one or more remote devices via a network. The control unit (and components thereof) can generally perform any of the steps and functions described herein. Where the system is connected to a remote device, the remote device (or devices) can perform any of the steps or features described herein. The systems can optionally include one or more detectors (e.g., CCD, CMOS) used to capture images. The systems can also optionally include one or more light sources (e.g., LED-based, diode-based, lasers) for illuminating a sample, a substrate with features, analytes from a biological sample captured on a substrate, and various control and calibration media. 
     The systems can optionally include software instructions encoded and/or implemented in one or more of tangible storage media and hardware components such as application specific integrated circuits. The software instructions, when executed by a control unit (and in particular, an electronic processor) or an integrated circuit, can cause the control unit, integrated circuit, or other component executing the software instructions to perform any of the method steps or functions described herein. 
     In some cases, the systems described herein can detect (e.g., register an image) the biological sample on the array. Exemplary methods to detect the biological sample on an array are described in PCT Application No. 2020/061064 and/or U.S. patent application Ser. No. 16/951,854. 
     Prior to transferring analytes from the biological sample to the array of features on the substrate, the biological sample can be aligned with the array. Alignment of a biological sample and an array of features including capture probes can facilitate spatial analysis, which can be used to detect differences in analyte presence and/or level within different positions in the biological sample, for example, to generate a three-dimensional map of the analyte presence and/or level. Exemplary methods to generate a two- and/or three-dimensional map of the analyte presence and/or level are described in PCT Application No. 2020/053655 and spatial analysis methods are generally described in WO 2020/061108 and/or U.S. patent application Ser. No. 16/951,864. 
     In some cases, a map of analyte presence and/or level can be aligned to an image of a biological sample using one or more fiducial markers, e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in the Substrate Attributes Section, Control Slide for Imaging Section of WO 2020/123320, PCT Application No. 2020/061066, and/or U.S. patent application Ser. No. 16/951,843. Fiducial markers can be used as a point of reference or measurement scale for alignment (e.g., to align a sample and an array, to align two substrates, to determine a location of a sample or array on a substrate relative to a fiducial marker) and/or for quantitative measurements of sizes and/or distances. 
     II. Targeted RNA Depletion 
     Targeted RNA depletion allows for depletion or removal of one or more species of undesirable RNA molecules (e.g., ribosomal RNA and/or mitochondrial RNA), thereby reducing the pool and concentration of undesirable RNA molecules in the sample which could interfere with desired target detection (e.g., detection of mRNA). To achieve depletion, one or more probes are designed that hybridize to one or more undesirable RNA molecules. For example, in one embodiment, probes can be administered to a biological sample that selectively hybridize to ribosomal RNA (rRNA), thereby reducing the pool and concentration of rRNA in the sample. In one embodiment, probes can be administered to a biological sample that selectively hybridize to mitochondria RNA (mtRNA), thereby reducing the pool and concentration of mtRNA in the sample. Subsequent or concurrent application of capture probes to the sample can result in improved capture of other types of RNA due to a reduction in undesirable RNA (e.g., down-selected RNA) present in the sample. 
     A non-limiting example of a method for identifying a location of an analyte (e.g., any of the analytes described herein) in a biological sample using targeted RNA depletion includes: (a) contacting the biological sample with a plurality of undesirable RNA depletion probes (e.g., any of the undesirable RNA depletion probes described herein), wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to all or a portion of the sequence of an undesirable RNA molecule (e.g., any of the undesirable RNA molecules described herein) in the biological sample; (b) hybridizing the undesirable RNA depletion probe to the undesirable RNA (e.g., using any of the methods for hybridizing the undesirable RNA depletion probe to the undesirable RNA described herein); (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes (e.g., using any of the methods for removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes described herein); (d) contacting the biological sample with a substrate (e.g., any of the substrates described herein) comprising a plurality of attached capture probes (e.g., any of the capture probes described herein), wherein a capture probe of the plurality includes (i) the spatial barcode (e.g., any of the spatial barcode described herein) and (ii) a capture domain (e.g., any of the capture domains described herein) that binds specifically to a sequence present in the analyte; (e) extending a 3′ end of the capture probe using the analyte that is specifically bound to the capture domain as a template to generate an extended capture probe; and (f) amplifying (e.g., using any of the methods for amplifying described herein) the extended capture probe to produce a nucleic acid. 
     A non-limiting example of a method for identifying a location of an analyte in a biological sample using RNA-templated ligation and targeted RNA depletion includes: (a) contacting a biological sample with a first probe oligonucleotide, a second probe oligonucleotide, and a plurality of undesirable RNA depletion probes, wherein the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of the analyte, wherein the second probe oligonucleotide includes a capture probe binding domain that is capable of binding to a capture domain of a capture probe, and wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample (b) hybridizing the first probe oligonucleotide and the second probe oligonucleotide to the analyte; (c) hybridizing the undesirable RNA depletion probe to the undesirable RNA molecule; (d) ligating the first probe oligonucleotide and the second probe oligonucleotide, thereby creating a ligated probe that is substantially complementary to the analyte; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes and releasing the ligated probe from the analyte; (f) hybridizing the capture probe binding domain of the ligated probe to a capture domain of a capture probe that is affixed to the substrate; and (g) determining (i) all or a part of the sequence of the ligated probe specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof, and using the determined sequence of (i) and (ii) to identify the location of the analyte in the biological sample. 
     A non-limiting example of the methods described herein using undesirable RNA depletion probes is shown in  FIG.  7 A  biological sample is contacted with undesirable RNA depletion probes  701  (e.g., ribosomal depletion probes) where the undesirable RNA depletion probes hybridize  703  to an undesirable RNA molecule  702  (e.g., rRNA). The RNA depletion probes can be ligated together, or not ligated together. The undesirable RNA that is bound to the undesirable RNA depletion probe are digested enzymatically  704  using RNAse H  705 . Treatment with RNAse H results in digested undesirable RNA  706 . In some embodiments where the RNA depletion probes are combined with RNA-template ligation, the method described in  FIG.  7    can happen prior to or concurrent with RTL probe (e.g., RHS and LHS probes) hybridization and ligation reaction with the target mRNA. The RNase H digestion of the RNA of the RNA:DNA hybrids of the RNA depletion method can happened concurrent with that for the mRNA of the target mRNA:DNA probe hybrids created for the RNA templated ligation reaction. In some embodiments, the methods described in  FIG.  7    can also be performed in any spatial analysis methodology which would benefit from the removal of undesirable RNA species. For example, RNA depletion as described herein could also be used in conjunction with the direct capture of a mRNA by the capture probe. 
     Upon depletion of the undesirable RNA, the sample will contain an enriched population of the RNA target of interest (e.g., an mRNA target). In some embodiments, the undesirable RNA comprises less than 20%, 19%, 18%, 17%, 16% 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or any range therein, of the total RNA in the sample after depletion of the undesirable RNA (i.e., less than 20%, 19%, 18%, 17%, 16% 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1%, or any range therein compared to a sample that undergoes no depletion step). Consequently, the enriched population of the RNA target of interest may comprise at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, or 80%, or any range therein, of the total RNA in the sample. 
     (a) Undesirable RNA Molecule(s) 
     As used herein, the term “undesirable RNA molecule”, or “undesirable RNA”, refers to an undesired RNA that is the target for depletion from the biological sample. In some embodiments, examples of the undesirable RNA include, but are not limited to, messenger RNA (mRNA), ribosomal RNA (rRNA), mitochondrial RNA (mtRNA), transfer RNA (tRNA), microRNA (miRNA), and viral RNA. In some embodiments, the undesirable RNA can be a transcript (e.g., present in a tissue section). 
     In some embodiments, the undesirable RNA molecule includes 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), a small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA), and small rDNA-derived RNA (srRNA), or mitochondrial RNA (mtRNA). In some embodiments, the undesirable RNA molecule includes an RNA molecule that is added (e.g., transfected) into a sample (e.g., a small interfering RNA (siRNA)). The undesirable RNA can be double-stranded RNA or single-stranded RNA. In embodiments where the undesirable RNA is double-stranded it is processed as a single-stranded RNA prior to depletion. In some embodiments, the undesirable RNA can be circular RNA. In some embodiments, the undesirable RNA can be a bacterial rRNA (e.g., 16s rRNA or 23s rRNA). In some embodiments, the undesirable RNA is from  E. coli.    
     In some embodiments, the undesirable RNA molecule is rRNA. In some embodiments, the rRNA is eukaryotic rRNA. In some embodiments, the rRNA is cytoplasmic rRNA. In some embodiments, the rRNA is mitochondrial rRNA. Cytoplasmic rRNAs include, for example, 28S, 5.8S, 5S and 18S rRNAs. Mitochondrial rRNAs include, for example, 12S and 16S rRNAs. The rRNA may also be prokaryotic rRNA, which includes, for example, 5S, 16S, and 23S rRNA. The sequences for rRNAs are well known to those skilled in the art and can be readily found in sequence databases such as GenBank or may be found in the literature. For example, the sequence for the human 18S rRNA can be found in GenBank as Accession No. M10098 and the human 28S rRNA as Accession No. M11167. 
     In some embodiments, the undesirable RNA molecule is mitochondrial RNA. Mitochondrial RNAs include, for example, 12S rRNA (encoded by MT-RNR1), and 16S rRNA (encoded by MT-RNR2), RNAs encoding electron transport chain proteins (e.g., NADH dehydrogenase, coenzyme Q-cytochrome c reductase/cytochrome b, cytochrome c oxidase, ATP synthase, or humanin), and tRNAs (encoded by MT-TA, MT-TR, MT-TN, MT-TD, MT-TC, MT-TE, MT-TQ, MT-TG, MT-TH, MT-TI, MT-TL1, MT-TL2, MT-TK, MT-TM, MT-TF, MT-TP, MT-TS1, MT-TS2, MT-TT, MT-TW, MT-TY, or MT-TV). 
     In some embodiments, the undesirable RNA is transfer RNA (tRNA). In some embodiments, the undesirable RNA may be a particular mRNA. For example, it may be desirable to remove cellular transcripts that are usually present in abundance. Thus, the undesirable mRNA may include, but is not limited to, ACTB, GAPDH, and TUBB. Other sequences for tRNA and specific mRNA are well known to those skilled in the art and can be readily found in sequence databases such as GenBank or may be found in the literature. 
     In some embodiments, mRNA is not targeted for depletion by undesirable RNA probes. In some embodiments, one or more undesirable RNA depletion probes do not have a poly-dT that will hybridize to the poly-A tail of eukaryotic mRNA. In yet another particular embodiment, the undesirable RNA depletion probe targets and specifically hybridizes to human 18S or human 28S rRNA. Examples of the sequence of undesirable RNA depletion probes targeting the full length sequence of human 18S and human 28S rRNA are illustrated in, e.g., US Appl. Publ. No. 2011/0111409 A1, which is incorporated herein by reference. 
     In some embodiments, the one or more undesirable RNA molecules is a single species of RNA. For example, in some embodiments, the one or more undesirable RNA molecule hybridizes only ribosomal RNA molecules. In some embodiments, the one or more undesirable RNA molecule hybridizes only mitochondrial RNA molecules. In some embodiments, the undesirable RNA molecule can be a combination of two or more species of RNA. In some embodiments, the undesirable RNA molecule is an RNA fragment of one of the undesirable RNA molecules described herein. In some embodiments, the undesirable RNA molecule is a full length RNA molecule of one of the undesirable RNA molecules described herein. 
     (b) Design of Undesirable RNA Depletion Probes 
     In some embodiments, the one or more undesirable RNA depletion probes is a DNA probe. In some embodiments, the DNA probe includes a single-stranded DNA oligonucleotide having a sequence partially or completely complementary to an undesirable RNA and specifically hybridizes to the undesirable RNA. In some embodiments, the one or more undesirable RNA depletion probes are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to one or more undesirable RNA molecules. In some embodiments, the one or more undesirable RNA depletion probes is 100% (i.e., completely) complementary to one or more undesirable RNA molecules. 
     In some embodiments, probes used herein have been described in Morlan et al., PLoS One. 2012; 7(8):e42882, which is incorporated by reference in its entirety. In some embodiments, probes used herein have been described in U.S. Appl. Publ. No. 2011/0111409, which is incorporated by reference in its entirety. In some embodiments, probes used herein have been described in Adiconis et al., Nat Methods. 2013 July; 10(7):623-9, which is incorporated by reference in its entirety. 
     The DNA probe can be produced by techniques known in the art. For example, in some embodiments, a DNA probe is produced by chemical synthesis, by in vitro expression from recombinant nucleic acid molecules, or by in vivo expression from recombinant nucleic acid molecules. The undesirable RNA depletion probe may also be produced by amplification of the undesirable RNA, e.g., RT-PCR, asymmetric PCR, or rolling circle amplification. 
     In some embodiments, the methods of targeted RNA depletion as disclosed herein include multiple undesirable RNA depletion probes. In some embodiments, the undesirable RNA depletion probes include sequences that are complementary or substantially complementary to one or more undesirable RNA molecules. Methods provided herein may be applied to a single undesirable RNA molecule or a plurality of undesirable RNA molecules. 
     In some embodiments, the undesirable RNA depletion probe is about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52 about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, about 75, about 76, about 77, about 78, about 79, about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1500, about 2000, about 3000, about 4000, or about 5000 nucleotides in length. 
     In some embodiments, a single undesirable RNA depletion probe spans the entire length of the undesirable RNA. In some embodiments, the undesirable RNA depletion probe has regions that are not complementary to un undesirable RNA, so long as such sequences do not substantially affect specific hybridization of the undesirable RNA depletion probe to the undesirable RNA. In some embodiments, the depletion probes are not contiguous, such that while they may collectively hybridize across a length of the undesirable RNA there may exist gaps between the individual depletion probes. For example, in some embodiments, the RNA depletion probes that target an undesirable RNA are spaced at least one, at least two, at least 5, at least 10, at least 20, at least 30, at least 50, at least 60 nucleotides apart along the length of the undesirable RNA. As such, there may be a plurality of RNA depletion probes that will hybridize adjacent to, or non-contiguous to, each other along the length, or partially along the length, of the undesirable RNA molecule. 
     In some embodiments, the undesirable RNA depletion probe is associated with (e.g., conjugated to) a detectable label, an optical label, and or a label as described herein. In some instances, the detectable label is a radioisotope, a fluorescent or chemiluminescent moiety, with an enzyme or ligand, which can be used for detection or confirmation that the probe has hybridized to the target sequence. The detectable label can be directly detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, can be indirectly detectable, e.g., by catalyzing chemical alterations of a chemical substrate compound or composition, which chemical substrate compound or composition is directly detectable. The detectable label can be qualitatively detected (e.g., optically or spectrally), or it can be quantified using methods known in the art and/or disclosed herein. 
     In some embodiments, the methods provided herein include a pool of two or more undesirable RNA depletion probes. In some embodiments, the pool of undesirable RNA depletion probes include about 100 nM, about 200 nM, about 300 nM, about 400 nM, about 500 nM, about 600 nM, about 700 nM, about 800 nM, about 900 nM, or about 1000 nM of each RNA depletion probe. In some embodiments, the pool of undesirable RNA depletion probes include about 1 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, or about 10 μM, or more, of each RNA depletion probe. In some embodiments, the concentration of an RNA depletion probe in a pool of RNA depletion probes depends on the relative abundance of the undesirable RNA targeted by the specific RNA depletion probe. For example, ribosomal transcirpts 18S and 28S can be highly abundant in a tissue sample. In this case, RNA depletion probes targeting 18S and/or 28S can be present in the pool of undesirable RNA depletion probes at a higher concentration that other RNA depletion probes present in the pool. 
     In some embodiments, an RNA depletion probe includes a nucleic acid sequence of any one of SEQ ID NOs: 1-195. In some embodiments, a pool of RNA depletion probes includes two or more probes each having a nucleic acid sequence selected from any one of SEQ ID NOs: 1-195. 
     (c) Hybridization of Undesirable RNA Depletion Probe to the Undesirable RNA Molecule 
     In some embodiments, one or more undesirable RNA depletion probes hybridize to an undesirable RNA. In some embodiments, one or more undesirable RNA depletion probes hybridize to one or more portions of the sequence of the undesirable RNA molecule. In some embodiments, one or more undesirable RNA depletion probes hybridize to the complete sequence of the undesirable RNA molecule. Hybridization can occur at an undesirable RNA having a sequence that is 100% complementary to the probe oligonucleotide(s). In some embodiments, hybridization can occur at a target having a sequence that is at least (e.g., at least about) 80%, at least (e.g., at least about) 85%, at least (e.g., at least about) 90%, at least (e.g., at least about) 95%, at least (e.g., at least about) 96%, at least (e.g., at least about) 97%, at least (e.g., at least about) 98%, or at least (e.g., at least about) 99% complementary to the probe oligonucleotide(s). 
     In some embodiments, the undesirable RNA depletion probe may be complementary to all or part of an undesirable RNA sequence and therefore, there may be more than one undesirable RNA probe that specifically hybridizes to the undesirable RNA. For example, there may be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more undesirable RNA depletion probes that specifically hybridize to an undesirable RNA. In some embodiments, the undesirable RNA has a tertiary structure and the undesirable RNA depletion probe can be complementary to an exposed portion of the undesirable RNA sequence. 
     In some embodiments, one or more undesirable RNA depletion probes can hybridize to the undesirable RNA such that at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% of the complete sequence of the undesirable RNA is hybridized by the undesirable RNA depletion probes. 
     In some embodiments, at least one undesirable RNA depletion probe specifically hybridizes to substantially the entire full length sequence of the undesirable RNA. As used herein, “substantially the entire full length sequence” refers to less than 100% but at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or any range therein, of the full length sequence. In some embodiments, a multiplicity of undesirable RNA depletion probes specifically binds to substantially the entire full length sequence of the target RNA. In another embodiment, a multiplicity of DNA probes specifically binds to the entire full length sequence, or portions thereof, of the target RNA, either adjacent or in a non-contiguous manner. 
     In some embodiments, the undesirable RNA depletion probe specifically hybridizes to the undesirable RNA molecule and creates a RNA:DNA hybrid. As used herein, “specifically hybridizes” refers to a state where a specific DNA probe is able to hybridize with a target RNA, for example, rRNA, over other nucleic acids present in a nucleic acid sample. In some instances, the DNA probe is first denatured into single-stranded DNA by methods known in the art, for example, by heating or under alkaline conditions, and then hybridized to the target RNA by methods also known in the art, for example, by cooling the heated DNA in the presence of the target RNA. In some instances, the double-stranded DNA probe is heated to achieve denaturation to a single strand prior to being added to the biological sample. In some instances, the DNA probe is produced as a single-stranded DNA molecule, in which case no denaturation would be required. The condition under which a DNA probe specifically hybridizes with an RNA are well known to those of ordinary skill in the art and it will be appreciated that these conditions may vary depending upon factors including the GC content and length of the probe, the hybridization temperature, the composition of the hybridization reagent or solution, and the degree of hybridization specificity sought. 
     In some embodiments, the RNA:DNA hybrid is then depleted from the nucleic acid sample. For example, in some embodiments, a ribonuclease (RNase) that specifically targets RNA:DNA hybrids is used to deplete the RNA:DNA hybrid. In some embodiments, RNAse H is used to specifically hydrolyze the RNA in the RNA:DNA hybrid so that the RNA becomes degraded. The remaining DNA is then available to hybridize with another undesirable RNA sequence. 
     In some instances, after the RNA:DNA hybrid is created, no further steps are taken to remove the hybrid (e.g., ribonuclease digestion as described below does not occur). Thus, in some instances, hybridization serves to “block” (e.g., inhibit binding of) single-stranded undesirable RNA molecules (e.g., rRNA) from associating with probe sequences that target e.g., poly(A) tails or other targets of interest. Accordingly, in some aspects, spatial detection methods disclosed herein occur in the presence of the RNA:DNA hybrid. In instances where the RNA:DNA hybrid is created but not removed, detection of RNA molecules of interest is increased relative to a setting in which no hybrid is created. In some instances, detection of target RNA molecules of interest is increased by about 5%, by about 10%, by about 15%, by about 20%, by about 25%, by about 30%, by about 35%, by about 40%, by about 45%, by about 50%, by about 55%, by about 60%, by about 65%, by about 70%, by about 75%, by about 80%, by about 85%, by about 90%, by about 95%, by about 1.5-fold, by about 2.0-fold, by about 2.5-fold, by about 3.0-fold, by about 3.5-fold, by about 4.0-fold, by about 4.5-fold, by about 5.0-fold, by about 6-fold, by about 7-fold, by about 8-fold, by about 9-fold, by about 10-fold, or more compared to a setting in which no hybrid is created. 
     (d) Removing the Plurality of Undesirable RNA Depletion Probe-Undesirable RNA Complexes. 
     (i) Ribonuclease Digestion 
     In some embodiments, the undesirable RNA depletion probe-undesirable RNA complex is removed. In some embodiments, the removing step includes the addition of RNAse H. In some embodiments, the removing step includes contacting the undesirable RNA depletion probe with a ribonuclease (e.g., RNAse H). In some embodiments, the ribonuclease is an endoribonuclease. In some embodiments (e.g., in the setting of RNA-templated ligation), an endoribonuclease also is used to release the probe from the analyte. In some embodiments, the endoribonuclease is one or more of RNase H, RNase A, RNase C, or RNase I, or any combinations thereof. In some embodiments, the endoribonuclease is RNase H. In some embodiments, the RNase H is RNase H1, RNase H2, or any combinations thereof. In some embodiments, the RNAse H is a thermostable RNAse H. Thermostable RNAse H may be obtained commercially, including, for example, Hybridase™ (Lucigen, Middleton, Wis.). 
     In some embodiments, the RNAse H degrades the RNA from a RNA:DNA hybrid at a temperature range of between 32° C. and 95° C. (e.g., using a thermostable RNAse H). In some embodiments, the RNAse H degrades the RNA from a RNA:DNA hybrid at a temperature range of between 32° C. and 60° C. In some embodiments, the RNAse H degrades the RNA from a RNA:DNA hybrid at a temperature range of between 37° C. and 60° C. In yet another embodiment, RNAse H degrades the RNA from a RNA:DNA hybrid at a temperature of about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C. or about 64° C. 
     In some embodiments, the hybridization step and RNA degradation with RNAse H is repeated more than once. In some instances, the hybridization step and RNA degradation step is repeated at least twice, at least three times, at least four times, at least five times, or more. In some instances, a wash step is performed between each step using methods and solutions (e.g., PBS, PBST) disclosed herein and known in the art. 
     In some embodiments, the ribonuclease can be inactivated by a permeabilization agent, for example concurrent inactivation and permeabilization of a biological sample. In some instances, the permeabilization agent is one or more of an organic solvent, a cross-linking agent, a detergent, and an enzyme known in the art. In some instances, the permeabilization agent is an endopeptidase or protease. In some instances, the endopeptidase is pepsin. In some instances, the endopeptidase is proteinase K. In some instances, the ribonuclease is heat inactivated. For example, in some instances, the ribonuclease (e.g., other than thermostable RNAse H) is heat inactivated at 65° C. 
     In some embodiments, DNA probes that have not hybridized with target undesirable RNA, or probes that have been released following RNase H degradation of the RNA from the RNA:DNA hybrid, can be removed at various stages of RNA isolation by DNA degrading enzymes or other techniques well known in the art. In some embodiments, the DNA degrading enzyme is an exonuclease that digests DNA from in a 5′ to 3′ direction. In some embodiments, the DNA degrading enzyme does not digest the capture probes attached on the substrate. In some embodiments, the DNA degrading enzyme is a RecJ exonuclease. A RecJ exonuclease degrades single-stranded DNA (ssDNA) in the 5′-3′ direction and can participate in homologous recombination and mismatch repair. In some instances, the RecJ exonuclease is isolated from  Escherichia coli . In some embodiments, DNA degrading enzyme can be inactivated by a permeabilization agent disclosed herein. 
     (ii) Removal of Undesirable RNA-Depletion Probe Complex 
     In some embodiments, the DNA:RNA complex that includes an undesirable RNA depletion probe and an undesirable RNA is removed using methods other than adding RNAse H. In some instances, the undesirable RNA depletion probe includes a capture moiety. As disclosed herein, a capture moiety of the undesirable RNA depletion probe is affixed to (e.g., conjugated to) the nucleic acid sequence of the undesirable RNA depletion probe. In some embodiments, the undesirable RNA depletion probe includes one or more capture moieties. In some embodiments, the capture moiety includes a label as described herein. In some embodiments, the label is used to identify and remove an undesirable RNA depletion probe, whether they are hybridized to undesirable RNA molecules or not. In some instances, using the label, the RNA depletion probe (including undesirable RNA depletion probes complexed with undesirable RNA) can be isolated and removed from the biological sample. In some embodiments, the label is directly associated with (i.e., conjugated to) the undesirable RNA depletion probe. The detectable label can be directly detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, can be indirectly detectable, e.g., by catalyzing chemical alterations of a chemical substrate compound or composition, which chemical substrate compound or composition is directly detectable. Detectable labels can be suitable for small scale detection and/or suitable for high-throughput screening. As such, suitable detectable labels include, but are not limited to, radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes. 
     In some embodiments, the capture moiety includes a small molecule. In some embodiments, the capture moiety includes a nucleic acid. In some embodiments, the nucleic acid is single-stranded. In some embodiments, the nucleic acid is double-stranded. In some embodiments, the nucleic acid is RNA. In some embodiments, the nucleic acid is DNA. In some embodiments, the capture moiety includes a carbohydrate. In some embodiments, the capture moiety is positioned 5′ to the domain in the undesirable RNA depletion probe. In some embodiments, the capture moiety is position 3′ to the domain in the undesirable RNA depletion probe. 
     In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety includes a protein. In some embodiments, the protein is an antibody. In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety comprises a nucleic acid. In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety comprises a small molecule. In some embodiments, the capture moiety-binding agent that binds specifically to the capture moiety is attached to a substrate. In some embodiments, the substrate is a bead. In some embodiments, the substrate is a well. In some embodiments, the substrate is a slide. In some embodiments, the substrate is a magnetic bead, for example a paramagnetic particle, such that the undesirable RNA depletion probe-undesirable RNA complexes, or the undesirable RNA depletion probe alone, can be removed magnetically from the biological sample, for example by a rare earth magnet or other magnetic devices. 
     In some embodiments, the capture moiety is biotin. In some embodiments, a biotin molecule is directly associated with (i.e., conjugated to) the undesirable RNA depletion probe at the 3′ end. In some embodiments, a biotin molecule is directly associated with (i.e., conjugated to) the undesirable RNA depletion probe at the 5′ end. In some embodiments, the biotin molecule can be associated to (e.g., conjugated to) an avidin molecule, allowing pulldown of the undesirable RNA depletion probe-undesirable RNA complexes, or the undesirable RNA depletion probe. In some embodiments, and as disclosed below, the biotin molecule can be associated to (e.g., conjugated to) a streptavidin molecule, such that the undesirable RNA depletion probe-undesirable RNA complexes, or the undesirable RNA depletion probe conjugated to a biotin molecule can be captured by streptavidin or avidin and depleted from the biological sample. 
     (e) In Situ Spatial RNA-Templated Ligation (RTL) Using Targeted RNA Depletion 
     In some instances, the undesirable RNA depletion probe is used in the setting of (e.g., concurrently with) in situ spatial RNA-templated ligation (RTL). In the setting of RTL, removal of undesireable RNA can be achieved concurrently. In some instances, both RTL probe oligonucleotides and undesirable RNA depletion probes can be added at the same time. After ligation of the RTL probes, an endonuclease such as RNAse H is added to the sample. RNAse H digests both the RNA analyte and the undesireable RNA. In some instances, at least one of the RTL probes includes a probe capture sequence such as a poly-A sequence, an oligo-d(T) sequence, or a particular capture sequence (in the setting of targeted RNA analysis). As a result of this process, undesireable RNA molecules (e.g., rRNA; mtRNA) are digested and thus are not available to interfere with downstream applications such as probe capture of the poly-A sequence or a complement thereof that occurs during spatial array-based methods disclosed herein. 
     In one feature of the disclosure, provided are methods for identifying a location of an analyte in a biological sample, the method comprising (a) contacting a biological sample with a first probe oligonucleotide, a second probe oligonucleotide, and a plurality of undesirable RNA depletion probes; (b) hybridizing the first probe oligonucleotide and the second probe oligonucleotide to the analyte; (c) hybridizing the undesirable RNA depletion probe to the undesirable RNA molecule; (d) ligating the first probe oligonucleotide and the second probe oligonucleotide, thereby creating a ligated probe that is substantially complementary to the analyte; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes and releasing the ligated probe from the analyte; (f) contacting the biological sample with a substrate, wherein the capture probe is affixed to the substrate, wherein the capture probe comprises a spatial barcode and the capture domain; (g) allowing the capture probe binding domain of the ligated probe to specifically bind to the capture domain; and (h) determining (i) all or a part of the sequence of the ligated probe specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof, and using the determined sequence of (i) and (ii) to identify the location of the analyte in the biological sample. 
     In some embodiments, the methods as disclosed herein include hybridizing of one or more probe oligonucleotides (e.g., RTL probes) to a target analyte (e.g., RNA; e.g., mRNA) of interest. In some embodiments, the methods include hybridization of 2, 3, 4, or more probe oligonucleotides. In some embodiments, the methods include hybridization of two probe oligonucleotides. In some embodiments, the probe oligonucleotide includes sequences that are complementary or substantially complementary to an analyte. For example, in some embodiments, each probe oligonucleotide includes a sequence that is complementary or substantially complementary to an mRNA of interest (e.g., to a portion of the sequence of an mRNA of interest). Methods provided herein may be applied to hybridization of two or more probe oligonucleotides to a single nucleic acid molecule. In some embodiments, each target analyte includes a first target region and a second target region. In some instances, the methods include providing a plurality of first probe oligonucleotides and a plurality of second probe oligonucleotides. In some instances, a first probe oligonucleotide hybridizes to a first target region of the nucleic acid. In some instances, a second probe oligonucleotide hybridizes to a second target region of the nucleic acid. 
     In some instances, a first probe oligonucleotide sequence of a first probe oligonucleotide of the plurality of first probe oligonucleotides may comprise a first reactive moiety. One or more first probe oligonucleotides of the plurality of first probe oligonucleotides may comprise the same first probe oligonucleotide sequence and/or the same second probe oligonucleotide sequence. The plurality of second probe oligonucleotides may each comprise a third probe oligonucleotide sequence complementary to the sequence of a second target region of a nucleic acid molecule of the plurality of nucleic acid molecules. The plurality of second probe oligonucleotides may further comprise a fourth probe oligonucleotide sequence. A third probe oligonucleotide sequence of a second probe oligonucleotide of the plurality of second probe oligonucleotides may comprise a second reactive moiety. One or more probe oligonucleotides of the second probe oligonucleotides of the plurality of second probe oligonucleotides may comprise the same third probe oligonucleotide sequence and/or, if present, the same fourth probe oligonucleotide sequence. A first probe oligonucleotide sequence of a first probe oligonucleotide of the plurality of first probe oligonucleotides may hybridize to first target region of a nucleic acid molecule of the plurality of nucleic acid molecules. A third probe oligonucleotide sequence of a second probe oligonucleotide of the plurality of second probe oligonucleotides may hybridize to the second target region of a nucleic acid molecule of the plurality of nucleic acid molecules. The first and third probe oligonucleotide sequences hybridized to the first and second target regions, respectively, of a nucleic acid molecule of the plurality of nucleic acid molecules may be adjacent to one another such that a first reactive moiety of the first probe oligonucleotide sequence is adjacent to a second reactive moiety of the third probe oligonucleotide sequence. The first and second reactive moieties of the first and second probe oligonucleotides hybridized to nucleic acid molecules of the plurality of nucleic acid molecules may react to provide a plurality of probe oligonucleotide-linked nucleic acid molecules. 
     In some embodiments, one of the probe oligonucleotides includes a poly(A) sequence or a complement thereof. In some instances, the poly(A) sequence or a complement thereof is on the 5′ end of one of the probe oligonucleotides. In some instances, the poly(A) sequence or a complement thereof is on the 3′ end of one of the probe oligonucleotides. In some embodiments, one probe oligonucleotides includes a degenerate or UMI sequence. In some embodiments, the UMI sequence is specific to a particular target or set of targets. In some instances, the UMI sequence or a complement thereof is on the 5′ end of one of the probe oligonucleotides. In some instances, the UMI sequence or a complement thereof is on the 3′ end of one of the probe oligonucleotides. 
     In some instances, the first and second target regions of a nucleic acid molecule of the plurality of nucleic acid molecules are adjacent to one another. In some embodiments, the first and second probe oligonucleotides bind to complementary sequences on the same transcript. In some embodiments, the complementary sequences to which the first probe oligonucleotide and the second probe oligonucleotide bind are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 125, or about 150 nucleotides away from each other. Gaps between the probe oligonucleotides may first be filled prior to ligation, using, for example, dNTPs in combination with a polymerase such as Mu polymerase, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase, and/or any combinations, derivatives, and variants (e.g., engineered mutants) thereof. In some embodiments, when the first and second probe oligonucleotides are separated from each other by one or more nucleotides, deoxyribonucleotides are used to extend and ligate the first and second probe oligonucleotides. 
     In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on the same transcript. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on the same exon. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on different exons. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte that is the result of a translocation event (e.g., in the setting of cancer). The methods provided herein make it possible to identify alternative splicing events, translocation events, and mutations that change the hybridization rate of one or both probe oligonucleotides (e.g., single nucleotide polymorphisms, insertions, deletions, point mutations). 
     In some embodiments, the first and/or second probe as disclosed herein includes at least two ribonucleic acid bases at the 3′ end; a functional sequence; a phosphorylated nucleotide at the 5′ end; and/or a capture probe binding domain. In some embodiments, the functional sequence is a primer sequence. The capture probe binding domain is a sequence that is complementary to a particular capture domain present in a capture probe. In some embodiments, the capture probe binding domain includes a poly(A) sequence. In some embodiments, the capture probe binding domain includes a poly-uridine sequence, a poly-thymidine sequence, or a combination thereof. In some embodiments, the capture probe binding domain includes a random sequence (e.g., a random hexamer or octamer). In some embodiments, the capture probe binding domain is complementary to a capture domain in a capture probe that detects a particular target(s) of interest. In some embodiments, a capture probe binding domain blocking moiety that interacts with the capture probe binding domain is provided. In some embodiments, a capture probe binding domain blocking moiety includes a sequence that is complementary or substantially complementary to a capture probe binding domain. In some embodiments, a capture probe binding domain blocking moiety prevents the capture probe binding domain from binding the capture probe when present. In some embodiments, a capture probe binding domain blocking moiety is removed prior to binding the capture probe binding domain (e.g., present in a ligated probe) to a capture probe. In some embodiments, a capture probe binding domain blocking moiety comprises a poly-uridine sequence, a poly-thymidine sequence, or a combination thereof. 
     In some embodiments, the first probe oligonucleotide hybridizes to an analyte and a second probe oligonucleotide hybridizes to an analyte in proximity to the first probe oligonucleotide. Hybridization can occur at a target having a sequence that is 100% complementary to the probe oligonucleotide(s). In some embodiments, hybridization can occur at a target having a sequence that is at least (e.g., at least about) 80%, at least (e.g., at least about) 85%, at least (e.g., at least about) 90%, at least (e.g., at least about) 95%, at least (e.g., at least about) 96%, at least (e.g., at least about) 97%, at least (e.g., at least about) 98%, or at least (e.g., at least about) 99% complementary to the probe oligonucleotide(s). After hybridization, in some embodiments, the first probe oligonucleotide is extended. After hybridization, in some embodiments, the second probe oligonucleotide is extended. For example, in some instances a first probe oligonucleotide hybridizes to a target sequence upstream for a second oligonucleotide probe, whereas in other instances a first probe oligonucleotide hybridizes to a target sequence downstream of a second probe oligonucleotide. 
     The method disclosed herein include addition of undesireable RNA probes described herein. In some instances, the undesireable RNA probes are added at the same time as the first probe oligonucleotide and the second probe oligonucleotide. In some instances, the undesireable RNA probes are added before the first probe oligonucleotide and the second probe oligonucleotide. In some instances, the undesireable RNA probes are added after the first probe oligonucleotide and the second probe oligonucleotide. 
     In some embodiments, methods disclosed herein include a wash step after hybridizing the first and the second probe oligonucleotides and/or the undesireable RNA probes. The wash step removes any unbound oligonucleotides and can be performed using any technique known in the art. In some embodiments, a pre-Hybridization buffer is used to wash the sample. In some embodiments, a phosphate buffer is used. In some embodiments, multiple wash steps are performed to remove unbound oligonucleotides. For example, it is advantageous to decrease the amount of unhybridized probes present in a biological sample as they may interfere with downstream applications and methods. 
     In some embodiments, after hybridization of probe oligonucleotides (e.g., first and the second probe oligonucleotides) to the target analyte, the probe oligonucleotides (e.g., the first probe oligonucleotide and the second probe oligonucleotide) are ligated together, creating a single ligated probe that is complementary to the target analyte. Ligation can be performed enzymatically or chemically, as described herein. For example, the first and second probe oligonucleotides are hybridized to the first and second target regions of the analyte, and the probe oligonucleotides are subjected to a nucleic acid reaction to ligate them together. For example, the probes may be subjected to an enzymatic ligation reaction using a ligase (e.g., T4 RNA ligase (Rnl2), a SplintR ligase, or a T4 DNA ligase). See, e.g., Zhang L., et al.; Archaeal RNA ligase from  Thermoccocus kodakarensis  for template dependent ligation RNA Biol. 2017; 14(1): 36-44 for a description of KOD ligase. 
     In some embodiments, adenosine triphosphate (ATP) is added during the ligation reaction. DNA ligase-catalyzed sealing of nicked DNA substrates is first activated through ATP hydrolysis, resulting in covalent addition of an AMP group to the enzyme. After binding to a nicked site in a DNA duplex, the ligase transfers this AMP to the phosphorylated 5′-end at the nick, forming a 5′-5′ pyrophosphate bond. Finally, the ligase catalyzes an attack on this pyrophosphate bond by the OH group at the 3′-end of the nick, thereby sealing it, whereafter ligase and AMP are released. If the ligase detaches from the substrate before the 3′ attack, e.g., because of premature AMP reloading of the enzyme, then the 5′ AMP is left at the 5′-end, blocking further ligation attempts. In some instances, ATP is added at a concentration of about 1 μM, about 10 μM, about 100 μM, about 1000 μM, or about 10000 μM during the ligation reaction. 
     In some instances, cofactors that aid in joining of the probe oligonuclotides are added during the ligation process. In some instances, the cofactors include magnesium ions (Mg 2+ ). In some instances, the cofactors include manganese ions (Mn 2+ ). In some instances, Mg 2+  is added in the form of MgCl 2 . In some instances, Mn 2+  is added in the form of MnCl 2 . In some instances, the concentration of MgCl 2  is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM. In some instances, the concentration of MnCl 2  is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM. 
     In some embodiments, the probe oligonucleotides (e.g., the first probe oligonucleotide and the second probe oligonucleotide) may each comprise a reactive moiety such that, upon hybridization to the target and exposure to appropriate ligation conditions, the probe oligonucleotides may ligate to one another. In some embodiments, probe oligonucleotides that include a reactive moiety are ligated chemically. For example, a probe oligonucleotide capable of hybridizing to a first target region of a nucleic acid molecule may comprise a first reactive moiety, and a probe oligonucleotide capable of hybridizing to a second target region of the nucleic acid molecule may comprise a second reactive moiety. When the first and second probe oligonucleotides are hybridized to the first and second target regions of the nucleic acid molecule, the first and second reactive moieties may be adjacent to one another. A reactive moiety of a probe may be selected from the non-limiting group consisting of azides, alkynes, nitrones (e.g., 1,3-nitrones), strained alkenes (e.g., trans-cycloalkenes such as cyclooctenes or oxanorbornadiene), tetrazines, tetrazoles, iodides, thioates (e.g., phorphorothioate), acids, amines, and phosphates. For example, the first reactive moiety of a first probe oligonucleotide may comprise an azide moiety, and a second reactive moiety of a second probe oligonucleotide may comprise an alkyne moiety. The first and second reactive moieties may react to form a linking moiety. A reaction between the first and second reactive moieties may be, for example, a cycloaddition reaction such as a strain-promoted azide-alkyne cycloaddition, a copper-catalyzed azide-alkyne cycloaddition, a strain-promoted alkyne-nitrone cycloaddition, a Diels-Alder reaction, a [3+2] cycloaddition, a [4+2] cycloaddition, or a [4+1] cycloaddition; a thiol-ene reaction; a nucleophilic substation reaction; or another reaction. In some instances, the ends of the probes are ligated together using bioorthogonal click chemistry, effectively locking the probes around the target. See Rouhanifard et al., Nat Biotechnol. 2018 Nov. 12; 10.1038/nbt.4286, which is incorporated by reference in its entirety. In some cases, reaction between the first and second reactive moieties may yield a triazole moiety or an isoxazoline moiety. A reaction between the first and second reactive moieties may involve subjecting the reactive moieties to suitable conditions such as a suitable temperature, pH, or pressure and providing one or more reagents or catalysts for the reaction. For example, a reaction between the first and second reactive moieties may be catalyzed by a copper catalyst, a ruthenium catalyst, or a strained species such as a difluorooctyne, dibenzylcyclooctyne, or biarylazacyclooctynone. Reaction between a first reactive moiety of a first probe oligonucleotide hybridized to a first target region of the nucleic acid molecule and a second reactive moiety of a third probe oligonucleotide hybridized to a second target region of the nucleic acid molecule may link the first probe oligonucleotide and the second probe oligonucleotide to provide a ligated probe. Accordingly, reaction of the first and second reactive moieties may comprise a chemical ligation reaction such as a copper-catalyzed 5′ azide to 3′ alkyne “click” chemistry reaction to form a triazole linkage between two probe oligonucleotides. In other non-limiting examples, an iodide moiety may be chemically ligated to a phosphorothioate moiety to form a phosphorothioate bond, an acid may be ligated to an amine to form an amide bond, and/or a phosphate and amine may be ligated to form a phosphoramidate bond. 
     In some embodiments, after ligation of the first and second probe oligonucleotides to create a ligated probe, the ligated probe is released from the analyte. At this stage of the method, (1) the ligated probe is created and is hybridized to the analyte, and (2) the undesireable RNA probe is hybridized to the undesireable RNA. To release the ligated probe is released from the analyte, an endoribonuclease is used. An endoribonuclease such as RNAse H specifically cleaves RNA in RNA:DNA hybrids. Thus, not only does RNAse H cleave the hybridization of the ligated probe to the analyte (releasing the ligated probe), RNAse H also cleaves the undesireable RNA. In some embodiments, the ligated probe is released enzymatically. In some embodiments, an endoribonuclease is used to release the probe from the analyte. In some embodiments, the endoribonuclease is one or more of RNase H. In some embodiments, the RNase H is RNase H1 or RNase H2. 
     In some embodiments, after creating a ligated probe from the probe oligonucleotides (e.g., a first probe oligonucleotide and second probe oligonucleotide), the biological sample is permeabilized. In some embodiments, permeabilization occurs using a protease. In some embodiments, the protease is an endopeptidase. Endopeptidases that can be used include but are not limited to trypsin, chymotrypsin, elastase, thermolysin, pepsin, clostripan, glutamyl endopeptidase (GluC), ArgC, peptidyl-asp endopeptidase (ApsN), endopeptidase LysC and endopeptidase LysN. In some embodiments, the endopeptidase is pepsin. 
     In some embodiments, the ligated probe includes a capture probe binding domain, which can hybridize to a capture probe (e.g., a capture probe immobilized, directly or indirectly, on a substrate). In some embodiments, methods provided herein include contacting a biological sample with a substrate, wherein the capture probe is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly). In some embodiments, the capture probe includes a spatial barcode and the capture domain. In some embodiments, the capture probe binding domain of the ligated probe specifically binds to the capture domain. After hybridization of the ligated probe to the capture probe, the ligated probe is extended at the 3′ end to make a copy of the additional components (e.g., the spatial barcode) of the capture probe. In some embodiments, methods of ligated probe capture as provided herein include permeabilization of the biological sample such that the capture probe can more easily hybridize to the captured ligated probe (i.e., compared to no permeabilization). In some embodiments, reverse transcription (RT) reagents can be added to permeabilized biological samples. Incubation with the RT reagents can produce spatially-barcoded full-length cDNA from the captured analytes (e.g., polyadenylated mRNA). Second strand reagents (e.g., second strand primers, enzymes) can be added to the biological sample on the slide to initiate second strand synthesis. 
     The resulting cDNA can be denatured from the capture probe template and transferred (e.g., to a clean tube) for amplification, and/or library construction as described herein. The spatially-barcoded, full-length cDNA can be amplified via PCR prior to library construction. The cDNA can then be enzymatically fragmented and size-selected in order to optimize the cDNA amplicon size. P5, P7, i7, and i5 can be used as sample indexes, and TruSeq Read 2 can be added via End Repair, A-tailing, Adaptor Ligation, and PCR. The cDNA fragments can then be sequenced using paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites. 
     In some embodiments, the biological sample is contacted with the undesirable RNA depletion probes and the RTL probes (e.g., the first probe oligonucleotide and the second probe oligonucleotide) at substantially the same time. In some embodiments, the biological sample is contacted with the RTL probes (e.g., the first probe oligonucleotide and the second probe oligonucleotide) after the undesirable RNA depletion probes. 
     In some embodiments, the hybridization between the RTL probes (e.g., the first probe oligonucleotide and the second probe oligonucleotide) to the analyte and the hybridization between the undesirable RNA depletion probes to the undesirable RNA occurs at substantially the same time. In some embodiments, the hybridization between the RTL probes (e.g., the first probe oligonucleotide and the second probe oligonucleotide) to the analyte occurs after the hybridization between the undesirable RNA depletion probes to the undesirable RNA occurs substantially the same time. 
     In some embodiments, the step of removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes and releasing the ligated probe from the analyte occur substantially the same time. In some embodiments, the step of removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes occurs before releasing the ligated probe from the analyte. 
     In some embodiments, the RTL probes (e.g., the first and second probe oligonucleotides) and the analyte (e.g., the target mRNA) hybridize to form an RNA:DNA hybrid at substantially the same time when the undesirable RNA depletion probes and the undesirable RNA hybridize to form an RNA:DNA hybrid. In some embodiments, a ribonuclease (e.g., RNase H) digests the RNA strands of the RNA:DNA hybrids, where the RNA strands include the analyte and the undesirable RNA molecule. 
     Detailed descriptions of targeted RNA capture using RNA-templated ligation (RTL) has been disclosed in U.S. application No. 62/952,736, the entirety of which is incorporated herein by reference. 
     (f) Targeted Capture of Analytes Using Hybridization of Target Oligonucleotide Probes 
     In some embodiments, one or more target oligonucleotide probes are designed to target and hybridize to a plurality of nucleic acids (e.g., to prepared spatial libraries; e.g., to prepared cDNA libraries). In this instance, before targeting one or more target nucleic acids of interest, in some embodiments, the biological sample is first contacted with the undesirable RNA depletion probes as described herein. In some embodiments, a complex of undesirable RNA depletion probes hybridized to an undesirable RNA molecule is formed. In some embodiments, a ribonuclease (e.g., RNase H) digests the RNA strands of the RNA:DNA hybrids, where the RNA strands undesirable RNA molecules (e.g., rRNA). 
     In some embodiments, disclosed herein are methods of depleting an unwanted RNA in a biological sample and include first contacting the biological sample with a plurality of undesirable RNA depletion probes, wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; hybridizing the undesirable RNA depletion probe to the undesirable RNA; and removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes. After removal of the undesirable RNA depletion probe-undesirable RNA complexes, identification of an analyte can be pursued. 
     In some instances, to create a non-specific library of analytes from a sample whose unwanted RNA molecules was depleted, the methods (after unwanted RNA depletion) include hybridizing the analytes to a plurality to capture probes, each including a spatial barcode and a capture domain that binds specifically to a sequence present in the analyte. In some embodiments, the capture probe is extended using the analyte that is specifically bound to the capture domain as a template to generate an extended capture probe. After template production, the capture probe/analyte complex can be amplified to produce a cDNA library using methods disclosed herein. 
     After RNA depletion, particular target analytes can be analyzed. For example, in one instance disclosed herein, target oligonucleotide probes are part of a “panel” that includes hundreds or thousands of oligonucleotide probes specific for certain settings. For example, a panel of oligonucleotides can detect analytes dysregulated during cancer, during immune-dysregulation, during neurological development and disease progression, or acting in the same pathway. Panels and particular oligonucleotides are disclosed in U.S. Appl. No. 62/970,066; 62/929,686; 62/980,124; and 62/980,116, each of which is incorporated by reference in its entirety. 
     In some instances, the target oligonucleotide probes hybridize to a target analyte, and then they are selectively enriched e.g., by amplification and/or pulldown methods disclosed herein. In some embodiments, the target oligonucleotide probe does not include a moiety affixed to the sequence (i.e., the target oligonucleotide probe is a naked target oligonucleotide probe). In some instances, the oligonucleotide probes are associated with one or more moieties. In some embodiments, the moiety is biotin. In some embodiments, a biotin molecule is directly associated with (i.e., conjugated to) the target oligonucleotide probe at the 3′ end. In some embodiments, a biotin molecule is directly associated with (i.e., conjugated to) the target oligonucleotide probe at the 5′ end. In some embodiments, and as disclosed below, the biotin molecule can be associated to (e.g., conjugated to) an avidin molecule, allowing pulldown of an analyte. In some embodiments, and as disclosed below, the biotin molecule can be associated to (e.g., conjugated to) a streptavidin molecule, allowing pulldown of an analyte. After pulldown of the analytes of interest, the resulting analyte can be amplified, creating an enriched library of analytes. By “enriched,” it is meant that there are increased concentrations of an analyte of interest compared to a sample of the same library of analytes that has not undergone the pulldown step. 
     (g) Methods of Targeted RNA Depletion 
     Provided herein are methods for identifying a location of an analyte (e.g., any of the analyte described herein) in a biological sample that include (a) contacting the biological sample with a substrate comprising a plurality of attached capture probes, wherein a capture probe of the plurality comprises (i) the spatial barcode and (ii) a capture domain that binds specifically to a capture probe capture domain; (b) contacting a biological sample with a first probe oligonucleotide, a second probe oligonucleotide, and a plurality of undesirable RNA depletion probes (e.g., any of the undesirable RNA depletion probes described herein), wherein the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of the analyte, wherein the second probe oligonucleotide comprises a capture probe binding domain (e.g., any of the capture probe binding domains described herein) that is capable of binding to a capture domain (e.g., any of the capture domains described herein) of a capture probe (e.g., any of the capture probes described herein), and wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to all or a portion of the sequence of an undesirable RNA molecule (e.g., any of the undesirable RNA molecules described herein) in the biological sample; (c) hybridizing the first probe oligonucleotide and the second probe oligonucleotide to the analyte; (d) hybridizing the undesirable RNA depletion probe to the undesirable RNA molecule (e.g., using any of the methods for hybridizing the undesirable RNA depletion probe to the undesirable RNA described herein); (e) ligating the first probe oligonucleotide and the second probe oligonucleotide, thereby creating a ligated probe (e.g., using any of the methods for ligating described herein) that is substantially complementary to the analyte; (f) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes (e.g., using any of the methods for removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes described herein) and releasing the ligated probe from the analyte (e.g., using any of the methods for releasing the ligated probe from the analyte described herein); (g) allowing the capture probe binding domain of the ligated probe to specifically bind to the capture domain; and (h) determining (i) all or a part of the sequence of the ligated probe specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof, and using the determined sequence of (i) and (ii) to identify the location of the analyte in the biological sample. 
     Provided herein are methods for identifying a location of an analyte (e.g., any of the analyte described herein) in a biological sample that include (a) contacting the biological sample with a substrate (e.g., any of the substrates described herein) comprising a plurality of attached capture probes (e.g., any of the capture probes described herein), wherein a capture probe of the plurality comprises (i) the spatial barcode (e.g., any of the spatial barcode described herein) and (ii) a capture domain (e.g., any of the capture domain described herein) that binds specifically to a sequence present in the analyte; (b) contacting the biological sample with a plurality of undesirable RNA depletion probes (e.g., any of the undesirable RNA depletion probes described herein), wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to all or a portion of the sequence of an undesirable RNA molecule (e.g., any of the undesirable RNA molecules described herein) in the biological sample; (c) hybridizing the undesirable RNA depletion probe to the undesirable RNA (e.g., using any of the methods for hybridizing the undesirable RNA depletion probe to the undesirable RNA described herein); (d) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes (e.g., using any of the methods for removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes described herein); (e) extending a 3′ end of the capture probe using the analyte that is specifically bound to the capture domain as a template to generate an extended capture probe; and (f) amplifying (e.g., using any of the methods for amplifying described herein) the extended capture probe to produce a nucleic acid. 
     Provided herein are methods for identifying a location of an analyte (e.g., any of the analyte described herein) in a biological sample that include (a) contacting the biological sample with a plurality of undesirable RNA depletion probes (e.g., any of the undesirable RNA depletion probes described herein), wherein an undesirable RNA depletion probe in the plurality of undesirable RNA depletion probes is substantially complementary to all or a portion of the sequence of an undesirable RNA molecule (e.g., any of the undesirable RNA molecule described herein) in the biological sample; (b) hybridizing the undesirable RNA depletion probe to the undesirable RNA (e.g., using any of the methods for hybridizing the undesirable RNA depletion probe to the undesirable RNA described herein); (c) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes (e.g., using any of the methods for removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes described herein); (d) contacting a plurality of nucleic acids with a plurality of target oligonucleotide probes (e.g., any of the target oligonucleotide probes described herein), wherein: a nucleic acid of the plurality of nucleic acids comprises (i) a spatial barcode (e.g., any of the spatial barcode described herein) or a complement thereof, and (ii) a portion of a sequence of an analyte from a biological sample, or a complement thereof; and a target oligonucleotide probe of the plurality of target oligonucleotide probes comprises: a domain that binds specifically to (i) all or a portion of the spatial barcode or a complement thereof, and/or (ii) all or a portion of the sequence of the analyte from the biological sample, or a complement thereof, and a molecular tag; (e) enriching a complex of the target oligonucleotide probe specifically bound to the nucleic acid using a substrate comprising an agent (e.g., any of the agent described herein) that binds specifically to the molecular tag; and (f) determining (i) all or a portion of the sequence of the spatial barcode or the complement thereof, and (ii) all or a portion of the sequence of the analyte from the biological sample, and using the determined sequences of (i) and (ii) to identify the location of the analyte in the biological sample. 
     In some instances, the undesirable RNA depletion probes are used in a setting where a protein-DNA molecule is used as a target probe. In some instances, the undesirable RNA depletion probes can be used in any of the spatial analysis methods described herein. For example, undesirable RNA depletion probes can hybridize to an undesirable RNA molecule in the presence of an antibody or antigen binding fragment thereof that is associated with a nucleic acid molecule, as disclosed herein. In some instances, the molecule (e.g., a nucleic acid molecule) having a barcode (e.g., a spatial barcode) can be coupled (e.g., associated with; conjugated to) an antibody or antigen binding fragment thereof in a manner that facilitates attachment of the molecule (e.g., a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., a cell; e.g., a surface of a cell) using the antibody or antigen binding fragment thereof. In some instances, the undesirable RNA depletion probes hybridize to undesirable RNA molecules, disallowing the undesirable RNA molecules from hybridizing to the nucleic acid molecule of the antibody or antigen binding fragment thereof. In some instances, detection of analytes of interest is increased by about 5%, by about 10%, by about 15%, by about 20%, by about 25%, by about 30%, by about 35%, by about 40%, by about 45%, by about 50%, by about 55%, by about 60%, by about 65%, by about 70%, by about 75%, by about 80%, by about 85%, by about 90%, by about 95%, by about 1.5-fold, by about 2.0-fold, by about 2.5-fold, by about 3.0-fold, by about 3.5-fold, by about 4.0-fold, by about 4.5-fold, by about 5.0-fold, by about 6-fold, by about 7-fold, by about 8-fold, by about 9-fold, by about 10-fold, or more compared to a setting in which no hybrid of undesirable RNA depletion probe-undesirable RNA is created. 
     In some instances, the undesirable RNA depletion probe is an RNA molecule. In some instances, the RNA molecule hybridizes to a DNA molecule that is conjugated to protein (e.g., an antibody), wherein the antibody binds to a protein of interest. The RNA molecule is complementary to the DNA molecule that is conjugated to the protein (e.g., the antibody). In some instances, the following steps are performed: the antibody-DNA molecule binds to a protein of interest; the RNA molecules (i.e., the RNA depletion probes) hybridize to the DNA molecule, thereby blocking other nucleic acids from hybridizing to the DNA molecule. 
     In some instances, the antibody binds to the protein of interest after hybridizing the RNA molecule to the DNA molecule. In the latter setting, in one embodiment, the RNA molecule is complexed to the antibody-DNA molecule before the antibody-DNA molecule binds to the protein of interest. After the antibody hybridizes to the protein, RNAse H can be added to cleave the RNA molecule from the DNA molecule such that the DNA molecule is free to hybridize to any spatial capture array as described herein. 
     (h) Pre-Hybridization Methods 
     (i) Imaging and Staining 
     Prior to addition of the probes (e.g., undesirable RNA depletion probes and/or RTL probes), in some instances, biological samples can be stained using a wide variety of stains and staining techniques. In some instances, the biological sample is a section on a slide (e.g., a 5 μm section, a 7 μm section, a 10 μm section, etc.). In some instances, the biological sample is dried after placement onto a glass slide. In some instances, the biological sample is dried at 42° C. In some instances, drying occurs for about 1 hour, about 2, hours, about 3 hours, or until the sections become transparent. In some instances, the biological sample can be dried overnight (e.g., in a desiccator at room temperature). 
     In some embodiments, a sample can be stained using any number of biological stains, including but not limited to, acridine orange, Bismarck brown, carmine, coomassie blue, cresyl violet, DAPI, eosin, ethidium bromide, acid fuchsine, hematoxylin, Hoechst stains, iodine, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide, propidium iodide, rhodamine, or safranin. In some instances, the methods disclosed herein include imaging the biological sample. In some instances, imaging the sample occurs prior to deaminating the biological sample. In some instances, the sample can be stained using known staining techniques, including Can-Grunwald, Giemsa, hematoxylin and eosin (H&amp;E), Jenner&#39;s, Leishman, Masson&#39;s trichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright&#39;s, and/or Periodic Acid Schiff (PAS) staining techniques. PAS staining is typically performed after formalin or acetone fixation. In some instances, the stain is an H&amp;E stain. 
     In some embodiments, the biological sample can be stained using a detectable label (e.g., radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes) as described elsewhere herein. In some embodiments, a biological sample is stained using only one type of stain or one technique. In some embodiments, staining includes biological staining techniques such as H&amp;E staining. In some embodiments, staining includes identifying analytes using fluorescently-conjugated antibodies. In some embodiments, a biological sample is stained using two or more different types of stains, or two or more different staining techniques. For example, a biological sample can be prepared by staining and imaging using one technique (e.g., H&amp;E staining and brightfield imaging), followed by staining and imaging using another technique (e.g., IHC/IF staining and fluorescence microscopy) for the same biological sample. 
     In some embodiments, biological samples can be destained. Methods of destaining or discoloring a biological sample are known in the art, and generally depend on the nature of the stain(s) applied to the sample. For example, H&amp;E staining can be destained by washing the sample in HCl, or any other acid (e.g., selenic acid, sulfuric acid, hydroiodic acid, benzoic acid, carbonic acid, malic acid, phosphoric acid, oxalic acid, succinic acid, salicylic acid, tartaric acid, sulfurous acid, trichloroacetic acid, hydrobromic acid, hydrochloric acid, nitric acid, orthophosphoric acid, arsenic acid, selenous acid, chromic acid, citric acid, hydrofluoric acid, nitrous acid, isocyanic acid, formic acid, hydrogen selenide, molybdic acid, lactic acid, acetic acid, carbonic acid, hydrogen sulfide, or combinations thereof). In some embodiments, destaining can include 1, 2, 3, 4, 5, or more washes in an acid (e.g., HCl). In some embodiments, destaining can include adding HCl to a downstream solution (e.g., permeabilization solution). In some embodiments, destaining can include dissolving an enzyme used in the disclosed methods (e.g., pepsin) in an acid (e.g., HCl) solution. In some embodiments, after destaining hematoxylin with an acid, other reagents can be added to the destaining solution to raise the pH for use in other applications. For example, SDS can be added to an acid destaining solution in order to raise the pH as compared to the acid destaining solution alone. As another example, in some embodiments, one or more immunofluorescence stains are applied to the sample via antibody coupling. Such stains can be removed using techniques such as cleavage of disulfide linkages via treatment with a reducing agent and detergent washing, chaotropic salt treatment, treatment with antigen retrieval solution, and treatment with an acidic glycine buffer. Methods for multiplexed staining and destaining are described, for example, in Bolognesi et al., J. Histochem. Cytochem. 2017; 65(8): 431-444, Lin et al., Nat Commun. 2015; 6:8390, Pirici et al., J. Histochem. Cytochem. 2009; 57:567-75, and Glass et al., J. Histochem. Cytochem. 2009; 57:899-905, the entire contents of each of which are incorporated herein by reference. 
     In some embodiments, immunofluorescence or immunohistochemistry protocols (direct and indirect staining techniques) can be performed as a part of, or in addition to, the exemplary spatial workflows presented herein. For example, tissue sections can be fixed according to methods described herein. The biological sample can be transferred to an array (e.g., capture probe array), wherein analytes (e.g., proteins) are probed using immunofluorescence protocols. For example, the sample can be rehydrated, blocked, and permeabilized (3×SSC, 2% BSA, 0.1% Triton X, 1 U/μl RNAse inhibitor for 10 minutes at 4° C.) before being stained with fluorescent primary antibodies (1:100 in 3×SSC, 2% BSA, 0.1% Triton X, 1 U/μl RNAse inhibitor for 30 minutes at 4° C.). The biological sample can be washed, coverslipped (in glycerol+1 U/μl RNAse inhibitor), imaged (e.g., using a confocal microscope or other apparatus capable of fluorescent detection), washed, and processed according to analyte capture or spatial workflows described herein. 
     In some instances, a glycerol solution and a cover slip can be added to the sample. In some instances, the glycerol solution can include a counterstain (e.g., DAPI). 
     As used herein, an antigen retrieval buffer can improve antibody capture in IF/IHC protocols. An exemplary protocol for antigen retrieval can be preheating the antigen retrieval buffer (e.g., to 95° C.), immersing the biological sample in the heated antigen retrieval buffer for a predetermined time, and then removing the biological sample from the antigen retrieval buffer and washing the biological sample. 
     In some embodiments, optimizing permeabilization can be useful for identifying intracellular analytes. Permeabilization optimization can include selection of permeabilization agents, concentration of permeabilization agents, and permeabilization duration. Tissue permeabilization is discussed elsewhere herein. 
     In some embodiments, blocking an array and/or a biological sample in preparation of labeling the biological sample decreases nonspecific binding of the antibodies to the array and/or biological sample (decreases background). Some embodiments provide for blocking buffers/blocking solutions that can be applied before and/or during application of the label, wherein the blocking buffer can include a blocking agent, and optionally a surfactant and/or a salt solution. In some embodiments, a blocking agent can be bovine serum albumin (BSA), serum, gelatin (e.g., fish gelatin), milk (e.g., non-fat dry milk), casein, polyethylene glycol (PEG), polyvinyl alcohol (PVA), or polyvinylpyrrolidone (PVP), biotin blocking reagent, a peroxidase blocking reagent, levamisole, Carnoy&#39;s solution, glycine, lysine, sodium borohydride, pontamine sky blue, Sudan Black, trypan blue, FITC blocking agent, and/or acetic acid. The blocking buffer/blocking solution can be applied to the array and/or biological sample prior to and/or during labeling (e.g., application of fluorophore-conjugated antibodies) to the biological sample. 
     (ii) Preparation of a Sample for Application of Probes 
     In some instances, the biological sample is deparaffinized. Deparaffinization can be achieved using any method known in the art. For example, in some instances, the biological samples is treated with a series of washes that include xylene and various concentrations of ethanol. In some instances, methods of deparaffinization include treatment of xylene (e.g., three washes at 5 minutes each). In some instances, the methods further include treatment with ethanol (e.g., 100% ethanol, two washes 10 minutes each; 95% ethanol, two washes 10 minutes each; 70% ethanol, two washes 10 minutes each; 50% ethanol, two washes 10 minutes each). In some instances, after ethanol washes, the biological sample can be washed with deionized water (e.g., two washes for 5 minutes each). It is appreciated that one skilled in the art can adjust these methods to optimize deparaffinization. 
     In some instances, the biological sample is decrosslinked. In some instances, the biological sample is decrosslinked in a solution containing TE buffer (comprising Tris and EDTA). In some instances, the TE buffer is basic (e.g., at a pH of about 9). In some instances, decrosslinking occurs at about 50° C. to about 80° C. In some instances, decrosslinking occurs at about 70° C. In some instances, decrosslinking occurs for about 1 hour at 70° C. Just prior to decrosslinking, the biological sample can be treated with an acid (e.g., 0.1M HCl for about 1 minute). After the decrosslinking step, the biological sample can be washed (e.g., with 1×PBST). 
     In some instances, the methods of preparing a biological sample for probe application include permeabilizing the sample. In some instances, the biological sample is permeabilized using a phosphate buffer. In some instances, the phosphate buffer is PBS (e.g., 1×PBS). In some instances, the phosphate buffer is PBST (e.g., 1×PBST). In some instances, the permeabilization step is performed multiple times (e.g., 3 times at 5 minutes each). 
     In some instances, the methods of preparing a biological sample for probe application include steps of equilibrating and blocking the biological sample. In some instances, equilibrating is performed using a pre-hybridization (pre-Hyb) buffer. In some instances, the pre-Hyb buffer is RNase-free. In some instances, the pre-Hyb buffer contains no bovine serum albumin (BSA), solutions like Denhardt&#39;s, or other potentially nuclease-contaminated biological materials. 
     In some instances, the equilibrating step is performed multiple times (e.g., 2 times at 5 minutes each; 3 times at 5 minutes each). In some instances, the biological sample is blocked with a blocking buffer. In some instances, the blocking buffer includes a carrier such as tRNA, for example yeast tRNA such as from brewer&#39;s yeast (e.g., at a final concentration of 10-20 μg/mL). In some instances, blocking can be performed for 5, 10, 15, 20, 25, or 30 minutes. 
     Any of the foregoing steps can be optimized for performance. For example, one can vary the temperature. In some instances, the pre-hybridization methods are performed at room temperature. In some instances, the pre-hybridization methods are performed at 4° C. (in some instances, varying the timeframes provided herein). 
     (i) Hybridizing the Probes 
     In some embodiments, the methods described herein include hybridizing undesirable RNA depletion probes prior to or contemporaneously with targeted RNA capture that includes hybridizing a first probe oligonucleotide and a second probe oligonucleotide (e.g., a probe pair). In some instances, the first and second probe oligonucleotides for targeted RNA capture each include sequences that are substantially complementary to one or more sequences (e.g., one or more target sequences) of an analyte of interest. In some embodiments, the first probe and the second probe bind to complementary sequences that are completely adjacent (i.e., no gap of nucleotides) to one another or are on the same transcript. 
     In some instances, the methods include hybridization of probe sets, wherein the probe pairs are in a medium at a concentration of about 1 to about 100 nM. In some instances, the concentration of the probe pairs is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 nM. In some instances, the concentration of the probe pairs is 5 nM. In some instances, the probe sets are diluted in a hybridization (Hyb) buffer. In some instances, the probe sets are at a concentration of 5 nM in Hyb buffer. 
     In some instances, probe hybridization (e.g., hybridizing the undesirable RNA depletion probes and/or the first and second probe oligonucleotides) occurs at about 50° C. In some instances, the temperature of probe hybridization ranges from about 30° C. to about 75° C., from about 35° C. to about 70° C., or from about 40° C. to about 65° C. In some embodiments, the temperature is about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., about 35° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., or about 70° C. In some instances, probe hybridization occurs for about 30 minutes, about 1 hour, about 2 hours, about 2.5 hours, about 3 hours, or more. In some instances, probe hybridization occurs for about 2.5 hours at 50° C. 
     In some instances, the hybridization buffer includes SSC (e.g., 1×SSC) or SSPE. In some instances, the hybridization buffer includes formamide or ethylene carbonate. In some instances, the hybridization buffer includes one or more salts, like Mg salt for example MgCl 2 , Na salt for example NaCl, Mn salt for example MnCl 2 . In some instances, the hybridization buffer includes Denhardt&#39;s solution, dextran sulfate, ficoll, PEG or other hybridization rate accelerators. In some instances, the hybridization buffer includes a carrier such as yeast tRNA, salmon sperm DNA, and/or lambda phage DNA. In some instances, the hybridization buffer includes one or more blockers. In some instances, the hybridization buffer includes RNase inhibitor(s). In some instances, the hybridization buffer can include BSA, sequence specific blockers, non-specific blockers, EDTA, RNase inhibitor(s), betaine, TMAC, or DMSO. In some instances, a hybridization buffer can further include detergents such as Tween, Triton-X 100, sarkosyl, and SDS. In some instances, the hybridization buffer includes nuclease-free water, DEPC water. 
     In some embodiments, the complementary sequences to which the first probe oligonucleotide and the second probe oligonucleotide bind are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 125, about 150, about 175, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, or about 1000 nucleotides away from each other. Gaps between the probe oligonucleotides may first be filled prior to ligation, using, for example, Mu polymerase, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase, and/or any combinations, derivatives, and variants (e.g., engineered mutants) thereof. In some embodiments, when the first and second probe oligonucleotides are separated from each other by one or more nucleotides, nucleotides are ligated between the first and second probe oligonucleotides. In some embodiments, when the first and second probe oligonucleotides are separated from each other by one or more nucleotides, deoxyribonucleotides are ligated between the first and second probe oligonucleotides. 
     In some instances, after hybridization, the biological sample is washed with a post-hybridization wash buffer. In some instances, the post-hybridization wash buffer includes one or more of SSC, yeast tRNA, formamide, ethylene carbonate, and nuclease-free water. 
     Additional embodiments regarding probe hybridization are further provided. 
     (i) Hybridizing Temperatures 
     In some embodiments, the method described utilizes oligonucleotides that include deoxyribonucleic acids (instead of strictly utilizing ribonucleotides) at the site of ligation. Utilizing deoxyribonucleic acids in the methods described herein create a more uniform efficiency that can be readily-controlled and flexible for various applications. In some embodiments, an undesirable RNA depletion probe includes deoxyribonucleic acids (instead of strictly utilizing ribonucleotides) at the site of ligation. In some embodiments, a first probe oligonucleotide and/or a second probe oligonucleotide include deoxyribonucleic acids (instead of strictly utilizing ribonucleotides) at the site of ligation. 
     In a non-limiting example, the methods disclosed herein include contacting a biological sample with a plurality of oligonucleotides (e.g., undesirable RNA depletion probes and/or RTL probes) including, an undesirable RNA depletion probe, a first oligonucleotide (e.g., a first probe) and a second oligonucleotide (e.g., a second probe), wherein the undesirable RNA depletion probe includes a sequence that is substantially complementary to at least a portion of an undesirable RNA, wherein the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) are complementary to a first sequence present in an analyte and a second sequence present in the analyte, respectively; hybridizing the undesirable RNA depletion probe, the first oligonucleotide (e.g., the first probe), and the second oligonucleotide (e.g., the second probe) to the analyte at a first temperature; hybridizing the undesirable RNA depletion probe, and the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) to a third oligonucleotide (e.g., a splint oligonucleotide) at a second temperature such that the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) abut each other; ligating the first oligonucleotide (e.g., the first probe) to the second oligonucleotide (e.g., the second probe) to create a ligation product; contacting the biological sample with a substrate, wherein a capture probe is immobilized on the substrate, wherein the capture probe includes a spatial barcode and a capture domain; allowing the ligation product to specifically bind to the capture domain; and determining (i) all or a part of the sequence of the ligation product specifically bound to the capture domain, or a complement thereof, and (ii) all or a part of the sequence of the spatial barcode, or a complement thereof, and using the determined sequence of (i) and (ii) to identify the location of the analyte in the biological sample; wherein the first oligonucleotide (e.g., the first probe), the second oligonucleotide (e.g., the second probe), and the third oligonucleotide are DNA oligonucleotides, and wherein the first temperature is a higher temperature than the second temperature. 
     In some embodiments, the undesirable RNA depletion probe, the first oligonucleotide (e.g., the first probe), and/or the second oligonucleotide (e.g., the second probe) hybridize to an analyte at a first temperature. In some embodiments, the first temperature ranges from about 50° C. to about 75° C., from about 55° C. to about 70° C., or from about 60° C. to about 65° C. In some embodiments, the first temperature is about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., or about 70° C. 
     In some embodiments, after the step of hybridizing the undesirable RNA depletion probe, first oligonucleotide (e.g., the first probe), and/or the second oligonucleotide (e.g., the second probe) to the analyte, a wash step is performed to remove unbound oligonucleotides (e.g., probes). The wash step can be performed using any of the wash methods and solutions described herein. 
     In some embodiments, after the step of hybridizing the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) to the analyte, a third oligonucleotide (e.g., a splint oligonucleotide) is added to the analyte. In some embodiments, the third oligonucleotide is an oligonucleotide. In some embodiments, the third oligonucleotide is a DNA oligonucleotide. 
     In some embodiments, the third oligonucleotide includes a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a portion of the first probe oligonucleotide (e.g., a portion of the first probe that is not hybridized to the analyte (e.g., an auxiliary sequence)). In some embodiments, the third oligonucleotide includes a sequence that is 100% complementary to a portion of the first oligonucleotide (e.g., the first probe). In some embodiments, the third oligonucleotide includes a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to a portion of the second probe oligonucleotide (e.g., a portion of the second probe that is not hybridized to the analyte (e.g., an auxiliary sequence)). In some embodiments, the third oligonucleotide includes a sequence that is 100% complementary to a portion of the second oligonucleotide (e.g., the second probe). In some embodiments, the third oligonucleotide hybridizes to the first oligonucleotide (e.g., the first probe) at the complementary portion. In some embodiments, the third oligonucleotide hybridizes to the second oligonucleotide (e.g., the second probe) at the complementary portion. 
     In some embodiments, the third oligonucleotide hybridizes to the first oligonucleotide (e.g., the first probe) and to the second oligonucleotide (e.g., the second probe) at a second temperature. In some embodiments, the second temperature is lower than the first temperature at which the first and second oligonucleotides (e.g., the first and second probes) bind the analyte. In some embodiments, the second temperature ranges from about 15° C. to about 35° C., from about 20° C. to about 30° C., or from about 25° C. to about 30° C. In some embodiments, the first temperature is about 15° C., about 16° C., about 17° C., about 18° C., about 19° C., about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., about 30° C., about 31° C., about 32° C., about 33° C., about 34° C., or about 35° C. Methods including a third, or splint, oligonucleotide have been described in U.S. Patent Pub. No. 2019/0055594A1, which is herein incorporated by reference in its entirety. 
     In some embodiments, after the step of hybridizing the third oligonucleotide to the analyte, a wash step is performed to remove unbound third oligonucleotides. The wash step can be performed using any of the wash methods and solutions described herein. In some embodiments, after the washing step, the first and second oligonucleotides (e.g., the first and second probes) are bound to (e.g., hybridized to) the analyte, and the third oligonucleotide is bound to (e.g., hybridized to) the first and second oligonucleotides (e.g., at portions of the first and second probes that are not bound to the analyte). 
     In some embodiments, the first oligonucleotide (e.g., the first probe), the second oligonucleotide (e.g., the second probe), and the third oligonucleotide are added to the biological sample at the same time. Then, in some embodiments, the temperature is adjusted to the first temperature to allow the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe) to hybridize to the analyte in the biological sample. Next, the temperature is adjusted to the second temperature to allow the third oligonucleotide to hybridize to the first oligonucleotide and the second oligonucleotide. 
     In some embodiments where a third oligonucleotide hybridizes to a first probe and a second probe that are hybridized to targets sequences that are not directly adjacent in the analyte, the third oligonucleotide is extended to fill the gap between the first probe and the second probe. In some instances, a polymerase (e.g., a DNA polymerase) can extend one of the probes (e.g., the first probe) prior to ligation. 
     In some embodiments, a ligation step is performed. Ligation can be performed using any of the methods described herein. In some embodiments, the step includes ligation of the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe), forming a ligation product. In some embodiments, the third oligonucleotide serves as an oligonucleotide splint to facilitate ligation of the first oligonucleotide (e.g., the first probe) and the second oligonucleotide (e.g., the second probe). In some embodiments, ligation is chemical ligation. In some embodiments, ligation is enzymatic ligation. In some embodiments, the ligase is a T4 RNA ligase (Rnl2), a splintR ligase, a single stranded DNA ligase, or a T4 DNA ligase. 
     (ii) Hybridization Buffer 
     In some embodiments, an undesirable RNA depletion probe, a first probe, and/or a second probe are hybridized to the analyte in a hybridization buffer. In some instances, the hybridization buffer contains formamide. In other instances the hybridization buffer is formamide free. Formamide is not human friendly and it is a known health hazard. Chemically, it can oxidize over time, thereby impacting reagent shelf life and, most importantly, reagent efficacy. As such, the methods described herein can include formamide-free buffers, including formamide-free hybridization buffer. 
     In some embodiments, the formamide-free hybridization buffer is a saline-sodium citrate (SSC) hybridization buffer. In some embodiment, the SSC is present in the SSC hybridization buffer from about 1×SSC to about 6×SSC (e.g., about 1×SSC to about 5×SSC, about 1×SSC to about 4×SSC, about 1×SSC to about 3×SSC, about 1×SSC to about 2×SSC, about 2×SSC to about 6×SSC, about 2×SSC to about 5×SSC, about 2×SSC to about 4×SSC, about 2×SSC to about 3×SSC, about 3×SSC to about 5×SSC, about 3×SSC to about 4×SSC, about 4×SSC to about 6×SSC, about 4×SSC to about 6×SSC, about 4×SSC to about 5×SSC, or about 5×SSC to about 6×SSC). In some embodiments, the SSC is present in the SSC hybridization buffer from about 2×SSC to about 4×SSC. In some embodiments, SSPE hybridization buffer can be used. 
     In some embodiments, the SSC hybridization buffer comprises a solvent. In some embodiments, the solvent comprises ethylene carbonate instead of formamide (2020, Kalinka et al.,  Scientia Agricola  78(4):e20190315). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer from about 10% (w/v) to about 25% (w/v) (e.g., about 10% (w/v) to about 20% (w/v), about 10% (w/v) to about 15% (w/v), about 15% (w/v) to about 25% (w/v), about 15% (w/v) to about 20% (w/v), or about 20% (w/v) to about 25% (w/v)). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer from about 15% (w/v) to about 20% (w/v). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer at about 10% (w/v), about 11% (w/v), about 12% (w/v), about 13% (w/v), about 14% (w/v), about 15% (w/v), about 16% (w/v), about 17% (w/v), about 18% (w/v), about 19% (w/v), about 20% (w/v), about 21% (w/v), about 22% (w/v), about 23% (w/v), about 24% (w/v), or about 25% (w/v). In some embodiments, ethylene carbonate is present in the SSC hybridization buffer at about 13% (w/v). 
     In some embodiments, the SSC hybridization buffer is at a temperature from about 40° C. to about 60° C. (e.g., about 40° C. to about 55° C., about 40° C. to about 50° C., about 40° C. to about 45° C., about 45° C. to about 60° C., about 45° C. to about 55° C., about 45° C. to about 50° C., about 50° C. to about 60° C., about 50° C. to about 55° C., or about 55° C. to about 60° C.). In some embodiments, the SSC hybridization buffer is at temperature from about 45° C. to about 55° C., or any of the subranges described herein. In some embodiments, the SSC hybridization buffer is at a temperature of about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., or about 60° C. In some embodiments, the SSC hybridization buffer is at a temperature of about 50° C. 
     In some embodiments, the SSC hybridization buffer further comprises one or more of a carrier, a crowder, or an additive. Non-limiting examples of a carrier that can be included in the hybridization buffer include: yeast tRNA, salmon sperm DNA, lambda phage DNA, glycogen, and cholesterol. Non-limiting examples of a molecular crowder that can be included in the hybridization buffer include: Ficoll, dextran, Denhardt&#39;s solution, and PEG. Non-limiting examples of additives that can be included in the hybridization buffer include: binding blockers, RNase inhibitors, Tm adjustors and adjuvants for relaxing secondary nucleic acid structures (e.g., betaine, TMAC, and DMSO). Further, a hybridization buffer can include detergents such as SDS, Tween, Triton-X 100, and sarkosyl (e.g., N-Lauroylsarcosine sodium salt). A skilled artisan would understand that a buffer for hybridization of nucleic acids could include many different compounds that could enhance the hybridization reaction. 
     (j) Washing 
     In some embodiments, the methods disclosed herein also include a wash step. The wash step removes any unbound probes. Wash steps could be performed between any of the steps in the methods disclosed herein. For example, a wash step can be performed after adding probes (e.g., any of the undesirable RNA probes and/or RTL probe pairs described herein) to the biological sample. As such, free/unbound probes are washed away, leaving only probes that have hybridized to an analyte and/or undesirable RNA (e.g., rRNA). In some instances, multiple (i.e., at least 2, 3, 4, 5, or more) wash steps occur between the methods disclosed herein. Wash steps can be performed at times (e.g., 1, 2, 3, 4, or 5 minutes) and temperatures (e.g., room temperature; 4° C. known in the art and determined by a person of skill in the art. 
     In some instances, wash steps are performed using a wash buffer. In some instances, the wash buffer includes SSC (e.g., 1×SSC). In some instances, the wash buffer includes PBS (e.g., 1×PBS). In some instances, the wash buffer includes PBST (e.g., 1×PBST). In some instances, the wash buffer can also include formamide or be formamide free. 
     Additional embodiments regarding wash steps are provided herein. 
     (i) Formamide Free Wash Buffer 
     In some embodiments, after hybridizing and/or ligating the undesirable RNA depletion probe, one or more unhybridized undesirable RNA depletion probes are removed from the array. In some embodiments, after ligating a first probe and a second probe, the one or more unhybridized first probes, one or more unhybridized second probes, or both, are removed from the array. In some embodiments, after ligating a first probe, a second probe, and a third oligonucleotide, the one or more unhybridized first probes, one or more unhybridized second probes, or one or more third oligonucleotides, or all the above, are removed from the array. 
     In some embodiments, a pre-hybridization buffer is used to wash the sample. In some embodiments, a phosphate buffer is used. In some embodiments, multiple wash steps are performed to remove unbound oligonucleotides. 
     In some embodiments, removing includes washing the one or more unhybridized probes (e.g., an undesirable RNA depletion probe, a first probe, a second probe, and a third oligonucleotide) from the array in a formamide-free wash buffer. 
     In some embodiments, the formamide-free wash buffer is an SSC wash buffer. In some embodiments, SSC is present in the SSC wash buffer from about 0.01×SSC to about 1×SSC (e.g., about 0.01×SSC to about 0.5×SSC, 0.01×SSC to about 0.1×SSC, about 0.01×SSC to about 0.05×SSC, about 0.05×SSC to about 1×SSC, about 0.05×SSC to about 0.5×SSC, about 0.05×SSC to about 0.1×SSC, about 0.1×SSC to about 1×SSC, about 0.1×SSC to about 0.5×SSC, or about 0.5×SSC to about 1×SSC). In some embodiments, SSC is present in the SSC wash buffer at about 0.01×SSC, about 0.02×SSC, about 0.03×SSC, about 0.04×SSC, about 0.05×SSC, about 0.06×SSC, about 0.07×SSC, about 0.08×SSC, about 0.09×SSC, about 0.1×SSC, about 0.2×SSC, about 0.3×SSC, about 0.4×SSC, about 0.5×SSC, about 0.6×SSC, about 0.7×SSC, about 0.8×SSC, about 0.9×SSC, or about 0.1×SSC. In some embodiments, SSC is present in the SSC wash buffer at about 0.1×SSC. 
     In some embodiments, the SSC wash buffer comprises a detergent. In some embodiments, the detergent comprises sodium dodecyl sulfate (SDS). In some embodiments, SDS is present in the SSC wash buffer from about 0.01% (v/v) to about 0.5% (v/v) (e.g., about 0.01% (v/v) to about 0.4% (v/v), about 0.01% (v/v) to about 0.3% (v/v), about 0.01% (v/v) to about 0.2% (v/v), about 0.01% (v/v) to about 0.1% (v/v), about 0.05% (v/v) to about 0.5% (v/v), about 0.05% (v/v) to about 0.4% (v/v), about 0.05% (v/v) to about 0.3% (v/v), about 0.05% (v/v) to about 0.2% (v/v), about 0.05% (v/v) to about 0.1% (v/v), about 0.1% (v/v) to about 0.5% (v/v), about 0.1% (v/v) to about 0.4% (v/v), about 0.1% (v/v) to about 0.3% (v/v), about 0.1% (v/v) to about 0.2% (v/v), about 0.2% (v/v) to about 0.5% (v/v), about 0.2% (v/v) to about 0.4% (v/v), about 0.2% (v/v) to about 0.3% (v/v), about 0.3% (v/v) to about 0.5% (v/v), about 0.3% (v/v) to about 0.4% (v/v), or about 0.4% (v/v) to about 0.5% (v/v)). In some embodiments, the SDS is present the SSC wash buffer at about 0.01% (v/v), about 0.02% (v/v), about 0.03% (v/v), about 0.04% (v/v), about 0.05% (v/v), about 0.06% (v/v), about 0.07% (v/v), about 0.08% (v/v), about 0.09% (v/v), about 0.10% (v/v), about 0.2% (v/v), about 0.3% (v/v), about 0.4% (v/v), or about 0.5% (v/v), In some embodiments, the SDS is present in the SSC wash buffer at about 0.1% (v/v). In some embodiments, sarkosyl may be present in the SSC wash buffer. 
     In some embodiments, the SSC wash buffer comprises a solvent. In some embodiments, the solvent comprises formamide or ethylene carbonate. In some embodiments, ethylene carbonate is present in the SSC wash buffer from about 10% (w/v) to about 25% (w/v), or any of the subranges described herein. In some embodiments, ethylene carbonate is present in the SSC wash buffer from about 15% (w/v) to about 20% (w/v). In some embodiments, ethylene carbonate is present in the SSC wash buffer at about 16% (w/v). 
     In some embodiments, the SSC wash buffer is at a temperature from about 50° C. to about 70° C. (e.g., about 50° C. to about 65° C., about 50° C. to about 60° C., about 50° C. to about 55° C., about 55° C. to about 70° C., about 55° C. to about 65° C., about 55° C. to about 60° C., about 60° C. to about 70° C., about 60° C. to about 65° C., or about 65° C. to about 70° C.). In some embodiments, the SSC wash buffer is at a temperature from about 55° C. to about 65° C. In some embodiments, the SSC wash buffer is at a temperature about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., about 60° C., about 61° C., about 62° C., about 63° C., about 64° C., about 65° C., about 66° C., about 67° C., about 68° C., about 69° C., or about 70° C. In some embodiments, the SSC wash buffer is at a temperature of about 60° C. 
     In some embodiments, the method includes releasing the ligation product, where releasing is performed after the array is washed to remove the one or more unhybridized first and second probes. 
     (k) Ligation 
     In some embodiments, after hybridization of the probe oligonucleotides (e.g., a first probe, a second probe, and/or a third oligonucleotide) to the analyte, the probes (e.g., a first probe, a second probe, and/or a third oligonucleotide) can be ligated together, creating a single ligation product that includes one or more sequences that are complementary to the analyte. In some embodiments, after hybridization of the undesirable RNA depletion probes, the undesirable RNA depletion probes can be ligated together. Ligation can be performed enzymatically or chemically, as described herein. 
     In some instances, the ligation is an enzymatic ligation reaction, using a ligase (e.g., T4 RNA ligase (Rnl2), a SplintR ligase, a single stranded DNA ligase, or a T4 DNA ligase). See, e.g., Zhang et al.;  RNA Biol.  2017; 14(1): 36-44, which is incorporated by reference in its entirety, for a description of KOD ligase. Following the enzymatic ligation reaction, the probes (e.g., a first probe, a second probe, and/or a third oligonucleotide) may be considered ligated. 
     In some embodiments, a polymerase catalyzes synthesis of a complementary strand of the ligation product, creating a double-stranded ligation product. In some instances, the polymerase is DNA polymerase. In some embodiments, the polymerase has 5′ to 3′ polymerase activity. In some embodiments, the polymerase has 3′ to 5′ exonuclease activity for proofreading. In some embodiments, the polymerase has 5′ to 3′ polymerase activity and 3′ to 5′ exonuclease activity for proofreading. 
     In some embodiments, the probe (e.g., a first probe, a second probe, and/or a third oligonucleotide) may each comprise a reactive moiety such that, upon hybridization to the target and exposure to appropriate ligation conditions, the probe oligonucleotides may ligate to one another. In some embodiments, probe oligonucleotides that include a reactive moiety are ligated chemically. For example, a first probe capable of hybridizing to a first target region (e.g., a first target sequence or a first portion) of a nucleic acid molecule may comprise a first reactive moiety, and a second probe oligonucleotide capable of hybridizing to a second target region (e.g., a second target sequence or a second portion) of the nucleic acid molecule may comprise a second reactive moiety. When the first and second probes are hybridized to the first and second target regions (e.g., first and second target sequences) of the nucleic acid molecule, the first and second reactive moieties may be adjacent to one another. A reactive moiety of a probe may be selected from the non-limiting group consisting of azides, alkynes, nitrones (e.g., 1,3-nitrones), strained alkenes (e.g., trans-cycloalkenes such as cyclooctenes or oxanorbornadiene), tetrazines, tetrazoles, iodides, thioates (e.g., phorphorothioate), acids, amines, and phosphates. For example, the first reactive moiety of a first probe may comprise an azide moiety, and a second reactive moiety of a second probe may comprise an alkyne moiety. The first and second reactive moieties may react to form a linking moiety. A reaction between the first and second reactive moieties may be, for example, a cycloaddition reaction such as a strain-promoted azide-alkyne cycloaddition, a copper-catalyzed azide-alkyne cycloaddition, a strain-promoted alkyne-nitrone cycloaddition, a Diels-Alder reaction, a [3+2] cycloaddition, a [4+2] cycloaddition, or a [4+1] cycloaddition; a thiol-ene reaction; a nucleophilic substation reaction; or another reaction. In some cases, reaction between the first and second reactive moieties may yield a triazole moiety or an isoxazoline moiety. A reaction between the first and second reactive moieties may involve subjecting the reactive moieties to suitable conditions such as a suitable temperature, pH, or pressure and providing one or more reagents or catalysts for the reaction. For example, a reaction between the first and second reactive moieties may be catalyzed by a copper catalyst, a ruthenium catalyst, or a strained species such as a difluorooctyne, dibenzylcyclooctyne, or biarylazacyclooctynone. Reaction between a first reactive moiety of a first probe hybridized to a first target region (e.g., a first target sequence or first portion) of the nucleic acid molecule and a second reactive moiety of a third probe oligonucleotide hybridized to a second target region (e.g., a first target sequence or a first portion) of the nucleic acid molecule may link the first probe and the second probe to provide a ligated probe. Upon linking, the first and second probe may be considered ligated. Accordingly, reaction of the first and second reactive moieties may comprise a chemical ligation reaction such as a copper-catalyzed 5′ azide to 3′ alkyne “click” chemistry reaction to form a triazole linkage between two probe oligonucleotides. In other non-limiting examples, an iodide moiety may be chemically ligated to a phosphorothioate moiety to form a phosphorothioate bond, an acid may be ligated to an amine to form an amide bond, and/or a phosphate and amine may be ligated to form a phosphoramidate bond. 
     In some instances, ligation is performed in a ligation buffer. In instances where probe ligation is performed on diribo-containing probes, the ligation buffer can include T4 RNA Ligase Buffer 2, enzyme (e.g., RNL2 ligase), and nuclease free water. In instances where probe ligation is performed on DNA probes, the ligation buffer can include Tris-HCl pH7.5, MnCl2, ATP, DTT, surrogate fluid (e.g., glycerol), enzyme (e.g., SplintR ligase), and nuclease-free water. 
     In some embodiments, the ligation buffer includes additional reagents. In some instances, the ligation buffer includes adenosine triphosphate (ATP) is added during the ligation reaction. DNA ligase-catalyzed sealing of nicked DNA substrates is first activated through ATP hydrolysis, resulting in covalent addition of an AMP group to the enzyme. After binding to a nicked site in a DNA duplex, the ligase transfers the AMP to the phosphorylated 5′-end at the nick, forming a 5′-5′ pyrophosphate bond. Finally, the ligase catalyzes an attack on this pyrophosphate bond by the OH group at the 3′-end of the nick, thereby sealing it, whereafter ligase and AMP are released. If the ligase detaches from the substrate before the 3′ attack, e.g., because of premature AMP reloading of the enzyme, then the 5′ AMP is left at the 5′-end, blocking further ligation attempts. In some instances, ATP is added at a concentration of about 1 μM, about 10 μM, about 100 μM, about 1000 μM, or about 10000 μM during the ligation reaction. 
     In some embodiments, cofactors that aid in joining of the probe oligonucleotides are added during the ligation process. In some instances, the cofactors include magnesium ions (Mg′). In some instances, the cofactors include manganese ions (Mn′). In some instances, Mg′ is added in the form of MgCl 2 . In some instances, Mn′ is added in the form of MnCl 2 . In some instances, the concentration of MgCl 2  is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM. In some instances, the concentration of MnCl 2  is at about 1 mM, at about 10 mM, at about 100 mM, or at about 1000 mM. 
     In some embodiments, the ligation product includes a capture probe capture domain, which can bind to a capture probe (e.g., a capture probe immobilized, directly or indirectly, on a substrate). In some embodiments, methods provided herein include contacting a biological sample with a substrate, wherein the capture probe is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly). In some embodiments, the capture probe capture domain of the ligated probe specifically binds to the capture domain. 
     After ligation, in some instances, the biological sample is washed with a post-ligation wash buffer. In some instances, the post-ligation wash buffer includes one or more of SSC (e.g., 1×SSC), ethylene carbonate or formamide, and nuclease free water. In some instances, the biological sample is washed at this stage at about 50° C. to about 70° C. In some instances, the biological sample is washed at about 60° C. 
     (i) Ligation Including Pre-Adenylated 5′ Phosphate on Second Probe 
     Provided herein are methods for determining a location of a target nucleic acid in a biological sample that include: (a) contacting the biological sample with a substrate comprising a plurality of capture probes, where a capture probe of the plurality of capture probes comprises a capture domain and a spatial barcode; (b) hybridizing a target nucleic acid in the biological sample with a first probe and a second probe, where the first probe comprises, from 3′ to 5′, a sequence substantially complementary to the capture domain and a sequence that is substantially complementary to a first sequence in the target nucleic acid and has a pre-adenylated phosphate group at its 5′ end; the second probe comprises a sequence substantially complementary to a second sequence in the target nucleic acid; (c) generating a ligation product by ligating a 3′ end of the second probe to the 5′ end of the first probe using a ligase that does not require adenosine triphosphate for ligase activity; (d) releasing the ligation product from the target nucleic acid and binding the capture domain of the ligation product specifically to the capture domain of capture probe; and (e) determining (i) all or a part of a sequence corresponding to the ligation product, or a complement thereof, and (ii) all or a part of a sequence corresponding to the spatial barcode, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location of the target nucleic acid in the biological sample 
     In some instances, the ligase that does not require adenosine triphosphate for ligase activity (e.g., thermostable 5′ AppDNA/RNA Ligase, truncated T4 RNA Ligase 2 (trRnl2), truncated T4 RNA Ligase 2 K227Q, truncated T4 RNA Ligase 2 KQ,  Chlorella  Virus PBCV-1 DNA Ligase, and combinations thereof). See, e.g., Nichols et al., “RNA Ligases,” Curr. Protocol. Molec. Biol. 84(1):3.15.1-.4 (2008); Viollet et al., “T4 RNA Ligase 2 Truncated Active Site Mutants: Improved Tools for RNA Analysis,” BMC Biotechnol. 11: 72 (2011); and Ho et al., “Bacteriophage T4 RNA Ligase 2 (gp24.1) Exemplifies a Family of RNA Ligases Found in All Phylogenetic Domains,” PNAS 99(20):12709-14 (2002), which are hereby incorporated by reference in their entirety for a description of T4 RNA Ligases and truncated T4 RNA Ligases. Thermostable 5′ AppDNA/RNA Ligase is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA or ssDNA to a 5′-adenylated ssDNA or 5′-adenylated ssRNA. Truncated T4 RNA Ligase 2 is an enzyme belonging to the Ligase family that catalyzes the ligation of dsRNA nicks and ssRNA to ssRNA. It can also ligate the 3′ end of RNA or DNA to a 5′-pDNA when annealed to an RNA complement, and the 3′ end of RNA to a 5′-pRNA when annealed to a DNA complement, with reduced efficiency. Truncated T4 RNA Ligase 2 K227Q is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA to 5′ adenylated ssDNA and 5′ adenylated ssRNA. It has a reduction of side products as compared to truncated T4 RNA Ligase 2. Truncated T4 RNA Ligase 2 KQ is an enzyme belonging to the Ligase family that catalyzes the ligation of the 3′ end of ssRNA to 5′ adenylated ssDNA and 5′ adenylated ssRNA. It is a preferred choice for ligation of ssRNA to preadenylated adapters and has a reduction of side products as compared to truncated T4 RNA Ligase 2. 
     In some embodiments, the T4 RNA Ligase comprises a K227Q mutation. See Viollet et al., “T4 RNA Ligase 2 Truncated Active Site Mutants: Improved Tools for RNA Analysis,”  BMC Biotechnol.  11, which is hereby incorporated by reference in its entirety. 
     In some instances, cofactors that aid in ligation of the first and second probe are added during ligation. In some instances, the cofactors include magnesium ions (Mg 2+ ). In some instances, the cofactors include manganese ions (Mn 2+ ). In some instances, Mg 2+  is added in the form of MgCl 2 . In some instances, Mn 2+  is added in the form of MnCl 2 . In some instances, the concentration of MgCl 2  is at about 1 mM to about 10 mM. In some instances, the concentration of MnCl 2  is at about 1 mM to about 10 mM. 
     In some instances, the ligation occurs at a pH in the range of about 6.5 to about 9.0, about 6.5 to about 8.0, or about 7.5 to about 8.0. 
     In some embodiments, the ligation buffer includes an enzyme storage buffer. In some embodiments, the enzymes storage buffer includes glycerol. In some embodiments, the ligation buffer is supplemented with glycerol. In some embodiments, the glycerol is present in the ligation buffer at a total volume of 15% v/v. 
     (l) Permeabilization and Releasing the Ligation Product 
     In some embodiments, the methods provided herein include a permeabilizing step. In some embodiments, permeabilization occurs using a protease. In some embodiments, the protease is an endopeptidase. Endopeptidases that can be used include but are not limited to trypsin, chymotrypsin, elastase, thermolysin, pepsin, clostripan, glutamyl endopeptidase (GluC), ArgC, peptidyl-asp endopeptidase (ApsN), endopeptidase LysC and endopeptidase LysN. In some embodiments, the endopeptidase is pepsin. In some embodiments, the biological sample is permeabilized contemporaneously with or prior to contacting the biological sample with undesirable RNA depletion probes. In some embodiments, the biological sample is permeabilized after the biological sample is contacted with undesirable RNA depletion probes. In some embodiments, the biological sample is permeabilized after the biological sample is contacted with undesirable RNA depletion probes but prior to contacting the array. In some embodiments, the biological sample is permeabilized after the biological sample is contacted with undesirable RNA depletion probes but prior to contacting a first probe oligonucleotide and a second probe oligonucleotide. In some embodiments, after creating a ligation product (e.g., by ligating a first probe and a second probe that are hybridized to adjacent sequences in the analyte), the biological sample is permeabilized. In some embodiments, the biological sample is permeabilized contemporaneously with or prior to contacting the biological sample with a first probe and a second probe, hybridizing the first probe and the second probe to the analyte, generating a ligation product by ligating the first probe and the second probe, and releasing the ligated product from the analyte. 
     In some embodiments, methods provided herein include permeabilization of the biological sample such that the capture probe can more easily bind to the captured ligated probe (i.e., compared to no permeabilization). In some embodiments, reverse transcription (RT) reagents can be added to permeabilized biological samples. Incubation with the RT reagents can produce spatially-barcoded full-length cDNA from the captured analytes (e.g., polyadenylated mRNA). Second strand reagents (e.g., second strand primers, enzymes) can be added to the biological sample on the slide to initiate second strand synthesis. 
     In some instances, the permeabilization step includes application of a permeabilization buffer to the biological sample. In some instances, the permeabilization buffer includes a buffer (e.g., Tris pH 7.5), MgCl2, sarkosyl detergent (e.g., sodium lauroyl sarcosinate), enzyme (e.g., proteinase K), and nuclease free water. In some instances, the permeabilization step is performed at 37° C. In some instances, the permeabilization step is performed for about 20 minutes to 2 hours (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 1.5 hours, or about 2 hours). In some instances, the releasing step is performed for about 40 minutes. 
     In some embodiments, after generating a ligation product, the ligation product is released from the analyte. In some embodiments, a ligation product is released from the analyte using an endoribonuclease. In some embodiments, the endoribonuclease is RNase H, RNase A, RNase C, or RNase I. In some embodiments, the endoribonuclease is RNase H. RNase H is an endoribonuclease that specifically hydrolyzes the phosphodiester bonds of RNA, when hybridized to DNA. RNase H is part of a conserved family of ribonucleases which are present in many different organisms. There are two primary classes of RNase H: RNase H1 and RNase H2. Retroviral RNase H enzymes are similar to the prokaryotic RNase H1. All of these enzymes share the characteristic that they are able to cleave the RNA component of an RNA:DNA heteroduplex. In some embodiments, the RNase H is RNase H1, RNase H2, or RNase H1, or RNase H2. In some embodiments, the RNase H includes but is not limited to RNase HII from  Pyrococcus furiosus , RNase HII from  Pyrococcus horikoshi , RNase HI from  Thermococcus litoralis , RNase HI from  Thermus thermophilus , RNAse HI from  E. coli , or RNase HII from  E. coli.    
     In some instances, the releasing step is performed using a releasing buffer. In some instances, the release buffer includes one or more of a buffer (e.g., Tris pH 7.5), enzyme (e.g., RNAse H) and nuclease-free water. In some instances, the releasing step is performed at 37° C. In some instances, the releasing step is performed for about 20 minutes to 2 hours (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 1.5 hours, or about 2 hours). In some instances, the releasing step is performed for about 30 minutes. 
     In some instances, the releasing step occurs before the permeabilization step. In some instances, the releasing step occurs after the permeabilization step. In some instances, the releasing step occurs at the same time as the permeabilization step (e.g., in the same buffer). 
     (m) Biological Samples 
     Methods disclosed herein can be performed on any type of sample. In some embodiments, the sample is a fresh tissue. In some embodiments, the sample is a frozen sample. In some embodiments, the sample was previously frozen. In some embodiments, the sample is a formalin-fixed, paraffin embedded (FFPE) sample. 
     Subjects from which biological samples can be obtained can be healthy or asymptomatic individuals, individuals that have or are suspected of having a disease (e.g., cancer) or a pre-disposition to a disease, and/or individuals that are in need of therapy or suspected of needing therapy. In some instances, the biological sample can include one or more diseased cells. A diseased cell can have altered metabolic properties, gene expression, protein expression, and/or morphologic features. Examples of diseases include inflammatory disorders, metabolic disorders, nervous system disorders, and cancer. In some instances, the biological sample includes cancer or tumor cells. Cancer cells can be derived from solid tumors, hematological malignancies, cell lines, or obtained as circulating tumor cells. In some instances, the biological sample is a heterogenous sample. In some instances, the biological sample is a heterogenous sample that includes tumor or cancer cells and/or stromal cells, 
     In some instances, the cancer is breast cancer. In some instances, the breast cancer is triple positive breast cancer (TPBC). In some instances, the breast cancer is triple negative breast cancer (TNBC). 
     In some instances, the cancer is colorectal cancer. In some instances, the cancer is ovarian cancer. In certain embodiments, the cancer is squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin&#39;s or non-Hodgkin&#39;s lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, salivary gland carcinoma, kidney cancer, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, or a type of head or neck cancer. In certain embodiments, the cancer treated is desmoplastic melanoma, inflammatory breast cancer, thymoma, rectal cancer, anal cancer, or surgically treatable or non-surgically treatable brain stem glioma. In some embodiments, the subject is a human. 
     FFPE samples generally are heavily cross-linked and fragmented, and therefore this type of sample allows for limited RNA recovery using conventional detection techniques. In certain embodiments, methods of targeted RNA capture provided herein are less affected by RNA degradation associated with FFPE fixation than other methods (e.g., methods that take advantage of oligo-dT capture and reverse transcription of mRNA). In certain embodiments, methods provided herein enable sensitive measurement of specific genes of interest that otherwise might be missed with a whole transcriptomic approach. 
     In some instances, FFPE samples are stained (e.g., using H&amp;E). The methods disclosed herein are compatible with H&amp;E will allow for morphological context overlaid with transcriptomic analysis. However, depending on the need some samples may be stained with only a nuclear stain, such as staining a sample with only hematoxylin and not eosin, when location of a cell nucleus is needed. 
     In some embodiments, a biological sample (e.g., tissue section) can be fixed with methanol, stained with hematoxylin and eosin, and imaged. In some embodiments, fixing, staining, and imaging occurs before one or more probes are hybridized to the sample. Some embodiments of any of the workflows described herein can further include a destaining step (e.g., a hematoxylin and eosin destaining step), after imaging of the sample and prior to permeabilizing the sample. For example, destaining can be performed by performing one or more (e.g., one, two, three, four, or five) washing steps (e.g., one or more (e.g., one, two, three, four, or five) washing steps performed using a buffer including HCl). The images can be used to map spatial gene expression patterns back to the biological sample. A permeabilization enzyme can be used to permeabilize the biological sample directly on the slide. 
     In some embodiments, the FFPE sample is deparaffinized, permeabilized, equilibrated, and blocked before target probe oligonucleotides are added. In some embodiments, deparaffinization using xylenes. In some embodiments, deparaffinization includes multiple washes with xylenes. In some embodiments, deparaffinization includes multiple washes with xylenes followed by removal of xylenes using multiple rounds of graded alcohol followed by washing the sample with water. In some aspects, the water is deionized water. In some embodiments, equilibrating and blocking includes incubating the sample in a pre-Hyb buffer. In some embodiments, the pre-Hyb buffer includes yeast tRNA. In some embodiments, permeabilizing a sample includes washing the sample with a phosphate buffer. In some embodiments, the buffer is PBS. In some embodiments, the buffer is PBST. 
     (n) Determining the Sequence of the Ligation Product 
     After an analyte (e.g., mRNA molecule) or a ligation product from the sample has hybridized or otherwise been associated with a capture probe according to any of the methods described above in connection with the general spatial cell-based analytical methodology, the barcoded constructs that result from hybridization/association are analyzed. 
     In some embodiments, after contacting a biological sample with a substrate that includes capture probes, a removal step can optionally be performed to remove all or a portion of the biological sample from the substrate. In some embodiments, the removal step includes enzymatic and/or chemical degradation of cells of the biological sample. For example, the removal step can include treating the biological sample with an enzyme (e.g., a proteinase, e.g., proteinase K) to remove at least a portion of the biological sample from the substrate. In some embodiments, the removal step can include ablation of the tissue (e.g., laser ablation). 
     In some embodiments, provided herein are methods for spatially detecting an analyte (e.g., detecting the location of an analyte, e.g., a biological analyte) from a biological sample (e.g., present in a biological sample), the method comprising: (a) optionally staining and/or imaging a biological sample on a substrate; (b) permeabilizing (e.g., providing a solution comprising a permeabilization reagent to) the biological sample on the substrate; (c) contacting the biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality captures the biological analyte; (d) hybridizing an undesirable RNA depletion probe to an undesirable RNA; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; (f) hybridizing the analyte to a capture domain of a capture probe that is affixed to the substrate; and (g) analyzing the captured biological analyte, thereby spatially detecting the biological analyte; wherein the biological sample is fully or partially removed from the substrate. 
     In some embodiments, a biological sample is not removed from the substrate. For example, the biological sample is not removed from the substrate prior to releasing a capture probe (e.g., a capture probe bound to an analyte) from the substrate. In some embodiments, such releasing comprises cleavage of the capture probe from the substrate (e.g., via a cleavage domain). In some embodiments, such releasing does not comprise releasing the capture probe from the substrate (e.g., a copy of the capture probe bound to an analyte can be made and the copy can be released from the substrate, e.g., via denaturation). In some embodiments, the biological sample is not removed from the substrate prior to analysis of an analyte bound to a capture probe after it is released from the substrate. In some embodiments, the biological sample remains on the substrate during removal of a capture probe from the substrate and/or analysis of an analyte bound to the capture probe after it is released from the substrate. In some embodiments, the biological sample remains on the substrate during removal (e.g., via denaturation) of a copy of the capture probe (e.g., complement). In some embodiments, analysis of an analyte bound to capture probe from the substrate can be performed without subjecting the biological sample to enzymatic and/or chemical degradation of the cells (e.g., permeabilized cells) or ablation of the tissue (e.g., laser ablation). 
     In some embodiments, at least a portion of the biological sample is not removed from the substrate. For example, a portion of the biological sample can remain on the substrate prior to releasing a capture probe (e.g., a capture prove bound to an analyte) from the substrate and/or analyzing an analyte bound to a capture probe released from the substrate. In some embodiments, at least a portion of the biological sample is not subjected to enzymatic and/or chemical degradation of the cells (e.g., permeabilized cells) or ablation of the tissue (e.g., laser ablation) prior to analysis of an analyte bound to a capture probe from the substrate. 
     In some embodiments, provided herein are methods for spatially detecting an analyte (e.g., detecting the location of an analyte, e.g., a biological analyte) from a biological sample (e.g., present in a biological sample) that include: (a) optionally staining and/or imaging a biological sample on a substrate; (b) permeabilizing (e.g., providing a solution comprising a permeabilization reagent to) the biological sample on the substrate; (c) contacting the biological sample with an array comprising a plurality of capture probes, wherein a capture probe of the plurality captures the biological analyte; (d) hybridizing an undesirable RNA depletion probe to an undesirable RNA; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; (f) hybridizing the analyte to a capture domain of a capture probe that is affixed to the substrate; and (g) analyzing the captured biological analyte, thereby spatially detecting the biological analyte; where the biological sample is not removed from the substrate. 
     In some embodiments, provided herein are methods for spatially detecting a biological analyte of interest from a biological sample that include: (a) staining and imaging a biological sample on a substrate; (b) providing a solution comprising a permeabilization reagent to the biological sample on the substrate; (c) contacting the biological sample with an array on a substrate, wherein the array comprises one or more capture probe pluralities thereby allowing the one or more pluralities of capture probes to capture the biological analyte of interest; (d) hybridizing an undesirable RNA depletion probe to an undesirable RNA; (e) removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes; (f) hybridizing the analyte to a capture domain of a capture probe that is affixed to the substrate; and (g) analyzing the captured biological analyte, thereby spatially detecting the biological analyte of interest; where the biological sample is not removed from the substrate. 
     In some embodiments, the method further includes subjecting a region of interest in the biological sample to spatial transcriptomic analysis. In some embodiments, one or more of the capture probes includes a capture domain. In some embodiments, one or more of the capture probes comprises a unique molecular identifier (UMI). In some embodiments, one or more of the capture probes comprises a cleavage domain. In some embodiments, the cleavage domain comprises a sequence recognized and cleaved by uracil-DNA glycosylase, apurinic/apyrimidinic (AP) endonuclease (APE1), U uracil-specific excision reagent (USER), and/or an endonuclease VIII. In some embodiments, one or more capture probes do not comprise a cleavage domain and is not cleaved from the array. 
     In some embodiments, a capture probe can be extended (an “extended capture probe,” e.g., as described herein). For example, extending a capture probe can include generating cDNA from a captured (hybridized) RNA. This process involves synthesis of a complementary strand of the hybridized nucleic acid, e.g., generating cDNA based on the captured RNA template (the RNA hybridized to the capture domain of the capture probe). Thus, in an initial step of extending a capture probe, e.g., the cDNA generation, the captured (hybridized) nucleic acid, e.g., RNA, acts as a template for the extension, e.g., reverse transcription, step. In some embodiments, the capture probe is extended after hybridizing an undesirable RNA depletion probe to an undesirable RNA and removing the plurality of undesirable RNA depletion probe-undesirable RNA complexes. 
     In some embodiments, the capture probe is extended using reverse transcription. For example, reverse transcription includes synthesizing cDNA (complementary or copy DNA) from RNA, e.g., (messenger RNA), using a reverse transcriptase. In some embodiments, reverse transcription is performed while the tissue is still in place, generating an analyte library, where the analyte library includes the spatial barcodes from the adjacent capture probes. In some embodiments, the capture probe is extended using one or more DNA polymerases. 
     In some embodiments, a capture domain of a capture probe includes a primer for producing the complementary strand of a nucleic acid hybridized to the capture probe, e.g., a primer for DNA polymerase and/or reverse transcription. The nucleic acid, e.g., DNA and/or cDNA, molecules generated by the extension reaction incorporate the sequence of the capture probe. The extension of the capture probe, e.g., a DNA polymerase and/or reverse transcription reaction, can be performed using a variety of suitable enzymes and protocols. 
     In some embodiments, a full-length DNA (e.g., cDNA) molecule is generated. In some embodiments, a “full-length” DNA molecule refers to the whole of the captured nucleic acid molecule. However, if a nucleic acid (e.g., RNA) was partially degraded in the tissue sample, then the captured nucleic acid molecules will not be the same length as the initial RNA in the tissue sample. In some embodiments, the 3′ end of the extended probes, e.g., first strand cDNA molecules, is modified. For example, a linker or adaptor can be ligated to the 3′ end of the extended probes. This can be achieved using single stranded ligation enzymes such as T4 RNA ligase or Circligase™ (available from Lucigen, Middleton, Wis.). In some embodiments, template switching oligonucleotides are used to extend cDNA in order to generate a full-length cDNA (or as close to a full-length cDNA as possible). In some embodiments, a second strand synthesis helper probe (a partially double stranded DNA molecule capable of hybridizing to the 3′ end of the extended capture probe), can be ligated to the 3′ end of the extended probe, e.g., first strand cDNA, molecule using a double stranded ligation enzyme such as T4 DNA ligase. Other enzymes appropriate for the ligation step are known in the art and include, e.g., Tth DNA ligase, Taq DNA ligase,  Thermococcus  sp. (strain 9° N) DNA ligase (9°N™ DNA ligase, New England Biolabs), Ampligase™ (available from Lucigen, Middleton, Wis.), and SplintR (available from New England Biolabs, Ipswich, Mass.). In some embodiments, a polynucleotide tail, e.g., a poly(A) tail, is incorporated at the 3′ end of the extended probe molecules. In some embodiments, the polynucleotide tail is incorporated using a terminal transferase active enzyme. 
     In some embodiments, double-stranded extended capture probes are treated to remove any unextended capture probes prior to amplification and/or analysis, e.g., sequence analysis. This can be achieved by a variety of methods, e.g., using an enzyme to degrade the unextended probes, such as an exonuclease enzyme, or purification columns. 
     In some embodiments, extended capture probes are amplified to yield quantities that are sufficient for analysis, e.g., via DNA sequencing. In some embodiments, the first strand of the extended capture probes (e.g., DNA and/or cDNA molecules) acts as a template for the amplification reaction (e.g., a polymerase chain reaction). 
     In some embodiments, the amplification reaction incorporates an affinity group onto the extended capture probe (e.g., RNA-cDNA hybrid) using a primer including the affinity group. In some embodiments, the primer includes an affinity group and the extended capture probes includes the affinity group. The affinity group can correspond to any of the affinity groups described previously. 
     In some embodiments, the extended capture probes including the affinity group can be coupled to a substrate specific for the affinity group. In some embodiments, the substrate can include an antibody or antibody fragment. In some embodiments, the substrate includes avidin or streptavidin and the affinity group includes biotin. In some embodiments, the substrate includes maltose and the affinity group includes maltose-binding protein. In some embodiments, the substrate includes maltose-binding protein and the affinity group includes maltose. In some embodiments, amplifying the extended capture probes can function to release the extended probes from the surface of the substrate, insofar as copies of the extended probes are not immobilized on the substrate. 
     In some embodiments, the extended capture probe or complement or amplicon thereof is released. The step of releasing the extended capture probe or complement or amplicon thereof from the surface of the substrate can be achieved in a number of ways. In some embodiments, an extended capture probe or a complement thereof is released from the array by nucleic acid cleavage and/or by denaturation (e.g., by heating to denature a double-stranded molecule). 
     In some embodiments, the extended capture probe or complement or amplicon thereof is released from the surface of the substrate (e.g., array) by physical means. For example, where the extended capture probe is indirectly immobilized on the array substrate, e.g., via hybridization to a surface probe, it can be sufficient to disrupt the interaction between the extended capture probe and the surface probe. Methods for disrupting the interaction between nucleic acid molecules include denaturing double stranded nucleic acid molecules are known in the art. A straightforward method for releasing the DNA molecules (i.e., of stripping the array of extended probes) is to use a solution that interferes with the hydrogen bonds of the double stranded molecules. In some embodiments, the extended capture probe is released by an applying heated solution, such as water or buffer, of at least 85° C., e.g., at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99° C. In some embodiments, a solution including salts, surfactants, etc. that can further destabilize the interaction between the nucleic acid molecules is added to release the extended capture probe from the substrate. 
     In some embodiments, where the extended capture probe includes a cleavage domain, the extended capture probe is released from the surface of the substrate by cleavage. For example, the cleavage domain of the extended capture probe can be cleaved by any of the methods described herein. In some embodiments, the extended capture probe is released from the surface of the substrate, e.g., via cleavage of a cleavage domain in the extended capture probe, prior to the step of amplifying the extended capture probe. 
     In some embodiments, probes complementary to the extended capture probe can be contacted with the substrate. In some embodiments, the biological sample can be in contact with the substrate when the probes are contacted with the substrate. In some embodiments, the biological sample can be removed from the substrate prior to contacting the substrate with probes. In some embodiments, the probes can be labeled with a detectable label (e.g., any of the detectable labels described herein). In some embodiments, probes that do not specially bind (e.g., hybridize) to an extended capture probe can be washed away. In some embodiments, probes complementary to the extended capture probe can be detected on the substrate (e.g., imaging, any of the detection methods described herein). 
     In some embodiments, probes complementary to an extended capture probe can be about 4 nucleotides to about 100 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 10 nucleotides to about 90 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 20 nucleotides to about 80 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 30 nucleotides to about 60 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 40 nucleotides to about 50 nucleotides long. In some embodiments, probes (e.g., detectable probes) complementary to an extended capture probe can be about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, about 75, about 76, about 77, about 78, about 79, about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, and about 99 nucleotides long. 
     In some embodiments, about 1 to about 100 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 1 to about 10 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 10 to about 100 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 20 to about 90 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 30 to about 80 probes (e.g., detectable probes) can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 40 to about 70 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 50 to about 60 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. In some embodiments, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, about 35, about 36, about 37, about 38, about 39, about 40, about 41, about 42, about 43, about 44, about 45, about 46, about 47, about 48, about 49, about 50, about 51, about 52, about 53, about 54, about 55, about 56, about 57, about 58, about 59, about 60, about 61, about 62, about 63, about 64, about 65, about 66, about 67, about 68, about 69, about 70, about 71, about 72, about 73, about 74, about 75, about 76, about 77, about 78, about 79, about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, and about 99 probes can be contacted to the substrate and specifically bind (e.g., hybridize) to an extended capture probe. 
     In some embodiments, the probes can be complementary to a single analyte (e.g., a single gene). In some embodiments, the probes can be complementary to one or more analytes (e.g., analytes in a family of genes). In some embodiments, the probes (e.g., detectable probes) can be for a panel of genes associated with a disease (e.g., cancer, Alzheimer&#39;s disease, Parkinson&#39;s disease). 
     In some instances, the analyte and capture probe can be amplified or copied, creating a plurality of cDNA molecules. In some instances, the ligated probe and capture probe can be amplified or copied, creating a plurality of cDNA molecules. In some embodiments, cDNA can be denatured from the capture probe template and transferred (e.g., to a clean tube) for amplification, and/or library construction. The spatially-barcoded cDNA can be amplified via PCR prior to library construction. The cDNA can then be enzymatically fragmented and size-selected in order to optimize for cDNA amplicon size. P5 and P7 sequences directed to capturing the amplicons on a sequencing flowcell (Illumina sequencing instruments) can be appended to the amplicons, i7, and i5 can be used as sample indexes, and TruSeq Read 2 can be added via End Repair, A-tailing, Adaptor Ligation, and PCR. The cDNA fragments can then be sequenced using paired-end sequencing using TruSeq Read 1 and TruSeq Read 2 as sequencing primer sites. The additional sequences are directed toward Illumina sequencing instruments or sequencing instruments that utilize those sequences; however a skilled artisan will understand that additional or alternative sequences used by other sequencing instruments or technologies are also equally applicable for use in the aforementioned methods. 
     In some embodiments, where a sample is barcoded directly via hybridization with capture probes or analyte capture agents hybridized, bound, or associated with either the cell surface, or introduced into the cell, as described above, sequencing can be performed on the intact sample. 
     A wide variety of different sequencing methods can be used to analyze barcoded analytes (e.g., an analyte and/or the ligation product). In general, sequenced polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded DNA or DNA/RNA hybrids, and nucleic acid molecules with a nucleotide analog). 
     Sequencing of polynucleotides can be performed by various systems. More generally, sequencing can be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR and droplet digital PCR (ddPCR), quantitative PCR, real time PCR, multiplex PCR, PCR-based single plex methods, emulsion PCR), and/or isothermal amplification. Non-limiting examples of methods for sequencing genetic material include, but are not limited to, DNA hybridization methods (e.g., Southern blotting), restriction enzyme digestion methods, Sanger sequencing methods, next-generation sequencing methods (e.g., single-molecule real-time sequencing, nanopore sequencing, and Polony sequencing), ligation methods, and microarray methods. 
     (o) Kits 
     In some embodiments, also provided herein are kits that include one or more reagents to detect one or more analytes described herein. In some instances, the kit includes a substrate comprising a plurality of capture probes comprising a spatial barcode and the capture domain. In some instances, the kit includes a plurality of probes (e.g., a first probe, a second probe, one or more spanning probes, and/or a third oligonucleotide). 
     A non-limiting example of a kit used to perform any of the methods described herein includes: (a) a substrate comprising a plurality of capture probes comprising a spatial barcode and a capture domain; (b) a system comprising: a plurality of undesirable RNA depletion probes, wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; and (c) instructions for performing the method of any one of the preceding claims. 
     A non-limiting example of a kit used to perform any of the methods described herein includes: (a) a substrate comprising a plurality of capture probes comprising a spatial barcode and a capture domain; (b) a system comprising: a first probe oligonucleotide, a second probe oligonucleotide, and a plurality of undesirable RNA depletion probes, wherein the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of the analyte, wherein the second probe oligonucleotide comprises a capture probe binding domain that is capable of binding to a capture domain of a capture probe, and wherein an undesirable RNA depletion probe of the plurality of undesirable RNA depletion probes is substantially complementary to a sequence of an undesirable RNA molecule in the biological sample; and (c) instructions for performing the method of any one of the preceding claims. 
     In some embodiments of any of the kits described herein, the kit includes a second probe that includes a preadenylated phosphate group at its 5′ end and a first probe comprising at least two ribonucleic acid bases at the 3′ end. 
     EXAMPLES 
     Example 1. Workflow of In Situ Spatial RTL (RNA-Templated Ligation) Ribosomal Depletion 
     Others have reported ribosomal probe designs and their application to ribosomal depletion from purified total RNA. See Morlan et al., “Selective depletion of rRNA enables whole transcriptome profiling of archival fixed tissue.” PloS one 7.8 (2012); US patent application publication No. 20110111409 A1; U.S. patent application No. 62/860,993; and Adiconis et al., “Comparative analysis of RNA sequencing methods for degraded or low-input samples.” Nature methods 10.7 (2013): 623; each of which is incorporated herein in its entirety by reference. Here, the RNA depletion procedure is incorporated into the workflow of RNA-templated ligation in a biological sample, wherein the ribosomal RNA for depletion is not purified, but located in a sample, such as a tissue. 
     As a non-limiting example, and as shown in  FIG.  7   , the RNA depletion procedure can be performed using a biological tissue sample comprising mRNA and ribosomal RNA (rRNA), where the rRNA is to be depleted from the sample. A plurality of ribosomal depletion probes can be added simultaneously to specifically hybridize with rRNA, forming RNA:DNA duplex structures. The ribosomal depletion probes can be designed to hybridize to the complete or partial sequence of the rRNA molecule. After hybridization, RNase H can be added to digest the RNA strand of the hybridized RNA:DNA duplex, such that the rRNA can be digested. The biological sample can then be permeabilized to release the ligated RTL probes. In this example, the capture of target mRNA can also be performed concurrently with the rRNA depletion method. To perform concurrent rRNA depletion and target mRNA capture, two RTL probes (i.e., LHS and RHS probes) can be applied to the sample simultaneously with the rRNA depletion probes. The probes are allowed to hybridize to their targets during a hybridization reaction and a ligation step ligates the RTL probes together, followed by RNase H digestion of the RNA of the DNA:RNA formed hybrids, thereby digesting the rRNA and depleting those molecules while at the same time releasing the RTL ligation product. The sample can be permeabilized, thereby contacting the RTL ligation products with a plurality of capture probes attached to a slide. The ligated RTL probes can diffuse and bind to a capture probe affixed to the surface of the slide, wherein the capture probe comprises a complementary sequence to a sequence on the RHS ligation product. After hybridization, the 3′ end of the capture probe can be extended using the ligated RTL probes as a template. The extended and ligated RTL probes can then be collected for downstream library preparation and subsequent spatial expression analysis. 
     As another non-limiting example, RNA depletion probes can be added to a biological sample to specifically hybridize with unwanted RNA molecules. RNase H can then be added to digest the RNA strand of the hybridized RNA:DNA duplex, such that the unwanted RNA molecules can be digested. The RNA depletion probes can also be removed using RecJ exonuclease. The biological sample can then be subjected to a spatial analysis workflow as described herein. 
     Example 2. In Situ Ribosomal Depletion Increases mRNA Capture with Spatial Transcriptomics in Clinical Samples 
     In general, ribosomal depletion can be performed by adding rRNA specific probes before permeabilizing tissue samples. As shown in  FIG.  8 A , ribosomal depletion probes (RD probes) can specifically hybridize to and inhibit rRNA molecules from non-specifically binding to capture probes on a substrate, thereby increasing mRNA capture with spatial transcriptomics in clinical samples. After rRNA molecules are removed, the tissue sample can be permeabilized by any permeabilization methods as described herein. Ribosomal depletion probes were designed to block cytoplasmic 18S, 28S, 5S and 5.8S rRNA, as well as mitochondrial 16S and 12S rRNA. For these set of experiments, the ribosomal depletion probes include the nucleic acid sequences of SEQ ID NOs: 1-195. The ribosomal depletion probes (e.g., SEQ ID NOs: 1-195) were combined into a pool including a concentration of 2 μM of each probe in IDTE buffer (10 mM Tris, 0.1 mM EDTA, pH 7.5-8.0). For spatial transcriptomic analysis, in the reverse transcription (RT) step, H 2 O (166.3 μl) was replaced with an equivalent volume (166.3 μl) of the pooled ribosomal depletion probes in IDTE buffer. The final concentration of each ribosomal depletion probe in the RT reaction mixture was about 1 μM. 
     As shown in  FIGS.  8 B- 8 C , ribosomal depletion using the probes described herein reduced the 18S rRNA level in the tissue sample. The results of  FIGS.  8 D- 8 E  also indicated that ribosomal depletion increased polyA-specific probe binding to mRNA. 
     Effects of ribosomal depletion on gene expression were assessed. The gene expression levels were compared between normal tissue and ribosomal depleted tissue samples. Mouse olfactory bulb (MOB), childhood brain tumor (PNET) and adipose tissues were analyzed and results are shown in  FIGS.  9 A- 9 C , respectively. The results show that most genes exhibited similar expression levels upon ribosomal depletion, as indicated by the R 2  values. MT-RNR1 and MT-RNR2, which encodes mitochondrial 12S and 16S rRNA, respectively, exhibited reduced expression levels in ribosomal depleted tissue samples. 
     Tissue plots indicating the gene expression levels of mitochondrial 12S and 16S rRNA are shown in  FIG.  10   . Both rRNA molecules presented a reduced expression level upon ribosomal depletion in a tissue. As shown in  FIGS.  11 - 12   , more UMIs per gene, as well as an increased detection rate, were observed with in tissue ribosomal depletion in adipose (fat), mouse olfactory bulb (MOB), MOB-181218, and childhood brain cancer (PNET) tissues. 
     Spatial expression patterns of different Seurat clusters were compared between a normal tissue and a ribosomal depleted tissue in  FIG.  13 A  and  FIG.  13 B , respectively. The results show that the ribosomal depleted tissue samples exhibited more clear patterns than the normal tissue samples (see, e.g.,  FIGS.  13 A-B ). Analysis of additional normal tissue and ribosomal depleted tissue in  FIGS.  14 A- 14 B  show that in a tSNE plot each Seurat cluster from the ribosomal depleted tissue presented clearer boundaries between Seurat clusters as compared to normal tissue samples, indicating an improved dataset quality. The spatial expression patterns for each of the Seurat clusters from  FIG.  14 A  (normal tissue) and  FIG.  14 B  (ribosomal depleted tissue) are shown in  FIG.  15    and  FIG.  16   , respectively. These results indicate that ribosomal depletion improved the overall analyzing capability and accuracy of the spatial gene expression analysis methods as described herein. 
     Another example is shown in  FIGS.  17 A- 17 B  and  FIGS.  18 A- 18 B , which further supported the conclusions above. In the normal tissue sample (see  FIGS.  17 A- 17 B ), clusters 1 and 5 (indicated by arrows) had high expression levels on substantially separate regions of the tissue sample ( FIG.  17 A ). However, these two clusters present interpenetrated patterns in the tSNE plot (see  FIG.  17 B , indicated by arrows). In contrast, clusters 3 and 4 (indicated by arrows) in the ribosomal depleted tissue sample (see  FIG.  18 A ) also had separate expression patterns, but presented a clearer boundary in the tSNE plot ( FIG.  18 B , indicated by arrows). Thus, ribosomal depletion improved the overall dataset quality to reflect a more accurate spatial gene expression pattern. 
     An additional example of using ribosomal depletion probes in a spatial transcriptomic workflow is shown in  FIGS.  19 - 21   , which provides data for both global gene expression and an exemplary set of individual genes, comparing the control samples to ribosomal depleted samples. As noted above, each of the 195 ribosomal depletion probes (e.g., the ribosomal depletion probes of SEQ ID NOs: 1-195) were included at 1 μM final concentration in the spatial transcriptomics RT reaction mix. As shown in  FIGS.  19 A- 19 D , ribosomal depletion improved detection of an exemplary subset of mRNA molecules, including Perk, Doc2g, and Kctd12,  FIGS.  19 B- 19 D , respectively. As the pool of ribosomal depletion probes included probes targeting MT-RNR1 and MT-RNR2, depletion of undesirable RNAs was confirmed by comparing detection of housekeeping genes (e.g., Actb and Gapdh) with detection of MT-RNR1 and MT-RNR2. As shown in  FIGS.  20 A- 20 D , there was no change in detection of the housekeeping genes but a reduction in detection of MT-RNR1 and MT-RNR2 when samples were exposed to the ribosomal depletion probes. Additionally, global gene expression was not affected by the inclusion of the ribosomal depletion probes in the spatial transcriptomics workflow. Comparison of global gene expression between control samples and ribosomal depleted samples showed significant correlation for all comparisons (Pearson&#39;s r&gt;0.97; p&lt;2.2e-16)). Thus, as noted above, this data shows that ribosomal depletion probes included in the spatial transcriptomics workflow increased resolution of spatial gene expression patterns by improving capture of mRNA molecules while not limiting analysis of global gene expression. 
     OTHER EMBODIMENTS 
     It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 
     
       
         
           
               
            
               
                   
               
               
                 Sequence Listing 
               
            
           
           
               
               
               
            
               
                 SEQ 
                   
                   
               
               
                 ID 
                   
                   
               
               
                 NO: 
                 Oligo Name 
                 Sequence (5′ to 3′) 
               
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 AG9327_18_ 
                 TAATGATCCTTCCGCAGGTTCACCTACGGAAACCTTGTTA 
               
               
                   
                 1 
                 CGACTTTTAC 
               
               
                   
               
               
                 2 
                 AG9328_18_ 
                 TTCCTCTAGATAGTCAAGTTCGACCGTCTTCTCAGCGCTC 
               
               
                   
                 2 
                 CGCCAGGGCC 
               
               
                   
               
               
                 3 
                 AG9329_18_ 
                 GTGGGCCGACCCCGGCGGGGCCGATCCGAGGGCCTCACT 
               
               
                   
                 3 
                 AAACCATCCAA 
               
               
                   
               
               
                 4 
                 AG9330_18_ 
                 TCGGTAGTAGCGACGGGCGGTGTGTACAAAGGGCAGGG 
               
               
                   
                 4 
                 ACTTAATCAACG 
               
               
                   
               
               
                 5 
                 AG9331_18 
                 CAAGCTTATGACCCGCACTTACTCGGGAATTCCCTCGTTC 
               
               
                   
                 _5 
                 ATGGGGAATA 
               
               
                   
               
               
                 6 
                 AG9332_18 
                 ATTGCAATCCCCGATCCCCATCACGAATGGGGTTCAACG 
               
               
                   
                 _6 
                 GGTTACCCGCG 
               
               
                   
               
               
                 7 
                 AG9333_18 
                 CCTGCCGGCGTAGGGTAGGCACACGCTGAGCCAGTCAGT 
               
               
                   
                 _7 
                 GTAGCGCGCGT 
               
               
                   
               
               
                 8 
                 AG9334_18 
                 GCAGCCCCGGACATCTAAGGGCATCACAGACCTGTTATT 
               
               
                   
                 _8 
                 GCTCAATCTCG 
               
               
                   
               
               
                 9 
                 AG9335_18 
                 GGTGGCTGAACGCCACTTGTCCCTCTAAGAAGTTGGGGG 
               
               
                   
                 _9 
                 ACGCCGACCGC 
               
               
                   
               
               
                 10 
                 AG9336_18 
                 TCGGGGGTCGCGTAACTAGTTAGCATGCCAGAGTCTCGT 
               
               
                   
                 _10 
                 TCGTTATCGGA 
               
               
                   
               
               
                 11 
                 AG9337_18 
                 ATTAACCAGACAAATCGCTCCACCAACTAAGAACGGCCA 
               
               
                   
                 _11 
                 TGCACCACCAC 
               
               
                   
               
               
                 12 
                 AG9338_18 
                 CCACGGAATCGAGAAAGAGCTATCAATCTGTCAATCCTG 
               
               
                   
                 _12 
                 TCCGTGTCCGG 
               
               
                   
               
               
                 13 
                 AG9339_18 
                 GCCGGGTGAGGTTTCCCGTGTTGAGTCAAATTAAGCCGC 
               
               
                   
                 _13 
                 AGGCTCCACTC 
               
               
                   
               
               
                 14 
                 AG9340_18 
                 CTGGTGGTGCCCTTCCGTCAATTCCTTTAAGTTTCAGCTTT 
               
               
                   
                 _14 
                 GCAACCATA 
               
               
                   
               
               
                 15 
                 AG9341_18 
                 CTCCCCCCGGAACCCAAAGACTTTGGTTTCCCGGAAGCT 
               
               
                   
                 _15 
                 GCCCGGCGGGT 
               
               
                   
               
               
                 16 
                 AG9342_18 
                 CATGGGAATAACGCCGCCGCATCGCCGGTCGGCATCGTT 
               
               
                   
                 _16 
                 TATGGTCGGAA 
               
               
                   
               
               
                 17 
                 AG9343_18 
                 CTACGACGGTATCTGATCGTCTTCGAACCTCCGACTTTCG 
               
               
                   
                 _17 
                 TTCTTGATTA 
               
               
                   
               
               
                 18 
                 AG9344_18 
                 ATGAAAACATTCTTGGCAAATGCTTTCGCTCTGGTCCGTC 
               
               
                   
                 _18 
                 TTGCGCCGGT 
               
               
                   
               
               
                 19 
                 AG9345_18 
                 CCAAGAATTTCACCTCTAGCGGCGCAATACGAATGCCCC 
               
               
                   
                 _19 
                 CGGCCGTCCCT 
               
               
                   
               
               
                 20 
                 AG9346_18 
                 CTTAATCATGGCCTCAGTTCCGAAAACCAACAAAATAGA 
               
               
                   
                 _20 
                 ACCGCGGTCCT 
               
               
                   
               
               
                 21 
                 AG9347_18 
                 ATTCCATTATTCCTAGCTGCGGTATCCAGGCGGCTCGGGC 
               
               
                   
                 _21 
                 CTGCTTTGAA 
               
               
                   
               
               
                 22 
                 AG9348_18 
                 CACTCTAATTTTTTCAAAGTAAACGCTTCGGGCCCCGCGG 
               
               
                   
                 _22 
                 GACACTCAGC 
               
               
                   
               
               
                 23 
                 AG9349_18 
                 TAAGAGCATCGAGGGGGCGCCGAGAGGCAAGGGGCGGG 
               
               
                   
                 _23 
                 GACGGGCGGTGG 
               
               
                   
               
               
                 24 
                 AG9350_18 
                 CTCGCCTCGCGGCGGACCGCCCGCCCGCTCCCAAGATCC 
               
               
                   
                 _24 
                 AACTACGAGCT 
               
               
                   
               
               
                 25 
                 AG9351_18 
                 TTTTAACTGCAGCAACTTTAATATACGCTATTGGAGCTGG 
               
               
                   
                 _25 
                 AATTACCGCG 
               
               
                   
               
               
                 26 
                 AG9352_18 
                 GCTGCTGGCACCAGACTTGCCCTCCAATGGATCCTCGTTA 
               
               
                   
                 _26 
                 AAGGATTTAA 
               
               
                   
               
               
                 27 
                 AG9353_18 
                 AGTGGACTCATTCCAATTACAGGGCCTCGAAAGAGTCCT 
               
               
                   
                 _27 
                 GTATTGTTATT 
               
               
                   
               
               
                 28 
                 AG9354_18 
                 TTTCGTCACTACCTCCCCGGGTCGGGAGTGGGTAATTTGC 
               
               
                   
                 _28 
                 GCGCCTGCTG 
               
               
                   
               
               
                 29 
                 AG9355_18 
                 CCTTCCTTGGATGTGGTAGCCGTTTCTCAGGCTCCCTCTC 
               
               
                   
                 _29 
                 CGGAATCGAA 
               
               
                   
               
               
                 30 
                 AG9356_18 
                 CCCTGATTCCCCGTCACCCGTGGTCACCATGGTAGGCACG 
               
               
                   
                 _30 
                 GCGACTACCA 
               
               
                   
               
               
                 31 
                 AG9357_18 
                 TCGAAAGTTGATAGGGCAGACGTTCGAATGGGTCGTCGC 
               
               
                   
                 _31 
                 CGCCACGGG 
               
               
                   
               
               
                 32 
                 AG9358_18 
                 GCGTGCGATCGGCCCGAGGTTATCTAGAGTCACCAAAGC 
               
               
                   
                 _32 
                 CGCCGGCGCCC 
               
               
                   
               
               
                 33 
                 AG9359_18 
                 GCCCCCCGGCCGGGGCCGGAGAGGGGCTGACCGGGTTGG 
               
               
                   
                 _33 
                 TTTTGATCTGA 
               
               
                   
               
               
                 34 
                 AG9360_18 
                 TAAATGCACGCATCCCCCCCGCGAAGGGGGTCAGCGCCC 
               
               
                   
                 _34 
                 GTCGGCATGTA 
               
               
                   
               
               
                 35 
                 AG9361_18 
                 TTAGCTCTAGAATTACCACAGTTATCCAAGTAGGAGAGG 
               
               
                   
                 _35 
                 AGCGAGCGACC 
               
               
                   
               
               
                 36 
                 AG9362_18 
                 AAAGGAACCATAACTGATTTAATGAGCCATTCGCAGTTT 
               
               
                   
                 _36 
                 CACTGTACCGG 
               
               
                   
               
               
                 37 
                 AG9363_18 
                 CCGTGCGTACTTAGACATGCATGGCTTAATCTTTGAGACA 
               
               
                   
                 _37 
                 AGCATATGCT 
               
               
                   
               
               
                 38 
                 AG9364_18 
                 TGGCTTAATCTTTGAGACAAGCATATGCTACTGGCAGGA 
               
               
                   
                 _38 
                 TCAACCAGGTA 
               
               
                   
               
               
                 39 
                 AG9365_28 
                 GACAAACCCTTGTGTCGAGGGCTGACTTTCAATAGATCG 
               
               
                   
                 _1 
                 CAGCGAGGGAG 
               
               
                   
               
               
                 40 
                 AG9366_28 
                 CTGCTCTGCTACGTACGAAACCCCGACCCAGAAGCAGGT 
               
               
                   
                 _2 
                 CGTCTACGAAT 
               
               
                   
               
               
                 41 
                 AG9367_28 
                 GGTTTAGCGCCAGGTTCCCCACGAACGTGCGGTGCGTGA 
               
               
                   
                 _3 
                 CGGGCGAGGG 
               
               
                   
               
               
                 42 
                 AG9368_28 
                 GCGGCCGCCTTTCCGGCCGCGCCCCGTTTCCCAGGACGA 
               
               
                   
                 _4 
                 AGGGCACTCCG 
               
               
                   
               
               
                 43 
                 AG9369_28 
                 CACCGGACCCCGGTCCCGGCGCGCGGCGGGGCACGCGCC 
               
               
                   
                 _5 
                 CTCCCGCGGCG 
               
               
                   
               
               
                 44 
                 AG9370_28 
                 GGGCGCGTGGAGGGGIGGGCGGCCCGCCGGCGGGGACAG 
               
               
                   
                 _6 
                 GCGGGGGACCG 
               
               
                   
               
               
                 45 
                 AG9371_28 
                 GCTATCCGAGGCCAACCGAGGCTCCGCGGCGCTGCCGTA 
               
               
                   
                 _7 
                 TCGTTCGCCTG 
               
               
                   
               
               
                 46 
                 AG9372_28 
                 GGCGGGATTCTGACTTAGAGGCGTTCAGTCATAATCCCA 
               
               
                   
                 _8 
                 CAGATGGTAGC 
               
               
                   
               
               
                 47 
                 AG9373_28 
                 TTCGCCCCATTGGCTCCTCAGCCAAGCACATACACCAAAT 
               
               
                   
                 _9 
                 GTCTGAACCT 
               
               
                   
               
               
                 48 
                 AG9374_28 
                 GCGGTTCCTCTCGTACTGAGCAGGATTACCATGGCAACA 
               
               
                   
                 _10 
                 ACACATCATCA 
               
               
                   
               
               
                 49 
                 AG9375_28 
                 GTAGGGTAAAACTAACCTGTCTCACGACGGTCTAAACCC 
               
               
                   
                 _11 
                 AGCTCACGTTC 
               
               
                   
               
               
                 50 
                 AG9376_28 
                 CCTATTAGTGGGTGAACAATCCAACGCTTGGCGAATTCT 
               
               
                   
                 _12 
                 GCTTCACAATG 
               
               
                   
               
               
                 51 
                 AG9377_28 
                 ATAGGAAGAGCCGACATCGAAGGATCAAAAAGCGACGT 
               
               
                   
                 _13 
                 CGCTATGAACGC 
               
               
                   
               
               
                 52 
                 AG9378_28 
                 TTGGCCGCCACAAGCCAGTTATCCCTGTGGTAACTTTTCT 
               
               
                   
                 _14 
                 GACACCTCCT 
               
               
                   
               
               
                 53 
                 AG9379_28 
                 GCTTAAAACCCAAAAGGTCAGAAGGATCGTGAGGCCCCG 
               
               
                   
                 _15 
                 CTTTCACGGTC 
               
               
                   
               
               
                 54 
                 AG9380_28 
                 TGTATTCGTACTGAAAATCAAGATCAAGCGAGCTTTTGCC 
               
               
                   
                 _16 
                 CTTCTGCTCC 
               
               
                   
               
               
                 55 
                 AG9381_28 
                 ACGGGAGGTTTCTGTCCTCCCTGAGCTCGCCTTAGGACAC 
               
               
                   
                 _17 
                 CTGCGTTACC 
               
               
                   
               
               
                 56 
                 AG9382_28 
                 GTTTGACAGGTGTACCGCCCCAGTCAAACTCCCCACCTG 
               
               
                   
                 _18 
                 GCACTGTCCCC 
               
               
                   
               
               
                 57 
                 AG9383_28 
                 GGAGCGGGTCGCGCCCGGCCGGGCGGGCGCTTGGCGCCA 
               
               
                   
                 _19 
                 GAAGCGAGAGC 
               
               
                   
               
               
                 58 
                 AG9384_28 
                 CCCTCGGGCTCGCCCCCCCGCCTCACCGGGTCAGTGAAA 
               
               
                   
                 _20 
                 AAACGATCAGA 
               
               
                   
               
               
                 59 
                 AG9385_28 
                 GTAGTGGTATTTCACCGGCGGCCCGCAGGGCCGCGGACC 
               
               
                   
                 _21 
                 CCGCCCCGGGC 
               
               
                   
               
               
                 60 
                 AG9386_28 
                 CCCTCGCGGGGACACCGGGIGGGCGCCGGGGGCCTCCCA 
               
               
                   
                 _22 
                 CTTATTCTACA 
               
               
                   
               
               
                 61 
                 AG9387_28 
                 CCTCTCATGTCTCTTCACCGTGCCAGACTAGAGTCAAGCT 
               
               
                   
                 _23 
                 CAACAGGGTC 
               
               
                   
               
               
                 62 
                 AG9388_28 
                 TTCTTTCCCCGCTGATTCCGCCAAGCCCGTTCCCTTGGCT 
               
               
                   
                 _24 
                 GTGGTTTCGC 
               
               
                   
               
               
                 63 
                 AG9389_28 
                 TGGATAGTAGGTAGGGACAGTGGGAATCTCGTTCATCCA 
               
               
                   
                 _25 
                 TTCATGCGCGT 
               
               
                   
               
               
                 64 
                 AG9390_28 
                 CACTAATTAGATGACGAGGCATTTGGCTACCTTAAGAGA 
               
               
                   
                 _26 
                 GTCATAGTTAC 
               
               
                   
               
               
                 65 
                 AG9391_28 
                 TCCCGCCGTTTACCCGCGCTTCATTGAATTTCTTCACTTTG 
               
               
                   
                 _27 
                 ACATTCAGA 
               
               
                   
               
               
                 66 
                 AG9392_28 
                 GCACTGGGCAGAAATCACATCGCGTCAACACCCGCCGCG 
               
               
                   
                 _28 
                 GGCCTTCGCGA 
               
               
                   
               
               
                 67 
                 AG9393_28 
                 TGCTTTGTTTTAATTAAACAGTCGGATTCCCCTGGTCCGC 
               
               
                   
                 _29 
                 ACCAGTTCTA 
               
               
                   
               
               
                 68 
                 AG9394_28 
                 AGTCGGCTGCTAGGCGCCGGCCGAGGCGAGGCGCGCGCG 
               
               
                   
                 _30 
                 GAACCGCGGCC 
               
               
                   
               
               
                 69 
                 AG9395_28 
                 CCGGGGGCGGACCCGGCGGGIGGGACCGGCCCGCGGCCC 
               
               
                   
                 _31 
                 CTCCGCCGCCT 
               
               
                   
               
               
                 70 
                 AG9396_28 
                 GCCGCCGCCGCCGCCGCGCGCCGAGGAGGAGGGGGGAA 
               
               
                   
                 _32 
                 CGGGGGGCGGAC 
               
               
                   
               
               
                 71 
                 AG9397_28 
                 GGGCCGGGIGGGTAGGGCGGGGGGACGAACCGCCCCGCC 
               
               
                   
                 _33 
                 CCGCCGCCCG 
               
               
                   
               
               
                 72 
                 AG9398_28 
                 CCGACCGCCGCCGCCCGACCGCTCCCGCCCCCAGCGGAC 
               
               
                   
                 _34 
                 GCGCGCGCGAC 
               
               
                   
               
               
                 73 
                 AG9399_28 
                 CGAGACGTGGGGTGGGGGTGGGGGGCGCGCCGCGCCGC 
               
               
                   
                 _35 
                 CGCCGGGCTCCC 
               
               
                   
               
               
                 74 
                 AG9400_28 
                 CGGGGGCGGCCGCGACGCCCGCCGCAGCTGGGGCGATCC 
               
               
                   
                 _36 
                 ACGGGAAGGGC 
               
               
                   
               
               
                 75 
                 AG9401_28 
                 CCGGCTCGCGTCCAGAGTCCGCGCCGCCGCCGGCCCCCC 
               
               
                   
                 _37 
                 GGGTCCCCGGG 
               
               
                   
               
               
                 76 
                 AG9402_28 
                 GCCCCCCTCGCGGGGACCTGCCCCCGCCGGCCGCCCCGG 
               
               
                   
                 _38 
                 CGGCCGCCGCG 
               
               
                   
               
               
                 77 
                 AG9403_28 
                 CGGCCCCTGCCGCCCCGACCCTTCTCCCCCCGCCGCGCCC 
               
               
                   
                 _39 
                 CCACGCGGCG 
               
               
                   
               
               
                 78 
                 AG9404_28 
                 CTCCCCCGGGGAGGGGGGAGGACGGGGAGCGGGGGAGA 
               
               
                   
                 _40 
                 GAGAGAGAGAGA 
               
               
                   
               
               
                 79 
                 AG9405_28 
                 GGGCGCGGGGTGGGGAGGGAGCGAGCGGCGCGCGCGGG 
               
               
                   
                 _41 
                 TGGGGCGGGGGA 
               
               
                   
               
               
                 80 
                 AG9406_28 
                 GGGCCGCGAGGGGGGTGCCCCGGGCGTGGGGIGGGCGCG 
               
               
                   
                 _42 
                 CGCCTCGTCCA 
               
               
                   
               
               
                 81 
                 AG9407_28 
                 GCCGCGGCGCGCGCCCAGCCCCGCTTCGCGCCCCAGCCC 
               
               
                   
                 _43 
                 GACCGACCCAG 
               
               
                   
               
               
                 82 
                 AG9408_28 
                 CCCTTAGAGCCAATCCTTATCCCGAAGTTACGGATCCGGC 
               
               
                   
                 _44 
                 TTGCCGACTT 
               
               
                   
               
               
                 83 
                 AG9409_28 
                 CCCTTACCTACATTGTTCCAACATGCCAGAGGCTGTTCAC 
               
               
                   
                 _45 
                 CTTGGAGACC 
               
               
                   
               
               
                 84 
                 AG9410_28 
                 TGCTGCGGATATGGGTACGGCCCGGCGCGAGATTTACAC 
               
               
                   
                 _46 
                 CCTCTCCCCCG 
               
               
                   
               
               
                 85 
                 AG9411_28 
                 GATTTTCAAGGGCCAGCGAGAGCTCACCGGACGCCGCCG 
               
               
                   
                 _47 
                 GAACCGCGACG 
               
               
                   
               
               
                 86 
                 AG9412_28 
                 CTTTCCAAGGCACGGGCCCCTCTCTCGGGGCGAACCCATT 
               
               
                   
                 _48 
                 CCAGGGCGCC 
               
               
                   
               
               
                 87 
                 AG9413_28 
                 CTGCCCTTCACAAAGAAAAGAGAACTCTCCCCGGGGCTC 
               
               
                   
                 _49 
                 CCGCCGGCTTC 
               
               
                   
               
               
                 88 
                 AG9414_28 
                 TCCGGGATCGGTCGCGTTACCGCACTGGACGCCTCGCGG 
               
               
                   
                 _50 
                 CGCCCATCTCC 
               
               
                   
               
               
                 89 
                 AG9415_28 
                 GCCACTCCGGATTCGGGGATCTGAACCCGACTCCCTTTCG 
               
               
                   
                 _51 
                 ATCGGCCGAG 
               
               
                   
               
               
                 90 
                 AG9416_28 
                 GGCAACGGAGGCCATCGCCCGTCCCTTCGGAACGGCGCT 
               
               
                   
                 _52 
                 CGCCCATCTCT 
               
               
                   
               
               
                 91 
                 AG9417_28 
                 CAGGACCGACTGACCCATGTTCAACTGCTGTTCACATGG 
               
               
                   
                 _53 
                 AACCCTTCTCC 
               
               
                   
               
               
                 92 
                 AG9418_28 
                 ACTTCGGCCTTCAAAGTTCTCGTTTGAATATTTGCTACTA 
               
               
                   
                 _54 
                 CCACCAAGAT 
               
               
                   
               
               
                 93 
                 AG9419_28 
                 CTGCACCTGCGGCGGCTCCACCCGGGCCCGCGCCCTAGG 
               
               
                   
                 _55 
                 CTTCAAGGCTC 
               
               
                   
               
               
                 94 
                 AG9420_28 
                 ACCGCAGCGGCCCTCCTACTCGTCGCGGCGTAGCGTCCG 
               
               
                   
                 _56 
                 CGGGGCTCCGG 
               
               
                   
               
               
                 95 
                 AG9421_28 
                 GGGCGGGGAGCGGGGCGTGGGCGGGAGGAGGGGAGGAG 
               
               
                   
                 _57 
                 GCGTGGG 
               
               
                   
               
               
                 96 
                 AG9422_28 
                 GGGCGGGGGAAGGACCCCACACCCCCGCCGCCGCCGCCG 
               
               
                   
                 _58 
                 CCGCCGCCCTC 
               
               
                   
               
               
                 97 
                 AG9423_28 
                 CGACGCACACCACACGCGCGCGCGCGCGCGCCGCCCCCG 
               
               
                   
                 _59 
                 CCGCTCCCGTC 
               
               
                   
               
               
                 98 
                 AG9424_28 
                 CACTCTCGACTGCCGGCGACGGCCGGGTATGGGCCCGAC 
               
               
                   
                 _60 
                 GCTCCAGCGCC 
               
               
                   
               
               
                 99 
                 AG9425_28 
                 ATCCATTTTCAGGGCTAGTTGATTCGGCAGGTGAGTTGTT 
               
               
                   
                 _61 
                 ACACACTCCT 
               
               
                   
               
               
                 100 
                 AG9426_28 
                 TAGCGGATTCCGACTTCCATGGCCACCGTCCTGCTGTCTA 
               
               
                   
                 _62 
                 TATCAACCAA 
               
               
                   
               
               
                 101 
                 AG9427_28 
                 CACCTTTTCTGGGGTCTGATGAGCGTCGGCATCGGGCGCC 
               
               
                   
                 _63 
                 TTAACCCGGC 
               
               
                   
               
               
                 102 
                 AG9428_28 
                 GTTCGGTTCATCCCGCAGCGCCAGTTCTGCTTACCAAAAG 
               
               
                   
                 _64 
                 TGGCCCACTA 
               
               
                   
               
               
                 103 
                 AG9429_28 
                 GGCACTCGCATTCCACGCCCGGCTCCACGCCAGCGAGCC 
               
               
                   
                 _65 
                 GGGCTTCTTAC 
               
               
                   
               
               
                 104 
                 AG9430_28 
                 CCATTTAAAGTTTGAGAATAGGTTGAGATCGTTTCGGCCC 
               
               
                   
                 _66 
                 CAAGACCTCT 
               
               
                   
               
               
                 105 
                 AG9431_28 
                 AATCATTCGCTTTACCGGATAAAACTGCGTGGCGGGGGT 
               
               
                   
                 _67 
                 GCGTCGGGTCT 
               
               
                   
               
               
                 106 
                 AG9432_28 
                 GCGAGAGCGCCAGCTATCCTGAGGGAAACTTCGGAGGGA 
               
               
                   
                 _68 
                 ACCAGCTACTA 
               
               
                   
               
               
                 107 
                 AG9433_28 
                 GATGGTTCGATTAGTCTTTCGCCCCTATACCCAGGTCGGA 
               
               
                   
                 _69 
                 CGACCGATTT 
               
               
                   
               
               
                 108 
                 AG9434_28 
                 GCACGTCAGGACCGCTACGGACCTCCACCAGAGTTTCCT 
               
               
                   
                 _70 
                 CTGGCTTCGCC 
               
               
                   
               
               
                 109 
                 AG9435_28 
                 CTGCCCAGGCATAGTTCACCATCTTTCGGGTCCTAACACG 
               
               
                   
                 _71 
                 TGCGCTCGTG 
               
               
                   
               
               
                 110 
                 AG9436_28 
                 CTCCACCTCCCCGGCGCGGCGGGCGAGACGGGCCGGTGG 
               
               
                   
                 _72 
                 TGCGCCCTCGG 
               
               
                   
               
               
                 111 
                 AG9437_28 
                 CGGACTGGAGAGGCCTCGGGATCCCACCTCGGCCGGCGA 
               
               
                   
                 _73 
                 GCGCGCCGGCC 
               
               
                   
               
               
                 112 
                 AG9438_28 
                 TTCACCTTCATTGCGCCACGGCGGCTTTCGTGCGAGCCCC 
               
               
                   
                 _74 
                 CGACTCGCGC 
               
               
                   
               
               
                 113 
                 AG9439_28 
                 ACGTGTTAGACTCCTTGGTCCGTGTTTCAAGACGGGTCGG 
               
               
                   
                 _75 
                 GTGGGTAGCC 
               
               
                   
               
               
                 114 
                 AG9440_28 
                 GACGTCGCCGCCGACCCCGTGCGCTCGCTCCGCCGTCCCC 
               
               
                   
                 _76 
                 CTCTTCGGG 
               
               
                   
               
               
                 115 
                 AG9441_28 
                 GACGCGCGCGTGGCCCCGAGAGAACCTCCCCCGGGCCCG 
               
               
                   
                 _77 
                 ACGGCGCGACC 
               
               
                   
               
               
                 116 
                 AG9442_28 
                 CGCCCGGGGCGCACTGGGGACAGTCCGCCCCGCCCCCCG 
               
               
                   
                 _78 
                 ACCCGCGCGCG 
               
               
                   
               
               
                 117 
                 AG9443_28 
                 GCACCCCCCCCGTCGCCGGGGCGGGGGCGCGGGGAGGA 
               
               
                   
                 _79 
                 GGGGTGGGAGAG 
               
               
                   
               
               
                 118 
                 AG9444_28 
                 CGGTCGCGCCGTGGGAGGGGTGGCCCGGCCCCCCCACGA 
               
               
                   
                 _80 
                 GGAGACGCCGG 
               
               
                   
               
               
                 119 
                 AG9445_28 
                 CGCGCCCCCGCGGGGGAGACCCCCCTCGCGGGGGATTCC 
               
               
                   
                 _81 
                 CCGCGGGGGTG 
               
               
                   
               
               
                 120 
                 AG9446_28 
                 GGCGCCGGGAGGGGGGAGAGCGCGGCGACGGGTCTCGC 
               
               
                   
                 _82 
                 TCCCTCGGCCCC 
               
               
                   
               
               
                 121 
                 AG9447_28 
                 GGGATTCGGCGAGTGCTGCTGCCGGGGGGGCTGTAACAC 
               
               
                   
                 _83 
                 TCGGGGIGGGT 
               
               
                   
               
               
                 122 
                 AG9448_28 
                 TTCGGTCCCGCCGCCCCCGCCGCCGCCGCCACCGCCGCC 
               
               
                   
                 _84 
                 GCCGCCGCCGC 
               
               
                   
               
               
                 123 
                 AG9449_28 
                 CCCGACCCGCGCGCCCTCCCGAGGGAGGACGCGGGGCCG 
               
               
                   
                 _85 
                 GGGGGCGGAGA 
               
               
                   
               
               
                 124 
                 AG9450_28 
                 CGGGGGAGGAGGAGGACGGACGGACGGACGGGGCCCCC 
               
               
                   
                 _86 
                 CGAGCCACCTTC 
               
               
                   
               
               
                 125 
                 AG9451_28 
                 CCCGCCGGGCCTTCCCAGCCGTCCCGGAGCCGGTCGCGG 
               
               
                   
                 _87 
                 CGCACCGCCGC 
               
               
                   
               
               
                 126 
                 AG9452_28 
                 GGTGGAAATGCGCCCGGCGGCGGCCGGTCGCCGGTCGGG 
               
               
                   
                 _88 
                 GGACGGTCCCC 
               
               
                   
               
               
                 127 
                 AG9453_28 
                 CGCCGACCCCACCCCCGGCCCCGCCCGCCCACCCCCGCA 
               
               
                   
                 _89 
                 CCCGCCGGAGC 
               
               
                   
               
               
                 128 
                 AG9454_28 
                 CCGCCCCCTCCGGGGAGGAGGAGGAGGGGCGGCGGGGG 
               
               
                   
                 _90 
                 AAGGGAGGGCGG 
               
               
                   
               
               
                 129 
                 AG9455_28 
                 GTGGAGGGGTCGGGAGGAACGGGGGGCGGGAAAGATCC 
               
               
                   
                 _91 
                 GCCGGGCCGCCG 
               
               
                   
               
               
                 130 
                 AG9456_28 
                 ACACGGCCGGACCCGCCGCCGGGTTGAATCCTCCGGGCG 
               
               
                   
                 _92 
                 GACTGCGCGGA 
               
               
                   
               
               
                 131 
                 AG9457_28 
                 CCCCACCCGTTTACCTCTTAACGGTTTCACGCCCTCTTGA 
               
               
                   
                 _93 
                 ACTCTCTCTT 
               
               
                   
               
               
                 132 
                 AG9458_28 
                 CAAAGTTCTTTTCAACTTTCCCTTACGGTACTTGTTGACT 
               
               
                   
                 _94 
                 ATCGGTCTCG 
               
               
                   
               
               
                 133 
                 AG9459_28 
                 TGCCGGTATTTAGCCTTAGATGGAGTTTACCACCCGCTTT 
               
               
                   
                 _95 
                 GGGCTGCATT 
               
               
                   
               
               
                 134 
                 AG9460_28 
                 CCCAAGCAACCCGACTCCGGGAAGACCCGGGCGCGCGCC 
               
               
                   
                 _96 
                 GGCCGCTACCG 
               
               
                   
               
               
                 135 
                 AG9461_28 
                 GCCTCACACCGTCCACGGGCTGGGCCTCGATCAGAAGGA 
               
               
                   
                 _97 
                 CTTGGGCCCCC 
               
               
                   
               
               
                 136 
                 AG9462_28 
                 CACGAGCGGCGCCGGGGAGCGGGTCTTCCGTACGCCACA 
               
               
                   
                 _98 
                 TGTCCCGCGCC 
               
               
                   
               
               
                 137 
                 AG9463_28 
                 CCGCGGGGCGGGGATTCGGCGCTGGGCTCTTCCCTGTTC 
               
               
                   
                 _99 
                 ACTCGCCGTTA 
               
               
                   
               
               
                 138 
                 AG9464_28 
                 CTGAGGGAATCCTGGTTAGTTTCTTTTCCTCCGCTGACTA 
               
               
                   
                 100 
                 ATATGCTTAA 
               
               
                   
               
               
                 139 
                 AG9465_28 
                 GACTAATATGCTTAAATTCAGCGGGTCGCCACGTCTGATC 
               
               
                   
                 101 
                 TGAGGTCGCG 
               
               
                   
               
               
                 140 
                 AG9466_5.8 
                 AAGCGACGCTCAGACAGGCGTAGCCCCGGGAGGAACCC 
               
               
                   
                 1 
                 GGGGCCGCAAGT 
               
               
                   
               
               
                 141 
                 AG9467_5.8 
                 GCGTTCGAAGTGTCGATGATCAATGTGTCCTGCAATTCAC 
               
               
                   
                 _2 
                 ATTAATTCTC 
               
               
                   
               
               
                 142 
                 AG9468 5.8 
                 GCAGCTAGCTGCGTTCTTCATCGACGCACGAGCCGAGTG 
               
               
                   
                 _3 
                 ATCCACCGCTA 
               
               
                   
               
               
                 143 
                 AG9469_16 
                 AAACCCTGTTCTTGGGTGGGTGTGGGTATAATACTAAGTT 
               
               
                   
                 _1 
                 GAGATGATAT 
               
               
                   
               
               
                 144 
                 AG9470_16 
                 CATTTACGGGGGAAGGCGCTTTGTGAAGTAGGCCTTATTT 
               
               
                   
                 _2 
                 CTCTTGTCCT 
               
               
                   
               
               
                 145 
                 AG9471_16 
                 TTCGTACAGGGAGGAATTTGAANGTAGATAGAAACCGAC 
               
               
                   
                 _3 
                 CTGGATTACTC 
               
               
                   
               
               
                 146 
                 AG9472_16 
                 CGGTCTGAACTCAGATCACGTAGGACTTTAATCGTTGAA 
               
               
                   
                 _4 
                 CAAACGAACCT 
               
               
                   
               
               
                 147 
                 AG9473_16 
                 TTAATAGCGGCTGCACCATCGGGATGTCCTGATCCAACA 
               
               
                   
                 _5 
                 TCGAGGTCGTA 
               
               
                   
               
               
                 148 
                 AG9474_16 
                 AACCCTATTGTTGATATGGACTCTAGAATAGGATTGCGCT 
               
               
                   
                 _6 
                 GTTATCCCTA 
               
               
                   
               
               
                 149 
                 AG9475_16 
                 GGGTAACTTGTTCCGTTGGTCAAGTTATTGGATCAATTGA 
               
               
                   
                 _7 
                 GTATAGTAGT 
               
               
                   
               
               
                 150 
                 AG9476_16 
                 TCGCTTTGACTGGTGAAGTCTTAGCATGTACTGCTCGGAG 
               
               
                   
                 _8 
                 GTTGGGTTCT 
               
               
                   
               
               
                 151 
                 AG9477_16 
                 GCTCCGAGGTCGCCCCAACCGAAATTTTTAATGCAGGTTT 
               
               
                   
                 _9 
                 GGTAGTTTAG 
               
               
                   
               
               
                 152 
                 AG9478_16 
                 GACCTGTGGGTTTGTTAGGTACTGTTTGCATTAATAAATT 
               
               
                   
                 _10 
                 AAAGCTCCAT 
               
               
                   
               
               
                 153 
                 AG9479_16 
                 AGGGTCTTCTCGTCTTGCTGTGTTATGCCCGCCTCTTCAC 
               
               
                   
                 _11 
                 GGGCAGGTCA 
               
               
                   
               
               
                 154 
                 AG9480_16 
                 ATTTCACTGGTTAAAAGTAAGAGACAGCTGAACCCTCGT 
               
               
                   
                 _12 
                 GGAGCCATTCA 
               
               
                   
               
               
                 155 
                 AG9481_16 
                 TACAGGTCCCTATTTAAGGAACAAGTGATTATGCTACCTT 
               
               
                   
                 _13 
                 TGCACGGTTA 
               
               
                   
               
               
                 156 
                 AG9482_16 
                 GGGTACCGCGGCCGTTAAACATGTGTCACTGGGCAGGCG 
               
               
                   
                 _14 
                 GTGCCTCTAAT 
               
               
                   
               
               
                 157 
                 AG9483_16 
                 ACTGGTGATGCTAGAGGTGATGTTTTTGGTAAACAGGCG 
               
               
                   
                 _15 
                 GGGTAAGATTT 
               
               
                   
               
               
                 158 
                 AG9484_16 
                 GCCGAGTTCCTTTTACTTTTTTTAACCTTTCCTTATGAGCA 
               
               
                   
                 _16 
                 TGCCTGTGT 
               
               
                   
               
               
                 159 
                 AG9485_16 
                 TGGGTTGACAGTGAGGGTAATAATGACTTGTTGGTTGATT 
               
               
                   
                 _17 
                 GTAGATATTG 
               
               
                   
               
               
                 160 
                 AG9486_16 
                 GGCTGTTAATTGTCAGTTCAGTGTTTTAATCTGACGCAGG 
               
               
                   
                 _18 
                 CTTATGCGGA 
               
               
                   
               
               
                 161 
                 AG9487_16 
                 GGAGAATGTTTTCATGTTACTTATACTAACATTAGTTCTT 
               
               
                   
                 _19 
                 CTATAGGGTG 
               
               
                   
               
               
                 162 
                 AG9488_16 
                 ATAGATTGGTCCAATTGGGTGTGAGGAGTTCAGTTATAT 
               
               
                   
                 _20 
                 GTTTGGGATTT 
               
               
                   
               
               
                 163 
                 AG9489_16 
                 TTTAGGTAGTGGGTGTTGAGCTTGAACGCTTTCTTAATTG 
               
               
                   
                 _21 
                 GTGGCTGCTT 
               
               
                   
               
               
                 164 
                 AG9490_16 
                 TTAGGCCTACTATGGGTGTTAAATTTTTTACTCTCTCTAC 
               
               
                   
                 _22 
                 AAGGTTTTTT 
               
               
                   
               
               
                 165 
                 AG9491_16 
                 CCTAGTGTCCAAAGAGCTGTTCCTCTTTGGACTAACAGTT 
               
               
                   
                 _23 
                 AAATTTACAA 
               
               
                   
               
               
                 166 
                 AG9492_16 
                 GGGATTTAGAGGGTTCTGTGGGCAAATTTAAAGTTGAAC 
               
               
                   
                 _24 
                 TAAGATTCTA 
               
               
                   
               
               
                 167 
                 AG9493_16 
                 TCTTGGACAACCAGCTATCACCAGGCTCGGTAGGTTTGTC 
               
               
                   
                 _25 
                 GCCTCTACCT 
               
               
                   
               
               
                 168 
                 AG9494_16 
                 ATAAATCTTCCCACTATTTTGCTACATAGACGGGTGTGCT 
               
               
                   
                 _26 
                 CTTTTAGCTG 
               
               
                   
               
               
                 169 
                 AG9495_16 
                 TTCTTAGGTAGCTCGTCTGGTTTCGGGGGTCTTAGCTTTG 
               
               
                   
                 _27 
                 GCTCTCCTTG 
               
               
                   
               
               
                 170 
                 AG9496_16 
                 CAAAGTTATTTCTAGTTAATTCATTATGCAGAAGGTATAG 
               
               
                   
                 _28 
                 GGGTTAGTCC 
               
               
                   
               
               
                 171 
                 AG9497_16 
                 TTGCTATATTATGCTTGGTTATAATTTTTCATCTTTCCCTT 
               
               
                   
                 _29 
                 GCGGTACTA 
               
               
                   
               
               
                 172 
                 AG9498_16 
                 TATCTATTGCGCCAGGTTTCAATTTCTATCGCCTATACTTT 
               
               
                   
                 _30 
                 ATTTGGGTA 
               
               
                   
               
               
                 173 
                 AG9499_16 
                 AATGGTTTGGCTAAGGTTGTCTGGTAGTAAGGTGGAGTG 
               
               
                   
                 _31 
                 GGTTTGGGGCT 
               
               
                   
               
               
                 174 
                 AG9500_12 
                 GTTCGTCCAAGTGCACTTTCCAGTACACTTACCATGTTAC 
               
               
                   
                 _1 
                 GACTTGTCTC 
               
               
                   
               
               
                 175 
                 AG9501_12 
                 CTCTATATAAATGCGTAGGGGTTTTAGTTAAATGTCCTTT 
               
               
                   
                 _2 
                 GAAGTATACT 
               
               
                   
               
               
                 176 
                 AG9502_12 
                 TGAGGAGGGTGACGGGCGGTGTGTACGCGCTTCAGGGCC 
               
               
                   
                 _3 
                 CTGTTCAACTA 
               
               
                   
               
               
                 177 
                 AG9503_12 
                 AGCACTCTACTCTTAGTTTACTGCTAAATCCACCTTCGAC 
               
               
                   
                 _4 
                 CCTTAAGTTT 
               
               
                   
               
               
                 178 
                 AG9504_12 
                 CATAAGGGCTATCGTAGTTTTCTGGGGTAGAAAATGTAG 
               
               
                   
                 _5 
                 CCCATTTCTTG 
               
               
                   
               
               
                 179 
                 AG9505_12 
                 CCACCTCATGGGCTACACCTTGACCTAACGTCTTTACGTG 
               
               
                   
                 _6 
                 GGTACTTGCG 
               
               
                   
               
               
                 180 
                 AG9506_12 
                 CTTACTTTGTAGCCTTCATCAGGGTTTGCTGAAGATGGCG 
               
               
                   
                 _7 
                 GTATATAGGC 
               
               
                   
               
               
                 181 
                 AG9507_12 
                 TGAGCAAGAGGTGGTGAGGTTGATCGGGGTTTATCGATT 
               
               
                   
                 _8 
                 ACAGAACAGGC 
               
               
                   
               
               
                 182 
                 AG9508_12 
                 TCCTCTAGAGGGATATGAAGCACCGCCAGGTCCTTTGAG 
               
               
                   
                 _9 
                 TTTTAAGCTGT 
               
               
                   
               
               
                 183 
                 AG9509_12 
                 GGCTCGTAGTGTTCTGGCGAGCAGTTTTGTTGATTTAACT 
               
               
                   
                 _10 
                 GTTGAGGTTT 
               
               
                   
               
               
                 184 
                 AG9510_12 
                 AGGGCTAAGCATAGTGGGGTATCTAATCCCAGTTTGGGT 
               
               
                   
                 _11 
                 CTTAGCTATTG 
               
               
                   
               
               
                 185 
                 AG9511_12 
                 TGTGTTCAGATATGTTAAAGCCACTTTCGTAGTCTATTTT 
               
               
                   
                 _12 
                 GTGTCAACTG 
               
               
                   
               
               
                 186 
                 AG9512_12 
                 GAGTTTTTTACAACTCAGGTGAGTTTTAGCTTTATTGGGG 
               
               
                   
                 _13 
                 AGGGGGTGAT 
               
               
                   
               
               
                 187 
                 AG9513_12 
                 CTAAAACACTCTTTACGCCGGCTTCTATTGACTTGGGTTA 
               
               
                   
                 _14 
                 ATCGTGTGAC 
               
               
                   
               
               
                 188 
                 AG9514_12 
                 CGCGGTGGCTGGCACGAAATTGACCAACCCTGGGGTTAG 
               
               
                   
                 _15 
                 TATAGCTTAGT 
               
               
                   
               
               
                 189 
                 AG9515_12 
                 TAAACTTTCGTTTATTGCTAAAGGTTAATCACTGCTGTTT 
               
               
                   
                 _16 
                 CCCGTGGG 
               
               
                   
               
               
                 190 
                 AG9516_12 
                 TGTGGCTAGGCTAAGCGTTTTGAGCTGCATTGCTGCGTGC 
               
               
                   
                 _17 
                 TTGATGCTTG 
               
               
                   
               
               
                 191 
                 AG9517_12 
                 TTCCTTTTGATCGTGGTGATTTAGAGGGTGAACTCACTGG 
               
               
                   
                 _18 
                 AACGGGGATG 
               
               
                   
               
               
                 192 
                 AG9518_12 
                 CTTGCATGTGTAATCTTACTAAGAGCTAATAGAAAGGCT 
               
               
                   
                 _19 
                 AGGACCAAACC 
               
               
                   
               
               
                 193 
                 AG9519_5_ 
                 AAAGCCTACAGCACCCGGTATTCCCAGGCGGTCTCCCAT 
               
               
                   
                 1 
                 CCAAGTACTAA 
               
               
                   
               
               
                 194 
                 AG9520_5_ 
                 CCAGGCCCGACCCTGCTTAGCTTCCGAGATCAGACGAGA 
               
               
                   
                 2 
                 TCGGGCGCGTT 
               
               
                   
               
               
                 195 
                 AG9521_5_ 
                 TTCCGAGATCAGACGAGATCGGGCGCGTTCAGGGTGGTA 
               
               
                   
                 3 
                 TGGCCGTAGAC